C40-, C28-and C-32 linked rapamycin analogs as mTOR inhibitors
By developing compounds with specific structural characteristics, the problem of insufficient selectivity between existing mTOR inhibitors between mTORC1 and mTORC2 was solved, selective inhibition of mTOR was achieved, Akt activation was protected, and signaling integrity was enhanced.
Patent Information
- Application Number
- CN202410748453.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-04-18
- Filing Date
- 2019-04-29
- Publication Date
- 2024-11-05
AI Technical Summary
The existing mTOR inhibitors lack selectivity between inhibiting mTORC1 and mTORC2, resulting in the inhibitory effect on mTORC2 affecting Akt activation, thereby blocking the phosphorylation of Akt S473 and affecting the integrity of signaling.
A new compound has been developed to inhibit mTOR activity through specific structural characteristics (such as substituents and linkage methods of R32, R28, R40) to provide a more selective inhibitor against mTORC1 or mTORC2, reducing the Nonspecific inhibition of mTORC2 protects Akt activation.
More selective inhibition of mTOR is achieved, nonspecific inhibition of mTORC2 is reduced, Akt activation is protected, and signaling integrity and pharmacological specificity are enhanced.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
[0001] This application is a divisional application of Chinese patent application No. 201980044255.9 (filing date: April 29, 2019, invention name: C40-, C28- and C-32-linked rapamycin analogs as mTOR inhibitors).
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 665,435, filed May 1, 2018, U.S. Provisional Application No. 62 / 752,874, filed October 30, 2018, and U.S. Provisional Application No. 62 / 836,036, filed April 18, 2019, the contents of which are incorporated herein by reference in their entirety.
[0004] Sequence Listing
[0005] The sequence listing associated with this application is provided in text format in lieu of a paper copy and is hereby incorporated by reference into the specification. The text file containing the sequence listing is named REME_008_01WO_SeqList_ST25.txt. This text file is approximately 40 kilobytes, was created on April 26, 2019, and was submitted electronically via EFS-Web. Technical Field
[0006] The present invention relates to mTOR inhibitors. Specifically, embodiments relate to compounds and compositions that inhibit mTOR, methods for treating mTOR-mediated diseases, and methods for synthesizing these compounds. Background Art
[0007] The mammalian target of rapamycin (mTOR) is a serine-threonine kinase related to the phosphatidylinositol 3-kinase (PI3K) family of lipid kinases. mTOR exists as two differentially regulated complexes (mTORC1 and mTORC2), each with distinct substrate specificities and sensitivities to rapamycin. mTORC1 integrates signals from growth factor receptors with cellular nutritional status and controls the level of cap-dependent mRNA translation by regulating the activity of key translational components, such as cap-binding proteins and the oncogene eIF4E.
[0008] mTOR signaling has been deciphered in increasing detail. The different pharmacologies of mTOR inhibitors are particularly rich. It is now understood that the first reported mTOR inhibitor, rapamycin, is an incomplete inhibitor of mTORC1. Rapamycin is a selective mTORC1 inhibitor that binds to the FK506 rapamycin binding (FRB) domain of mTOR kinase with the help of FK506 binding protein 12 (FKBP12). The FRB domain of mTOR is accessible in the mTORC1 complex, but is less accessible in the mTORC2 complex. Interestingly, the efficacy of rapamycin treatment for the inhibitory activity of downstream substrates of mTORC1 varies among mTORC1 substrates. For example, rapamycin strongly inhibits the phosphorylation of the mTORC1 substrate S6K and indirectly inhibits the phosphorylation of the downstream ribosomal protein S6 that controls ribosome biogenesis. On the other hand, rapamycin shows only partial inhibitory activity on the phosphorylation of 4E-BP1, a major regulator of eIF4E that controls the initiation of CAP-dependent translation. As a result, more complete inhibitors of mTORC1 signaling are of interest.
[0009] A second class of "ATP-site" inhibitors of mTOR kinase has been reported. This class of mTOR inhibitors is referred to as TORi (ATP-site TOR inhibitors). These molecules compete with ATP (the substrate of the kinase reaction) in the active site of mTOR kinase (and are therefore also mTOR active site inhibitors). As a result, these molecules inhibit downstream phosphorylation of a wider range of substrates.
[0010] While mTOR inhibition may have the effect of blocking 4E-BP1 phosphorylation, these agents may also inhibit mTORC2, which results in a blockade of Akt activation due to inhibition of Akt S473 phosphorylation.
[0011] Disclosed herein are mTOR inhibitors. In some embodiments, the compounds disclosed herein are inhibitors that are more selective for mTORC1 relative to mTORC2. In some embodiments, the compounds disclosed herein are inhibitors that are more selective for mTORC2 relative to mTORC1. In some embodiments, the compounds disclosed herein do not exhibit differential selectivity between mTORC1 and mTORC2. Summary of the Invention
[0012] The present invention relates to compounds that inhibit the activity of mTOR. The present invention further provides methods for preparing the compounds of the present invention, pharmaceutical formulations containing these compounds, and methods of using these compounds and compositions in the management of diseases or conditions mediated by mTOR.
[0013] The present invention provides a compound of formula Ic:
[0014]
[0015] or a pharmaceutically acceptable salt or tautomer thereof, wherein:
[0016] R 32 -H, =O, -OR 3 、-N3 or -OC(=Z 1 )-R 32a ;
[0017] R 28 is -H, (C1-C6) alkyl or -C(=Z 1 )-R 28a ;
[0018] R 40 is -H or -C(=Z 1 )-R 40a ;
[0019] When R 28 and R 40 When H, R 32 Not = O;
[0020] Z 1 Each independently is O or S;
[0021] R 28a 、R 32a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B, -O-(C1-C6)alkyl, or -O-(C6-C 10 ) aryl; wherein -O-(C6-C 10 ) the aryl group of the aryl group is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen;
[0022] A 1 and A 2 are independently absent or independently selected from
[0023]
[0024]
[0025] As shown, A1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The key on the right side of the part is bound to B or L 3 ;
[0026] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0027] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0028] X 1 each independently a heteroarylene or heterocyclylene ring;
[0029] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0030] W 1 each independently a heteroarylene or heterocyclylene ring;
[0031] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0032] G 1 and G 2 each independently a heteroarylene or heterocyclylene ring;
[0033] L 1 Each independently selected from
[0034]
[0035] L 2 and L 3 are independently absent or independently selected from
[0036] B are each independently selected from
[0037]
[0038] B 1 Each independently selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, NR 3 -(C(R 3 )2) n -heteroarylene-(C(R 3 )2) n -、 (C6-C 10 )arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-,
[0039]
[0040] NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)- and NR 3 -(C(R 3 )2) n -S(O)2-arylene-(C(R 3 )2) n -, where as depicted, B 1 On the left Bonded to A 2 、L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;
[0041] R 3 Each is independently H or (C1-C6) alkyl;
[0042] R 4 Each is independently H, (C1-C6) alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C6-C10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are each independently optionally substituted by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 -heterocyclyl substitution;
[0043] R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl groups of (C1-C6)alkyl are each independently optionally substituted with -N(R 3 )2OR-OR 3 replace;
[0044] R 6 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl groups of (C1-C6)alkyl are each independently optionally substituted with -N(R 3 )2OR-OR 3 replace;
[0045] R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl groups of (C1-C6)alkyl are each independently optionally substituted with -N(R 3 )2OR-OR 3 replace;
[0046] R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl groups of (C1-C6)alkyl are each independently optionally substituted with -N(R 3 )2OR-OR 3 replace;
[0047] Y is each independently C(R 3 )2 or key;
[0048] n is each independently an integer from 1 to 12;
[0049] o are each independently an integer from 0 to 30;
[0050] p is each independently an integer from 0 to 12;
[0051] q is each independently an integer from 0 to 30; and
[0052] r is an integer of 1 to 6, each independently.
[0053] The present invention provides a compound of formula Ia:
[0054]
[0055] or a pharmaceutically acceptable salt or tautomer thereof, wherein:
[0056] R 32 -H, =O, -OR 3 、-N3 or -OC(=Z 1 )-R 32a ;
[0057] R 28 is -H, (C1-C6) alkyl or -C(=Z 1 )-R 28a ;
[0058] R 40 is -H or -C(=Z 1 )-R 40a ;
[0059] When R 28 and R 40 When H, R 32 Not = O;
[0060] Z 1 Each independently is O or S;
[0061] R 28a 、R 32a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B, -O-(C1-C6)alkyl, or -O-(C6-C 10 ) aryl; wherein -O-(C6-C 10 ) the aryl group of the aryl group is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen;
[0062] A 1 and A 2are independently absent or independently selected from
[0063]
[0064] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The key on the right side of the part is bound to B or L 3 ;
[0065] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0066] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0067] X 1 each independently a heteroarylene or heterocyclylene ring;
[0068] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0069] W 1 each independently a heteroarylene or heterocyclylene ring;
[0070] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0071] G 1 and G 2 each independently a heteroarylene or heterocyclylene ring;
[0072] L 1 Each independently selected from
[0073]
[0074] L 2 and L 3 are independently absent or independently selected from
[0075]
[0076] B are each independently selected from
[0077]
[0078] B 1 Each independently selected from NR 3 -(C(R 3 )2) n-、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, (C6-C 10 )arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-,
[0079] and NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)-, wherein as shown, B 1 On the left Bonded to A 2 、L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;
[0080] R 3 Each is independently H or (C1-C6) alkyl;
[0081] R 4 Each is independently H, (C1-C6) alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C6-C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are each independently optionally substituted by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN, -C(O)NR3 -heteroaryl or -C(O)NR 3 -heterocyclyl substitution;
[0082] R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl groups of (C1-C6)alkyl are each independently optionally substituted with -N(R 3 )2OR-OR 3 replace;
[0083] R 6 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl groups of (C1-C6)alkyl are each independently optionally substituted with -N(R 3 )2OR-OR 3 replace;
[0084] R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl groups of (C1-C6)alkyl are each independently optionally substituted with -N(R 3 )2OR-OR 3 replace;
[0085] R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl groups of (C1-C6)alkyl are each independently optionally substituted with -N(R 3 )2OR-OR 3 replace;
[0086] Y is each independently -C(R 3 )2 or key;
[0087] n is each independently an integer from 1 to 12;
[0088] o are each independently an integer from 0 to 30;
[0089] p is each independently an integer from 0 to 12;
[0090] q is each independently an integer from 0 to 30; and
[0091] r is an integer of 1 to 6, each independently.
[0092] The present invention provides a compound of formula I:
[0093]
[0094] or a pharmaceutically acceptable salt or tautomer thereof, wherein:
[0095] R 32 -H, =O or -OR 3 ;
[0096] R 28 is -H or -C(=Z 1 )-R 28a ;
[0097] R 40 is -H or -C(=Z 1 )-R 40a ;
[0098] where R 28 and R 40 At least one of them is not H;
[0099] Z 1 independently O or S;
[0100] R 28a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B, -O-(C1-C6)alkyl; or -O-(C6-C 10 ) aryl; wherein -O-(C6-C 10 ) the aryl group of the aryl group is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen;
[0101] A 1 and A 2 are independently absent or independently selected from
[0102]
[0103] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The key on the right side of the part is bound to B or L 3 ;
[0104] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0105] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0106] X 1 each independently a heteroarylene or heterocyclylene ring;
[0107] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0108] W 1 each independently a heteroarylene or heterocyclylene ring;
[0109] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0110] G 1 and G 2 each independently a heteroarylene or heterocyclylene ring;
[0111] L 1 Each independently selected from
[0112]
[0113] L 2 and L 3 are independently absent or independently selected from
[0114]
[0115] B are each independently selected from
[0116]
[0117] B 1 Each independently selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, (C6-C10 )arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-,
[0118] and NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)-, wherein as shown, B 1 On the left Bonded to A 2 、L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;
[0119] R 3 Each is independently H or (C1-C6) alkyl;
[0120] R 4 Each is independently H, (C1-C6) alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C6-C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are each independently optionally substituted by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 -heterocyclyl substitution;
[0121] R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0122] R 6 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0123] R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0124] R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0125] Y is each independently -C(R 3 )2 or key;
[0126] n is each independently an integer from 1 to 12;
[0127] o are each independently an integer from 0 to 30;
[0128] p is each independently an integer from 0 to 12;
[0129] q is each independently an integer from 0 to 30; and
[0130] r is an integer of 1 to 6, each independently.
[0131] The present invention provides a compound of formula II:
[0132]
[0133] or a pharmaceutically acceptable salt or tautomer thereof, wherein:
[0134] R 32 -H, =O or -OR 3 ;
[0135] R 28 is -H or -C(=Z 1 )-R 28a ;
[0136] R 40 is -H or -C(=Z 1 )-R 40a ;
[0137] where R 28 and R 40 At least one of them is not H;
[0138] Z 1 independently O or S;
[0139] R 28a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -O-(C1-C6)alkyl; or -O-(C6-C 10 ) aryl; wherein -O-(C6-C 10 ) the aryl group of the aryl group is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen;
[0140] A 1 and A 2 are independently absent or independently selected from
[0141]
[0142]
[0143] As shown, A 1 The left bond is bound to -C(=Z 1 )-; and wherein, as shown, A 2 The bond on the right side of the part is bound to B;
[0144] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0145] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0146] X 1 each independently a heteroarylene or heterocyclylene ring;
[0147] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0148] W 1 each independently a heteroarylene or heterocyclylene ring;
[0149] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0150] G 1 and G 2 each independently a heteroarylene or heterocyclylene ring;
[0151] L 1 Each independently selected from
[0152]
[0153] B are each independently selected from
[0154]
[0155] B 1 Each independently selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, (C6-C 10 )arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-, and NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)-, wherein as shown, B 1 On the left Bonded to A 2 or L1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;
[0156] R 3 Each is independently H or (C1-C6) alkyl;
[0157] R 4 Each is independently H, (C1-C6) alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C6-C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are each independently optionally substituted by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 -heterocyclyl substitution;
[0158] R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0159] R 6 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0160] R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0161] R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR3 replace;
[0162] Y is each independently C(R 3 )2 or key;
[0163] n is each independently an integer from 1 to 12;
[0164] o are each independently an integer from 0 to 30;
[0165] p is each independently an integer from 0 to 12;
[0166] q is each independently an integer from 0 to 30; and
[0167] r is an integer of 1 to 6, each independently.
[0168] In some embodiments, the compound of Formula I or II is represented by the structure of Formula 1-28:
[0169]
[0170] or a pharmaceutically acceptable salt or tautomer thereof.
[0171] In some embodiments, the compound of Formula Ia, Ic, I, or II is represented by the structure of Formula I-28b:
[0172]
[0173] or a pharmaceutically acceptable salt or tautomer thereof.
[0174] In some embodiments, the compound of Formula I or II is represented by the structure of Formula I-40:
[0175]
[0176] or a pharmaceutically acceptable salt or tautomer thereof.
[0177] In some embodiments, the compound of Formula Ia, Ic, I, or II is represented by the structure of Formula I-40b:
[0178]
[0179] or a pharmaceutically acceptable salt or tautomer thereof.
[0180] In some embodiments, the compound of Formula Ia, Ic, I, or II is represented by the structure of Formula I-32b:
[0181]
[0182] or a pharmaceutically acceptable salt or tautomer thereof.
[0183] The present invention provides a method for treating a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compounds. The present invention provides a method for preventing a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compounds. The present invention provides a method for reducing the risk of a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compounds.
[0184] Another aspect of the present invention relates to a pharmaceutical composition comprising a compound of Formula I, Ia, Ib, Ic, II, or IIb, or a pharmaceutically acceptable salt or tautomer of any of the foregoing, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further include an excipient, a diluent, or a surfactant. The pharmaceutical composition is effective for treating, preventing, or reducing the risk of a disease or condition mediated by mTOR in a subject in need thereof.
[0185] Another aspect of the present invention relates to a compound of Formula I, Ia, Ib, Ic, II or IIb, or a pharmaceutically acceptable salt or tautomer of any of the foregoing, for use in treating, preventing or reducing the risk of a disease or condition mediated by mTOR in a subject in need thereof.
[0186] Another aspect of the present invention relates to the use of a compound of Formula I, Ia, Ib, Ic, II or IIb, or a pharmaceutically acceptable salt or tautomer of any of the foregoing, in the preparation of a medicament for treating, preventing, or reducing the risk of a disease or condition mediated by mTOR in a subject in need thereof.
[0187] The present invention also provides compounds useful for inhibiting mTOR. DETAILED DESCRIPTION
[0188] The present invention relates to mTOR inhibitors. Specifically, embodiments relate to compounds and compositions that inhibit mTOR, methods for treating diseases mediated by mTOR, and methods for synthesizing these compounds.
[0189] The details of the present invention are described in the following accompanying description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects and advantages of the present invention will be apparent from the specification and from the claims. In this specification and the appended claims, unless the context clearly indicates otherwise, the singular form may also include the plural form. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as generally understood by those skilled in the art to which the present invention belongs. The full text of all patents and publications cited in this specification are incorporated herein by reference.
[0190] the term
[0191] The articles "a" and "an" are used herein and, unless otherwise specified, refer to one or more than one (i.e., at least one) of the grammatical object of the article. For example, "an element" may mean one element or more than one element unless otherwise specified.
[0192] Unless otherwise stated, the term "or" means "and / or." Unless otherwise stated, the term "and / or" means "and" or "or" or both.
[0193] Unless otherwise indicated, the term "optionally substituted" means that the group may be unsubstituted or substituted with one or more (e.g., 0, 1, 2, 3, 4, or 5 or more) of the substituents listed for that group, wherein the substituents may be the same or different. In one embodiment, the optionally substituted group has 1 substituent. In another embodiment, the optionally substituted group has 2 substituents. In another embodiment, the optionally substituted group has 3 substituents. In another embodiment, the optionally substituted group has 4 substituents. In another embodiment, the optionally substituted group has 5 substituents.
[0194] Unless otherwise indicated, the term "alkyl" by itself or as part of another substituent means a linear (i.e., unbranched) or branched, non-cyclic carbon chain (or carbon), or combinations thereof, which may be fully saturated, monounsaturated, or polyunsaturated and may contain groups having the specified number of carbon atoms (i.e., C1-C 10"" refers to divalent and polyvalent groups of 1 to 10 carbon atoms. Examples of saturated hydrocarbon groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, and homologs and isomers thereof, such as n-pentyl, n-hexyl, n-heptyl, and n-octyl. Unsaturated alkyl groups are those having one or more double or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, 2-butenyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher carbon number homologs and isomers.
[0195] Unless otherwise indicated, the term "alkylene," by itself or as part of another substituent, means a divalent radical derived from an alkyl group. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, such as those having 10 or fewer carbon atoms.
[0196] The term "alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched, having from about 2 to about 6 carbon atoms in the chain. Certain alkenyl groups have from 2 to about 4 carbon atoms in the chain. Branched can mean that one or more lower alkyl groups (such as methyl, ethyl, or propyl) are attached to a straight alkenyl chain. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, and isobutenyl. C2-C6 alkenyl is an alkenyl group containing from 2 to 6 carbon atoms.
[0197] The term "alkenylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkenyl group.
[0198] The term "alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which can be straight or branched, having from about 2 to about 6 carbon atoms in the chain. Certain alkynyl groups have from 2 to about 4 carbon atoms in the chain. Branched can mean that one or more lower carbon number alkyl groups (such as methyl, ethyl or propyl) are attached to a straight alkynyl chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl and n-pentynyl. C2-C6 alkynyl is an alkynyl group containing from 2 to 6 carbon atoms.
[0199] The term "alkynylene" by itself or as part of another substituent means, unless otherwise stated, a divalent radical derived from an alkynyl group.
[0200] The term "cycloalkyl" refers to a monocyclic or polycyclic saturated or partially unsaturated carbocyclic ring containing 3 to 18 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, norbornenyl, bicyclo[2.2.2]octyl, or bicyclo[2.2.2]octenyl. C3-C8 cycloalkyl groups are cycloalkyl groups containing 3 to 8 carbon atoms. Cycloalkyl groups can be fused (e.g., decalin) or bridged (e.g., norbornane).
[0201] "Cycloalkylene" by itself or as part of another substituent means a divalent radical derived from a cycloalkyl group.
[0202] The term "heterocyclyl" or "heterocycloalkyl" or "heterocycle" refers to a monocyclic or polycyclic 3- to 24-membered ring containing carbon and at least one heteroatom selected from oxygen, phosphorus, nitrogen and sulfur, and wherein there are no delocalized pi electrons shared among the ring carbons or heteroatoms (aromaticity). Heterocyclyl rings include, but are not limited to, oxetane, azetidine, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, aza oxepinyl, diazepine The heterocyclyl or heterocycloalkyl rings may also be fused or bridged, for example, they may be bicyclic.
[0203] "Heterocyclylene" or "heterocycloalkylene" alone or as part of another substituent means a divalent radical derived from "heterocyclyl" or "heterocycloalkyl" or "heterocycle".
[0204] Unless otherwise indicated, the term "aryl" means a polyunsaturated aromatic hydrocarbon substituent, which can be a single ring or multiple rings (preferably 1 to 3 rings) fused together (i.e., fused-ring aryl) or covalently linked. A fused-ring aryl can refer to multiple rings fused together, wherein at least one of the fused rings is an aryl ring.
[0205] "Arylene" by itself or as part of another substituent means a divalent radical derived from an aryl group.
[0206] The term "heteroaryl" refers to an aromatic group (or ring) containing at least one heteroatom (such as N, O, or S), wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally quaternized. Thus, the term "heteroaryl" includes fused-ring heteroaryls (i.e., multiple rings fused together, wherein at least one of the fused rings is a heteroaryl ring). A 5,6-fused-ring heteroarylene group refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Similarly, a 6,6-fused-ring heteroarylene group refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused-ring heteroarylene group refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the rest of the molecule via a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl ... Substituents for each of the above aryl and heteroaryl ring systems are selected from the group consisting of acceptable substituents described herein.
[0207] The term "heteroaryl" may also include polycondensed ring systems having at least one such aromatic ring, which are further described below. The term may also include polycondensed ring systems (e.g., ring systems comprising 2, 3, or 4 rings), wherein the heteroaryl as defined above may be fused to one or more rings selected from heteroaryl (to form, for example, naphthyridinyl, such as 1,8-naphthyridinyl), heterocycle (to form, for example, 1,2,3,4-tetrahydronaphthyridine, such as 1,2,3,4-tetrahydro-1,8-naphthyridinyl), carbocycle (to form, for example, 5,6,7,8-tetrahydroquinolinyl), and aryl (to form, for example, indazolyl) to form a polycondensed ring system. When valence requirements permit, the rings of the polycondensed ring system may be connected to each other via fusion, spiro, and bridging bonds. It should be understood that the individual rings of the polycondensed ring system may be connected in any order relative to each other. It is also to be understood that the points of attachment of the multi-fused ring system (as defined above for heteroaryl) may be at any position of the multi-fused ring system, including the heteroaryl, heterocyclic, aryl or carbocyclic portion of the multi-fused ring system, and at any suitable atom of the multi-fused ring system, including carbon and heteroatom (e.g., nitrogen).
[0208] "Heteroarylene" by itself or as part of another substituent means a divalent radical derived from heteroaryl.
[0209] Non-limiting examples of aryl and heteroaryl groups include pyridyl, pyrimidinyl, thiophenyl, thienyl, furanyl, indolyl, benzoxadiazolyl, benzodioxolyl, benzodioxanyl, thianaphthanyl, pyrrolopyridinyl, indazolyl, quinolinyl, quinoxalinyl, pyridopyrazinyl, quinazolinonyl, benzisoxazolyl, imidazopyridinyl, benzofuranyl, benzothiophene
[0014] Examples include phenyl, benzothiophenyl, phenyl, naphthyl, biphenyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furylthienyl, pyridyl, pyrimidinyl, benzothiazolyl, purinyl, benzimidazolyl, isoquinolinyl, thiadiazolyl, oxadiazolyl, pyrrolyl, oxadiazolyl, triazolyl, tetrazolyl, benzothiadiazolyl, isothiazolyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, benzotriazolyl, benzoxazolyl, or quinolinyl. The above examples may be substituted or unsubstituted, and the divalent radical of each of the above heteroaryl examples is a non-limiting example of a heteroarylene group. The heteroaryl moiety may include one ring heteroatom (e.g., O, N, or S). The heteroaryl moiety may include two optionally different ring heteroatoms (e.g., O, N, or S). The heteroaryl moiety may contain three optionally different ring heteroatoms (e.g., O, N, or S). The heteroaryl moiety may contain four optionally different ring heteroatoms (e.g., O, N, or S). The heteroaryl moiety may contain five optionally different ring heteroatoms (e.g., O, N, or S). The aryl moiety may have a single ring. The aryl moiety may have two optionally different rings. The aryl moiety may have three optionally different rings. The aryl moiety may have four optionally different rings. The heteroaryl moiety may have one ring. The heteroaryl moiety may have two optionally different rings. The heteroaryl moiety may have three optionally different rings. The heteroaryl moiety may have four optionally different rings. The heteroaryl moiety may have five optionally different rings.
[0210] Unless otherwise indicated, the term "halo" or "halogen," by itself or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom. Furthermore, terms such as "haloalkyl" may include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl" may include, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, 1-fluoro-2-bromoethyl, and the like.
[0211] As used herein, the term "hydroxy" means -OH.
[0212] As used herein, the term "hydroxyalkyl" means an alkyl moiety, as defined herein, substituted with one or more (such as 1, 2, or 3) hydroxy groups. In some cases, the same carbon atom does not carry more than one hydroxy group. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl, and 2-(hydroxymethyl)-3-hydroxypropyl.
[0213] As used herein, the term "oxo" means an oxygen double bonded to a carbon atom.
[0214] As used herein, a substituent may be a group selected from the following moieties:
[0215] (A) oxo, halogen, -CF3, -CN, -OH, -OCH3, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC=(O)NHNH2, -NHC=(O)NH2, -NHSO2H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF3, -OCHF2, -OCH2F, unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
[0216] (B) an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group substituted with at least one substituent selected from the group consisting of:
[0217] (i) oxo, halogen, -CF3, -CN, -OH, -OCH3, -NH2, -COOH, -CONH2,
[0218] -NO2, -SH, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC=(O)NHNH2,
[0219] -NHC=(O)NH2, -NHSO2H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF3,
[0220] -OCHF2, -OCH2F, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
[0221] (ii) an alkyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group substituted with at least one substituent selected from the group consisting of:
[0222] (a) Oxo, halogen, -CF3, -CN, -OH, -OCH3, -NH2, -COOH, -CONH2,
[0223] -NO2, -SH, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -
[0224] NHC=(O)NHNH2, -NHC=(O)NH2, -NHSO2H, -NHC=(O)H, -NHC(O)-
[0225] OH, -NHOH, -OCF3, -OCHF2, -OCH2F, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
[0226] (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl substituted with at least one substituent selected from the group consisting of oxo, halogen, -CF3, -CN, -OH, -OCH3, -
[0227] NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -SO4H, -SO2NH2, -NHNH2,
[0228] -ONH2, -NHC=(O)NHNH2, -NHC=(O)NH2, -NHSO2H, -NHC=(O)H,
[0229] -NHC(O)-OH, -NHOH, -OCF3, -OCHF2, -OCH2F, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl.
[0230] When used in conjunction with a compound, an "effective amount" is an amount effective to treat or prevent a disease in a subject as described herein.
[0231] As used herein, the term "carrier" encompasses carriers, excipients, and diluents and may refer to a material, composition, or vehicle involved in carrying or transporting an agent from one organ or part of the body to another organ or part of the subject's body, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material.
[0232] The term "treating" with respect to a subject refers to ameliorating at least one symptom of a condition in the subject. Treating can include curing, ameliorating, or at least partially ameliorating a condition.
[0233] The terms "prevent" or "preventing" with respect to a subject refer to preventing a disease or condition from affecting the subject. Prevention can include prophylactic treatment. For example, prevention can include administering a compound disclosed herein to the subject before the subject develops a disease, and the administration will protect the subject from developing the disease.
[0234] The term "disorder" is used herein and unless otherwise indicated, is intended to refer to and is used interchangeably with the terms disease, condition, or illness.
[0235] As used herein, the terms "administer" or "administering" or "administration" refer to the direct administration of a disclosed compound or a pharmaceutically acceptable salt or tautomer or composition of a disclosed compound to a subject, or the administration of a prodrug derivative or analog of a compound or a pharmaceutically acceptable salt or tautomer or composition of a compound to a subject, which can form an equivalent amount of the active compound in the body of the subject.
[0236] A "patient" or "subject" is a mammal, eg, a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate (such as a monkey, chimpanzee, baboon, or rhesus monkey).
[0237] Compound
[0238] The present invention provides a compound having a structure of formula Ic,
[0239]
[0240] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 、R 28 and R 40 As mentioned above.
[0241] The present invention provides a compound having a structure of Formula Ia,
[0242]
[0243] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 、R 28 and R 40 As mentioned above.
[0244] The present invention provides a compound having a structure of formula I,
[0245]
[0246] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 、R 28 and R 40 As mentioned above.
[0247] The present invention provides a compound having the structure of Formula Ib:
[0248]
[0249] or a pharmaceutically acceptable salt and / or tautomer thereof, wherein R 32 、R 28 and R 40 As described above for Formula I.
[0250] The present invention provides a compound having a structure of formula II,
[0251]
[0252] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 、R 28 and R 40 As mentioned above.
[0253] The present invention provides a compound having a structure of Formula IIb:
[0254]
[0255] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 、R 28 and R 40 As described above for Formula II.
[0256] In certain embodiments, the compound has the formula:
[0257]
[0258] or a pharmaceutically acceptable salt or tautomer thereof.
[0259] In certain embodiments, R 32 =0. In certain embodiments, R 32 For-OR 3 In certain embodiments, R 32 is H. In certain embodiments, R 32 It is -N3.
[0260] As mentioned above, R 3Each is independently H or (C1-C6) alkyl. In certain embodiments, R 3 is H. In certain embodiments, R 3 is (C1-C6) alkyl. In certain embodiments, R 3 It is a methyl group.
[0261] In certain embodiments, R 28 is H. In certain embodiments, R 28 is (C1-C6) alkyl. In certain embodiments, R 40 For H.
[0262] In certain embodiments, the compound is represented by the structure of Formula I-40b:
[0263]
[0264] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 and R 40 As described above for Formula Ia, Ic, I or II.
[0265] In certain embodiments, the compound is represented by the structure of Formula 1-40:
[0266]
[0267] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 and R 40 As mentioned above.
[0268] In certain embodiments, R 40 -C(=Z 1 )-R 40a In certain embodiments, Z 1 is O. In certain embodiments, Z 1 For S.
[0269] In certain embodiments, R 40a is -O-(C1-C6)alkyl or -O-(C6-C 10 ) aryl; wherein the aryl is unsubstituted or substituted with 1 to 5 substituents selected from NO2 and halogen.
[0270] In certain embodiments, R 40a -A 1 -L 1 -A 2 -B. In certain embodiments, R 40a -A 1 -A 2 -B. In certain embodiments, R 40a-L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0271] In certain embodiments, R 40a -A 1 -L 1 -A 2 -B, where A 1 and A 2 In certain embodiments, R 40a -A 1 -L 1 -A 2 -B, where A 2 In certain embodiments, R 40a -A 1 -L 1 -A 2 -B, where A 1 In certain embodiments, R 40a -A 1 -L 1 -A 2 -B. In certain embodiments, R 40a -A 1 -A 2 -B. In certain embodiments, R 40a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 In certain embodiments, R 40a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 In certain embodiments, R 40a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.
[0272] In certain embodiments, the compound is represented by the structure of Formula I-28b:
[0273]
[0274] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 and R 28 As described above for Formula Ia, Ic, I or II.
[0275] In certain embodiments, the compound is represented by the structure of Formula 1-28:
[0276]
[0277] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 and R 28 As mentioned above.
[0278] In certain embodiments, R 28 -C(=Z 1 )-R 28a In certain embodiments, Z 1 is O. In certain embodiments, Z 1 For S.
[0279] In certain embodiments, R 28a is -O-(C1-C6)alkyl or -O-(C6-C 10 ) aryl; wherein the aryl is unsubstituted or substituted with 1 to 5 substituents selected from NO2 and halogen.
[0280] In certain embodiments, R 28a -A 1 -L 1 -A 2 -B. In certain embodiments, R 28a -A 1 -A 2 -B. In certain embodiments, R 28a -L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0281] In certain embodiments, R 28a -A 1 -L 1 -A 2 -B, where A 1 and A 2 In certain embodiments, R 28a -A 1 -L 1 -A 2 -B, where A 2In certain embodiments, R 28a -A 1 -L 1 -A 2 -B, where A 1 In certain embodiments, R 28a -A 1 -L 1 -A 2 -B. In certain embodiments, R 28a -A 1 -A 2 -B. In certain embodiments, R 28a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 In certain embodiments, R 28a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 In certain embodiments, R 28a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.
[0282] In certain embodiments, the compound is represented by the structure of Formula I-32b:
[0283]
[0284] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 As described above for Formula Ia, Ic, I or II.
[0285] In certain embodiments, R 32 =-OC( 1 )-R 32a In certain embodiments, Z 1 is O. In certain embodiments, Z 1 For S.
[0286] In certain embodiments, R 32a is -O-(C1-C6)alkyl or -O-(C6-C 10) aryl; wherein the aryl is unsubstituted or substituted with 1 to 5 substituents selected from NO2 and halogen.
[0287] In certain embodiments, R 32a -A 1 -L 1 -A 2 -B. In certain embodiments, R 32a -A 1 -A 2 -B. In certain embodiments, R 32a -L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0288] In certain embodiments, R 32a -A 1 -L 1 -A 2 -B, where A 1 and A 2 In certain embodiments, R 32a -A 1 -L 1 -A 2 -B, where A 2 In certain embodiments, R 32a -A 1 -L 1 -A 2 -B, where A 1 In certain embodiments, R 32a -A 1 -L 1 -A 2 -B. In certain embodiments, R 32a -A 1 -A 2 -B. In certain embodiments, R 32a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 In certain embodiments, R 32a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2In certain embodiments, R 32a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.
[0289] As mentioned above, L 1 Each independently selected from
[0290]
[0291] As described above for Formula Ia, L 1 Each independently selected from
[0292]
[0293] As described above for Formula Ic, L 1 Each independently selected from
[0294]
[0295] In certain embodiments, L 1 for
[0296] In certain embodiments, L 1 for
[0297] In certain embodiments, L 1 for
[0298] In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for
[0299] In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L1 for In certain embodiments, L 1 for
[0300] As mentioned above, L 2 and L 3 are independently absent or independently selected from
[0301]
[0302] As described above for Formulas Ia and Ic, L 2 and L 3 are independently absent or independently selected from
[0303]
[0304] In certain embodiments, L 2 In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for
[0305] In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for
[0306] In certain embodiments, L 2 for
[0307] In certain embodiments, L 2 for
[0308] In certain embodiments, L 2 for
[0309] In certain embodiments, L 3 In certain embodiments, L 3 for In certain embodiments, L3 for In certain embodiments, L 3 for In certain embodiments, L 3 for In certain embodiments, L 3 for In certain embodiments, L 3 for
[0310] In certain embodiments, L 3 for In certain embodiments, L 3 for In certain embodiments, L 3 In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for
[0311] In certain embodiments, L 3 for
[0312] In certain embodiments, L 3 for
[0313] In certain embodiments, L 3 for
[0314] As mentioned above, A 1 and A 2 are independently absent or independently selected from
[0315]
[0316] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0317] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0318] X 1 each independently a heteroarylene or heterocyclylene ring;
[0319] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0320] W 1each independently a heteroarylene or heterocyclylene ring;
[0321] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0322] G 1 and G 2 Each is independently a heteroarylene or heterocyclylene ring.
[0323] As described above for Formula Ia, A 1 and A 2 are independently absent or independently selected from
[0324]
[0325] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0326] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0327] X 1 each independently a heteroarylene or heterocyclylene ring;
[0328] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0329] W 1 each independently a heteroarylene or heterocyclylene ring;
[0330] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0331] G 1 and G 2 Each is independently a heteroarylene or heterocyclylene ring.
[0332] As described above for Formula Ic, A 1 and A 2 are independently absent or independently selected from
[0333]
[0334] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0335] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0336] X 1 each independently a heteroarylene or heterocyclylene ring;
[0337] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0338] W 1 each independently a heteroarylene or heterocyclylene ring;
[0339] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0340] G 1 and G 2 Each is independently a heteroarylene or heterocyclylene ring.
[0341] For formula I, as shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and as shown, A 2 The key on the right side of the part is bound to B or L 3 For Formula II, as shown, A 1 The left bond is bound to -C(=Z 1 )-; and as shown, A 2 The bond on the right side of the portion is bound to B. For Formulas Ia and Ic, as shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The key on the right side of the part is bound to B or L 3 .
[0342] In certain embodiments, A 1 In certain embodiments, A 1 for In certain embodiments, A 1 for In certain embodiments, A 1 for In certain embodiments, A 1 for
[0343] In certain embodiments, A 1 for wherein each Q is independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.
[0344] In certain embodiments, A 1 for wherein each Q is independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.
[0345] In certain embodiments, A 1 for wherein each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and each X 1 is a heteroarylene or heterocyclylene ring.
[0346] In certain embodiments, A 1 for wherein each W is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and each W 1 is a heteroarylene or heterocyclylene ring.
[0347] In certain embodiments, A 1 for wherein each W is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and each W 1 is a heteroarylene or heterocyclylene ring.
[0348] In certain embodiments, A 1 for wherein each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.
[0349] In certain embodiments, A 1 for wherein each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and G 1 and G 2 Each is independently a heteroarylene or heterocyclylene ring.
[0350] In certain embodiments, A 1 for
[0351] In certain embodiments, A 1 for In certain embodiments, A 1 for In certain embodiments, A 1 for In certain embodiments, A 1 for
[0352] In certain embodiments, A 2In certain embodiments, A 2 for In certain embodiments, A 2 for In certain embodiments, A 2 for In certain embodiments, A 2 for
[0353] In certain embodiments, A 2 for wherein each Q is independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.
[0354] In certain embodiments, A 2 for wherein each Q is independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.
[0355] In certain embodiments, A 2 for wherein each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and X 1 Each is independently a heteroarylene or heterocyclylene ring.
[0356] In certain embodiments, A 2 for wherein each W is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and W 1 Each is independently a heteroarylene or heterocyclylene ring.
[0357] In certain embodiments, A 2 for wherein each W is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and W 1 Each is independently a heteroarylene or heterocyclylene ring.
[0358] In certain embodiments, A 2 for wherein each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.
[0359] In certain embodiments, A 2 for wherein each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and G 1 and G 2Each is independently a heteroarylene or heterocyclylene ring.
[0360] In certain embodiments, A 2 for
[0361] In certain embodiments, A 2 for In certain embodiments, A 2 for In certain embodiments, A 2 for In certain embodiments, A 2 for
[0362] As mentioned above, B is each independently selected from
[0363]
[0364] In certain embodiments, B is
[0365] In certain embodiments, B is
[0366] In certain embodiments, B is
[0367] In certain embodiments, B is
[0368] As mentioned above, B 1 Each independently selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, (C6-C 10 )arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-, and NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)-, wherein as shown, B 1 On the left Bonded to A 2 or L 1 and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy.
[0369] As described above for Formula Ic, B 1 Each independently selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, NR 3 -(C(R 3 )2) n -heteroarylene-(C(R 3 )2) n -、 (C6-C 10 )arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-, 、
[0370]
[0371] S(O)2-arylene-C(O)- and NR 3 -(C(R 3 )2) n -S(O)2-arylene-(C(R 3 )2) n -; where, as depicted, B 1 On the left Bonded to A 2 、L 3 or L 1 and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy.
[0372] In certain embodiments, B 1 for NR 3 -(C(R 3 )2) n -.
[0373] In certain embodiments, B 1 for In certain embodiments, B 1 for wherein the arylene group is optionally substituted with a haloalkyl group.
[0374] In certain embodiments, B 1 for NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, (C6-C 10 )arylene-, NR 3-(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene- or Heteroarylene-heterocyclylene-(C6-C 10 )arylene-. In certain embodiments, B 1 for .
[0375] In certain embodiments, B 1 for In certain embodiments, B 1 for In certain embodiments, B 1 for NR 3 -(C(R 3 )2) n -S(O)2-Arylene-C(O)-.
[0376] In certain embodiments, B 1 for NR 3 -(C(R 3 )2) n -heteroarylene-(C(R 3 )2) n -. In certain embodiments, B 1 for In certain embodiments, B 1 for In certain embodiments, B 1 for NR 3 -(C(R 3 )2) n -S(O)2-arylene-(C(R 3 )2) n -.
[0377] In certain embodiments, in B 1 In the above, the heteroaryl, heterocyclyl and arylene groups are optionally substituted by alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy.
[0378] In certain embodiments, R 3 is H. In certain embodiments, R 3 It is a (C1-C6) alkyl group.
[0379] In certain embodiments, R 4 is H. In certain embodiments, R 4 is (C1-C6) alkyl. In certain embodiments, R 4 In certain embodiments, R 4 is a 5- to 12-membered heteroaryl, a 5- to 12-membered heterocyclic group or (C6-C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN or -C(O)NR 3 -heteroaryl substitution. In certain embodiments, R 4 -C(O)NR 3 -heterocyclyl. In certain embodiments, R 4 is optionally replaced by -N(R 3 )2OR-OR 3 Substituted 5- to 12-membered heteroaryl.
[0380] As mentioned above, R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 In certain embodiments, R 5 is H. In certain embodiments, R 5 is (C1-C6)alkyl, wherein the alkyl group is optionally substituted with -N(R 3 )2OR-OR 3 In certain embodiments, R 5 -C(O)OR 3 In certain embodiments, R 5 -N(R 3 )2.
[0381] As mentioned above, R 6 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 In certain embodiments, R 6 is H. In certain embodiments, R 6is (C1-C6)alkyl, wherein the alkyl group is optionally substituted with -N(R 3 )2OR-OR 3 In certain embodiments, R 6 -C(O)OR 3 In certain embodiments, R 6 -N(R 3 )2.
[0382] As mentioned above, R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 In certain embodiments, R 7 is H. In certain embodiments, R 7 is (C1-C6)alkyl, wherein the alkyl group is optionally substituted with -N(R 3 )2OR-OR 3 In certain embodiments, R 7 -C(O)OR 3 In certain embodiments, R 7 -N(R 3 )2.
[0383] As mentioned above, R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 In certain embodiments, R 8 is H. In certain embodiments, R 8 is (C1-C6)alkyl, wherein the alkyl group is optionally substituted with -N(R 3 )2OR-OR 3 In certain embodiments, R 8 -C(O)OR 3 In certain embodiments, R 8 -N(R 3 )2.
[0384] As described above, each Y is independently C(R 3 )2 or a bond. In certain embodiments, Y is C(R 3 ) 2. In certain embodiments, Y is CH 2. In certain embodiments, Y is a bond.
[0385] In certain embodiments, n is 1, 2, 3, 4, 5, 6, 7, or 8, or any range derivable therein. In certain embodiments, n is 1, 2, 3, or 4. In certain embodiments, n is 5, 6, 7, or 8. In certain embodiments, n is 9, 10, 11, or 12.
[0386] In certain embodiments, o is an integer from 0 to 10, or any range derivable therein. In certain embodiments, o is 0, 1, 2, 3, 4, or 5. In certain embodiments, o is 6, 7, 8, 9, or 10. In certain embodiments, o is from 1 to 7. In certain embodiments, o is from 1 to 8. In certain embodiments, o is from 1 to 9. In certain embodiments, o is from 3 to 8.
[0387] In certain embodiments, o is an integer from 0 to 30, or any range derivable therein. In certain embodiments, o is an integer from 0 to 30, 29, 28, 27, or 26. In certain embodiments, o is an integer from 0 to 25, 24, 23, 22, or 21. In certain embodiments, o is an integer from 0 to 20, 19, 18, 17, or 16. In certain embodiments, o is an integer from 0 to 15, 14, 13, 12, or 11.
[0388] In certain embodiments, p is 0, 1, 2, 3, 4, 5, or 6, or any range derivable therein. In certain embodiments, p is 7, 8, 9, 10, 11, or 12. In certain embodiments, p is 0, 1, 2, or 3. In certain embodiments, p is 4, 5, or 6.
[0389] In certain embodiments, q is an integer from 0 to 10, or any range derivable therein. In certain embodiments, q is 0, 1, 2, 3, 4, or 5. In certain embodiments, q is 6, 7, 8, 9, or 10. In certain embodiments, q is from 1 to 7. In certain embodiments, q is from 1 to 8. In certain embodiments, q is from 1 to 9. In certain embodiments, q is from 3 to 8.
[0390] In certain embodiments, q is an integer from 0 to 30, or any range derivable therein. In certain embodiments, q is an integer from 0 to 30, 29, 28, 27, or 26. In certain embodiments, q is an integer from 0 to 25, 24, 23, 22, or 21. In certain embodiments, q is an integer from 0 to 20, 19, 18, 17, or 16. In certain embodiments, q is an integer from 0 to 15, 14, 13, 12, or 11.
[0391] As described above, r is an integer from 1 to 6. In certain embodiments, r is 1. In certain embodiments, r is 2. In certain embodiments, r is 3. In certain embodiments, r is 4. In certain embodiments, r is 5. In certain embodiments, r is 6.
[0392] As mentioned above, when R 28 and R 40 When H, R 32 Is not =0. In certain embodiments, the compound is not rapamycin, as shown below:
[0393]
[0394] In certain embodiments, in Formula Ia or Ic, R 32 =-OC( 1 )-R 32a In certain embodiments, R 32 =-OC( 1 )-R 32a ; where R 32a -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B. In certain embodiments, in Formula Ia or Ic, R 28 -C(=Z 1 )-R 28a In certain embodiments, R 28 -C(=Z 1 )-R 28a ; where R 28a -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B. In certain embodiments, in Formula Ia or Ic, R 40 -C(=Z 1 )-R 40a In certain embodiments, R 40 -C(=Z 1 )-R40a , where R 40a -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0395] The present invention provides a compound of Formula Ia or Ic, or a pharmaceutically acceptable salt or tautomer thereof, having one, two, or three of the following characteristics:
[0396] a)R 32 = -OC( 1 )-R 32a ;
[0397] b)R 28 -C(=Z 1 )-R 28a ;
[0398] c)R 40 -C(=Z 1 )-R 40a .
[0399] The present invention provides a compound of Formula Ia or Ic, or a pharmaceutically acceptable salt or tautomer thereof, having one, two, or three of the following characteristics:
[0400] a)R 32 = -OC( 1 )-R 32a ; where R 32a -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B;
[0401] b)R 28 -C(=Z 1 )-R 28a ; where R 28a -A 1 -L 1 -A 2 -B; -A 1 -A2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B;
[0402] c)R 40 -C(=Z 1 )-R 40a , where R 40a -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0403] The present invention provides a compound of Formula Ia or Ic, or a pharmaceutically acceptable salt or tautomer thereof, having one, two, or three of the following characteristics:
[0404] a)R 40 -C(=Z 1 )-R 40a ;
[0405] b)R 40a -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; -L 2 -A 1 -L 1 -A 2 -L 3 -B;
[0406] c)R 32 For-OR 3 , such as -OH.
[0407] The present invention provides a compound of Formula Ia or Ic, or a pharmaceutically acceptable salt or tautomer thereof, having one, two, three, or four of the following characteristics:
[0408] a)R 28a 、R 32a and R 40a One of them is -A 1 -L 1 -A 2 -B;
[0409] b)A 1 for non-existence;
[0410] c)A 2 for non-existence;
[0411] d)L 1 for
[0412] e) B is
[0413] f)B 1 for NR 3 -(C(R 3 )2) n -or
[0414] g)R 4 is optionally replaced by -N(R 3 )2OR-OR 3 Substituted 5- to 12-membered heteroaryl.
[0415] The present invention provides a compound of the following formula:
[0416]
[0417] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:
[0418] a)Z 1 is O;
[0419] b)A 1 for non-existence;
[0420] c)L 1 for
[0421] d) B is
[0422] e)B 1 for NR 3 -(C(R 3 )2) n -or
[0423] f)R 4 is optionally replaced by -N(R 3 )2OR-OR 3 substituted 5- to 12-membered heteroaryl; and
[0424] g)R 32 =O.
[0425] In the above, R 40a Can be -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0426] The present invention provides a compound of the following formula:
[0427]
[0428] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:
[0429] a)Z 1 is O;
[0430] b)A 1 for non-existence;
[0431] c)L 1 for
[0432] d) B is
[0433] e)B 1 for NR 3 -(C(R 3 )2) n -or
[0434] f)R 4 is optionally replaced by -N(R 3 )2OR-OR 3 substituted 5- to 12-membered heteroaryl; and
[0435] g)R 32 It is -OH.
[0436] In the above, R 40a Can be -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0437] The present invention provides a compound of the following formula:
[0438]
[0439] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:
[0440] a)Z 1 is O;
[0441] b)A 1 for
[0442] c)L 1 for
[0443] d) B is
[0444] e)B 1 for NR 3 -(C(R 3 )2) n -or
[0445] f)R 4 is optionally replaced by -N(R 3 )2OR-OR 3 substituted 5- to 12-membered heteroaryl; and
[0446] g)R 32 =O.
[0447] In the above, R 40a Can be -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0448] The present invention provides a compound of the following formula:
[0449]
[0450] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:
[0451] a)Z 1 is O;
[0452] b)A 1 for non-existence;
[0453] c)L 1 for
[0454] d) B is
[0455] e)B 1 for NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)-, wherein the arylene group is optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen, or hydroxy;
[0456] f)R 4 is optionally replaced by -N(R 3 )2OR-OR 3 substituted 5- to 12-membered heteroaryl; and
[0457] g)R 32 It is -OH.
[0458] In the above, R 40a Can be -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0459] The present invention provides a compound of the following formula:
[0460]
[0461] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:
[0462] a)Z 1 is O;
[0463] b)A 1 for
[0464] c)A 2 for
[0465] d)L 1 for
[0466] e) B is
[0467] f)B 1 for NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)-, wherein the arylene group is optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen, or hydroxy;
[0468] g)R 4 is optionally replaced by -N(R 3 )2OR-OR 3 substituted 5- to 12-membered heteroaryl; and
[0469] h)R 32 It is -OH.
[0470] In the above, R 40a Can be -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B or -L 2 -A 1 -L 1 -A 2 -L 3 -B.
[0471] In certain embodiments, in Formula Ia or Ic, R 40a is any organic moiety, which can have a molecular weight (e.g., the sum of the atomic weights of the atoms of the substituents) of less than 15 g / mol, 50 g / mol, 100 g / mol, 150 g / mol, 200 g / mol, 250 g / mol, 300 g / mol, 350 g / mol, 400 g / mol, 450 g / mol, or 500 g / mol.
[0472] In certain embodiments, the present invention provides a compound selected from the group consisting of, or a pharmaceutically acceptable salt or tautomer thereof,
[0473]
[0474]
[0475]
[0476]
[0477]
[0478]
[0479]
[0480]
[0481]
[0482]
[0483]
[0484]
[0485]
[0486]
[0487]
[0488] In certain embodiments, the present invention provides a compound selected from the group consisting of, or a pharmaceutically acceptable salt or tautomer thereof,
[0489]
[0490]
[0491]
[0492]
[0493]
[0494]
[0495]
[0496]
[0497]
[0498]
[0499]
[0500]
[0501]
[0502]
[0503] In certain embodiments, the present invention provides a compound selected from the group consisting of, or a pharmaceutically acceptable salt or tautomer thereof,
[0504]
[0505]
[0506]
[0507]
[0508]
[0509] The compounds of the present invention may include pharmaceutically acceptable salts of the compounds disclosed herein. Representative "pharmaceutically acceptable salts" may include, for example, water-soluble and water-insoluble salts, such as acetate, aminostilbenesulfonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromate, butyrate, calcium salt, calcium edetate, dextrorotatory camphorsulfonic acid, carbonate, hydrochloride, citrate, clavulanate, dihydrochloride, edetate, edisulphonate, propionate lauryl sulfate (estolate), ethanesulfonate, fumarate, glucose enanthate, gluconate, glutamate, glycolyl p-aminophenylarsonic acid salt (glycollylarsanilate), hexafluorophosphate, hexylresorcinol salt, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, Iodide, isethionate, lactate, lactobionate, laurate, magnesium salt, malate, maleate, mandelate, methanesulfonate, methyl bromide, methylnitrate, methylsulfate, mucate, naphthenate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate, 1,1-methylene-bis-2-hydroxy-3-naphthoate, einbonate, pantothenate, phosphate / hydrogen phosphate, picrate, polygalacturonate, propionate, p-toluenesulfonic acid, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethyl iodide, and valerate.
[0510] "Pharmaceutically acceptable salts" may also include both acid and base addition salts. "Pharmaceutically acceptable acid addition salts" may refer to those salts that retain the biological effectiveness and properties of the free bases which are not biologically or otherwise undesirable and which may be formed using inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, decanoic acid, hexanoic acid, octanoic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid , formic acid, fumaric acid, galactonic acid, gentisic acid, glucoheptanoic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphate, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, l-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, etc.
[0511] "Pharmaceutically acceptable base addition salts" may refer to salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts can be prepared by addition of inorganic or organic bases to the free acids. Salts derived from inorganic bases may include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. For example, inorganic salts may include, but are not limited to, ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases can include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, denanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrazine, choline, betaine, phenethylbenzylamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like.
[0512] Unless otherwise indicated, structures depicted herein may also include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures differ in that a hydrogen atom is replaced by a deuterium or tritium, or a carbon atom is replaced by a 13 C or 14 C replacement, or nitrogen atoms15 N replacement, or oxygen atoms 17 O or 18 O-substituted compounds are within the scope of the present invention. Such isotopically labeled compounds are useful as research or diagnostic tools.
[0513] In some embodiments, one or more deuterium atoms can be introduced into the PEG portion of any compound of the invention. Starting from commercially available starting materials (such as isotopically enriched hydroxylamine building blocks), the mechanism of such modifications is known in the art. In some embodiments, tritium or deuterium can be introduced at the C32 position of the compounds of the invention using, for example, commercially available isotopically pure reducing agents and methods known to those skilled in the art. In some embodiments, tritium or deuterium can be introduced at the C32 position of the compounds of the invention using commercially available materials and methods known to those skilled in the art. 14 In some embodiments, isotopes (such as deuterium or tritium) can be introduced into the R of a compound of Formula Ia, Ic, I, or II using commercially available starting materials and methods known to those skilled in the art. 40a substituent.
[0514] Methods for synthesizing the disclosed compounds
[0515] The compounds of the present invention can be prepared by a variety of methods, including standard chemistry. Suitable synthetic routes are described in the reaction schemes provided below.
[0516] Any of the compounds of the formula described herein can be prepared by methods known in the art of organic synthesis, such as those described in part by the following synthetic reaction schemes and examples. In the following reaction schemes, it should be fully understood that, where necessary, protective groups for sensitive or reactive groups are employed according to general principles or chemistry. Protective groups are manipulated according to standard methods of organic synthesis (TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis," 3rd edition, Wiley, New York 1999). These groups are removed at a convenient stage of compound synthesis using methods obvious to those skilled in the art. The selection method, reaction conditions, and the order in which they are performed should be consistent with the preparation of a pharmaceutically acceptable salt or tautomer of a compound of Formula I, Ia, Ib, II, or IIb, or any of the above.
[0517] Compounds of any of the formulae described herein can be prepared by methods that avoid the use of metal-mediated cycloaddition reactions that require the use of azide-containing compounds. Azide-containing compounds present potential safety hazards associated with their preparation and storage (e.g., explosion due to high-energy decomposition). The reaction schemes herein can also avoid the use of copper or ruthenium metal in the penultimate or final synthetic step, which can be advantageous. Avoiding the use of copper or ruthenium metal in the penultimate or final synthetic step reduces the likelihood of contamination of the final compound with undesirable metallic impurities.
[0518] Because rapamycin can be an expensive starting material, a good reaction yield is advantageous. The reaction scheme herein provides better yields than other reaction schemes. In the reaction scheme herein, alkylation at the C40-hydroxyl group of rapamycin is unnecessary, which advantageously provides an overall yield of up to 5-fold higher in the preparation of divalent compounds from rapamycin compared to other reaction schemes.
[0519] There are additional synthetic improvements associated with better yields. Avoiding the need for alkylation at the C40-hydroxy group results in up to a 5-fold improvement in the overall yield in the preparation of divalent compounds from rapamycin.
[0520] Those skilled in the art will know whether a stereocenter is present in any one of the compounds of this invention. Therefore, the present invention may include possible stereoisomers (unless specified in the synthesis) and may include not only racemic compounds, but also individual enantiomers and / or diastereomers. When the desired compound is a single enantiomer or diastereomer, it can be synthesized by stereospecificity or obtained by the splitting of the final product or any convenient intermediate. The splitting of the final product, intermediate or starting material can be achieved by any suitable method known in the art. See, for example, " Stereochemistry of Organic Compounds " (Wiley-Interscience, 1994) by E.L. Eliel, S.H. Wilen and L.N. Mander.
[0521] Preparation of compounds
[0522] The compounds described herein can be prepared from commercially available starting materials or synthesized using known organic, inorganic and / or enzymatic methods.
[0523] The compounds of the present invention can be prepared by a variety of methods well known to those skilled in the art of organic synthesis. For example, the compounds of the present invention can be synthesized using the following methods, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as will be appreciated by those skilled in the art. These methods may include, but are not limited to, those described below.
[0524] The term "tautomer" may refer to a group of compounds that have the same number and type of atoms, but different bond connections, and are in equilibrium with each other. A "tautomer" is a single member of this group of compounds. Typically, a single tautomer is drawn, but it is understood that this single structure can represent all possible tautomers that may exist. An example may include enol-keto tautomerism. When a ketone is drawn, it is understood that both the enol and keto forms are part of the present invention.
[0525] In addition to the tautomers that may exist at all amide, carbonyl, and oxime groups within compounds of Formula I, Ia, Ib, Ic, II, or IIb, compounds in this family readily interconvert via ring-opening species between two major isomeric forms, referred to as pyran and oxepane isomers (shown below). This interconversion can be facilitated by magnesium ions, mildly acidic conditions, or alkylamine salts, as described in the following references: i) Hughes, PF, Musser, J.; Conklin, M., Russo, R. 1992. Tetrahedron Lett. 33(33):4739-32. ii) Zhu, T. 2007. U.S. Patent 7,241,771; Wyeth. iii) Hughes, PF 1994. U.S. Patent 5,344,833; American Home Products Corp. The following schemes show the interconversion between pyran and oxepane isomers in compounds of Formula I, Ia, Ib, Ic, II, or lib.
[0526]
[0527] Because this interconversion occurs under mild conditions and the position of thermodynamic equilibrium can vary between different members of the compound of Formula I, Ia, Ib, Ic, II or IIb, the compound of Formula I, Ia, Ib, Ic, II or IIb encompasses both isomers. For the sake of brevity, all intermediates and pyranomeric forms of the compound of Formula I, Ia, Ib, Ic, II or IIb are shown.
[0528] General assembly method for bifunctional rapalogs
[0529] Regarding the following regimens, rapamycin is of the formula RAP,
[0530]
[0531] where R 16 -OCH3; R 26 =O; R 28 is -OH; R 32 =O; and R 40"Rapalog" refers to an analog or derivative of rapamycin. For example, with respect to the following schemes, a rapamycin analog may be present at any position (such as R 16 、R 26 、R 28 、R 32 or R 40 ) is a rapamycin substituted at the position of succinylcholine. Active site inhibitors (AS inhibitors) are active site mTOR inhibitors. In certain embodiments, the AS inhibitor is described by B in Formula I, Ia, Ib, Ic, II, or IIb.
[0532] Series 1 bifunctional rapamycin analogs
[0533] The general structure of a series 1 bifunctional rapamycin analog is shown in Scheme 1 below. For these types of bifunctional rapamycin analogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7, and r = 1 to 6. The linker amine may include substituents such as R = H and C1-C6 alkyl groups. The carbamate moiety (where Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.
[0534] Scheme 1. Series 1 bifunctional rapamycin analogs.
[0535]
[0536] Series 2 bifunctional rapamycin analogs
[0537] The general structure of a series 2 bifunctional rapalog is shown below in Scheme 2. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The pre-linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.
[0538] Scheme 2. Series 2 bifunctional rapamycin analogs.
[0539]
[0540] Series 3 bifunctional rapamycin analogs
[0541] The general structure of a series 3 bifunctional rapamycin analog is shown below in Scheme 3. For these types of bifunctional rapamycin analogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The latter linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.
[0542] Scheme 3. Series 3 Bifunctional Rapalogs
[0543]
[0544] Series 4 bifunctional rapamycin analogs
[0545] The general structure of a series 4 bifunctional rapalog is shown in Scheme 4 below. For these types of bifunctional rapalogs, the linker may comprise variations where q = 0 to 30, such as q = 1 to 7. The linker amine may comprise substituents such as R = H and C1-C6 alkyl. The front linker amine and the back linker amine may each comprise substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.
[0546] Scheme 4. Series 4 Bifunctional Rapalogs
[0547]
[0548] Series 5 bifunctional rapamycin analogs
[0549] The general structure of a series 5 bifunctional rapalog is shown below in Scheme 5. For these types of bifunctional rapalogs, the front linker amine may contain a substituent such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.
[0550] Scheme 5. Series 5 Bifunctional Rapaxoids
[0551]
[0552] Series 6 bifunctional rapamycin analogs
[0553] The general structure of a series 6 bifunctional rapalog is shown below in Scheme 6. For these types of bifunctional rapalogs, the linker may comprise variations where q = 0 to 30, such as q = 1 to 7. The linker amine may comprise substituents such as R = H and C1-C6 alkyl. The latter linker amine may comprise substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.
[0554] Scheme 6. Series 6 Bifunctional Rapaxoids
[0555]
[0556] Series 7 bifunctional rapamycin analogs
[0557] The general structure of a series 7 bifunctional rapalogs is shown below in Scheme 7. For these types of bifunctional rapalogs, the linker may comprise variations where q = 0 to 30, such as q = 1 to 7. The linker amine may comprise substituents such as R = H and C1-C6 alkyl. The front linker amine and the back linker amine may each comprise substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1=O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.
[0558] Scheme 7. Series 7 Bifunctional Rapaxoids
[0559]
[0560] Series 8 bifunctional rapamycin analogs
[0561] The general structure of a series 8 bifunctional rapamycin analog is shown below in Scheme 8. For these types of bifunctional rapamycin analogs, the linker may contain variations where q = 0 to 30, such as q = 1 to 7. The linker amine may contain substituents such as R = H and C1-C6 alkyl. The latter linker amine may contain substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.
[0562] Scheme 8. Series 8 Bifunctional Rapaxoids
[0563]
[0564] Pharmaceutical composition
[0565] Another aspect provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the present invention or a pharmaceutically acceptable salt or tautomer thereof.
[0566] In embodiments of pharmaceutical compositions, the compound of the present invention, or a pharmaceutically acceptable salt or tautomer thereof, may be included in a therapeutically effective amount.
[0567] Administration of the disclosed compounds or compositions can be achieved via any mode of administration of the therapeutic agent. These modes can include systemic or local administration, such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal, topical, intrathecal or intracranial modes of administration.
[0568] In certain embodiments, administration may include oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or implantation of a slow-release device (e.g., a mini-osmotic pump) into an individual. Administration may be by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intraventricular and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like. The compositions of the present invention may be delivered transdermally, by topical routes, formulated into applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jelly, pigments, powders, and aerosols. Oral formulations include tablets, pills, powders, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, and the like suitable for patient ingestion. Solid form formulations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form formulations include solutions, suspensions, and emulsions, for example, water or water / propylene glycol solutions. The compositions of the present invention may additionally comprise components that provide sustained release and / or comfort. Such components include high molecular weight anionic mucus-mimicking polymers, gelatinized polysaccharides, and finely divided drug carrier substrates. These components are discussed in more detail in U.S. Patents Nos. 4,911,920, 5,403,841, 5,212,162, and 4,861,760. The entire contents of these patents are incorporated herein by reference for all purposes. The compositions of the present invention may also be delivered in the form of microspheres for slow release in vivo. For example, microspheres can be administered via intradermal injection of drug-containing microspheres that are slowly released subcutaneously (see Rao, J. Biomater Set Polym., ed. 7:623-645, 1995); as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997). In another embodiment, formulations of the compositions of the present invention can be delivered using liposomes that fuse with cell membranes, or by endocytosis, i.e., by employing receptor ligands attached to the liposomes that bind to surface membrane protein receptors of the cell, leading to endocytosis. By using liposomes, particularly where receptor ligands specific for the target cell are carried on the liposome surface or are otherwise preferentially directed to a particular organ, one can focus delivery of the compositions of the present invention to target cells in vivo.(See, eg, Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46:1576-1587, 1989.) The compositions of the present invention can also be delivered as nanoparticles.
[0569] Depending on the intended mode of administration, the disclosed compounds or pharmaceutical compositions can be in solid, semisolid or liquid dosage forms, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions or the like, sometimes in unit doses and in accordance with conventional pharmaceutical practices. Likewise, they can also be administered in intravenous (both pills and infusions), intraperitoneal, intrathecal, subcutaneous or intramuscular forms and all forms of use well known to those skilled in the art of medicine.
[0570] Illustrative pharmaceutical compositions are tablets and gelatin capsules comprising a compound of the invention and a pharmaceutically acceptable carrier, such as a) a diluent, for example, purified water, a triglyceride (such as a hydrogenated or partially hydrogenated vegetable oil or a mixture thereof), corn oil, olive oil, sunflower oil, safflower oil, fish oil (such as EPA or DHA) or an ester or triglyceride or a mixture thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and / or glycine; b) a lubricant, for example, silica, talc, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and / or or polyethylene glycol; also used in tablets; c) if necessary, binders, for example, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars (such as glucose or β-lactose), corn sweeteners, natural and synthetic gums (such as acacia, tragacanth or sodium alginate), waxes and / or polyvinylpyrrolidone; d) disintegrants, for example, starch, agar, methylcellulose, bentonite, xanthan gum, alginic acid or its sodium salt, or effervescent mixtures; e) adsorbents, colorants, flavorings and sweeteners; f) emulsifiers or dispersants, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifiers; and / or g) agents that enhance compound absorption, such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.
[0571] Liquid (especially injectable) compositions can be prepared, for example, by dissolution, dispersion, etc. For example, the disclosed compounds are dissolved in a pharmaceutically acceptable solvent (such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, etc.) or mixed with to form an injectable isotonic solution or suspension. Proteins (such as albumin, chylomicrons, or serum proteins) can be used to dissolve the disclosed compounds.
[0572] The disclosed compounds may also be formulated as suppositories, which may be prepared from fatty emulsions or suspensions using polyalkylene glycols, such as propylene glycol, as carriers.
[0573] The disclosed compounds can also be administered in the form of liposome delivery systems (such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles). Liposomes can be formed from various phospholipids (including cholesterol, stearylamine, or phosphatidylcholine). In some embodiments, the membrane of the lipid component is hydrated with an aqueous solution of the drug to form a lipid layer that encapsulates the drug, as described, for example, in U.S. Patent No. 5,262,564, the contents of which are incorporated herein by reference.
[0574] The disclosed compounds can also be delivered by using monoclonal antibodies as individual carriers, and the disclosed compounds are coupled to such carriers. The disclosed compounds can also be coupled with water-soluble polymers as targetable drug carriers. Such polymers may include polyvinyl pyrrolidone, pyran copolymer, polyhydroxypropyl methacrylamide-phenol, polyhydroxyethyl asparagine phenol, or polyethylene oxide polylysine substituted with palmitoyl residues. In addition, the disclosed compounds can be coupled with a class of biodegradable polymers (e.g., crosslinked or amphiphilic block copolymers of polylactic acid, polycaprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and hydrogels) that can be used to achieve controlled release of drugs. In one embodiment, the disclosed compounds are non-covalently bound to a polymer (e.g., a polycarboxylic acid polymer or a polyacrylate).
[0575] Parenteral injectable administration is generally for subcutaneous, intramuscular or intravenous injection and infusion. Injectables can be prepared in conventional forms as liquid solutions or suspensions or solid forms suitable for dissolution in liquid prior to injection.
[0576] Another aspect of the present invention relates to a pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt or tautomer thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further include an excipient, a diluent, or a surfactant.
[0577] The compositions can each be prepared according to conventional mixing, granulating or coating methods, and the pharmaceutical compositions of the present invention can contain about 0.1% to about 99%, about 5% to about 90%, or about 1% to about 20% of the disclosed compound by weight or volume.
[0578] The compounds described herein can be used in combination with other active agents known to be useful in treating cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, fungal infections, or transplant rejection, or with adjuvants that may not be effective alone but may enhance the efficacy of the active agents. The compounds described herein can be used in combination with other active agents known to be longevity agents or anti-aging agents.
[0579] In embodiments of the pharmaceutical composition, the pharmaceutical composition may include a second agent (e.g., a therapeutic agent). In embodiments of the pharmaceutical composition, the pharmaceutical composition may include a therapeutically effective amount of a second agent (e.g., a therapeutic agent). In certain embodiments, the second agent is an anticancer agent. In certain embodiments, the second agent is an immunotherapeutic agent. In certain embodiments, the second agent is an immuno-oncology agent. In certain embodiments, the second agent is an anti-autoimmune disease agent. In certain embodiments, the second agent is an anti-inflammatory disease agent. In certain embodiments, the second agent is an anti-neurodegenerative disease agent. In certain embodiments, the second agent is an anti-metabolic disease agent. In certain embodiments, the second agent is an anti-cardiovascular disease agent. In certain embodiments, the second agent is an anti-aging agent. In certain embodiments, the second agent is a longevity agent. In certain embodiments, the second agent is an agent for treating or preventing transplant rejection. In certain embodiments, the second agent is an agent for treating or preventing fungal infection. In certain embodiments, the second agent is an immune system suppressant. In certain embodiments, the second agent is an mTOR regulator. In certain embodiments, the second agent is an mTOR inhibitor. In certain embodiments, the second agent is an active site mTOR inhibitor. In certain embodiments, the second agent is rapamycin. In certain embodiments, the second agent is a rapamycin analog. In certain embodiments, the second agent is an mTOR pathway inhibitor. In certain embodiments, the second agent is a CDK4 / 6 inhibitor; an anti-PD1 / PD-L1, PI3K inhibitor; or a Ras inhibitor.
[0580] "Anticancer" or "anticancer drug" is used according to its ordinary meaning and refers to a composition (e.g., compound, drug, antagonist, inhibitor, modulator) that has anti-tumor properties or the ability to inhibit cell growth or proliferation. In some embodiments, the anticancer agent is a chemotherapeutic agent. In some embodiments, the anticancer agent is an agent approved for the treatment of cancer by the FDA or similar regulatory agencies of countries other than the USA. Examples of anticancer agents include, but are not limited to, rapamycin, rapamycin analogs, bevacizumab, PP242, ΓΝ128, MLN0128, antiandrogens (e.g., Casodex, Flutamide, MDV3100, or ARN-509), MEK (e.g., MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g., XL518, CI-1040, PD035901, selumetinib / AZD6244, GSK1 120212 / trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa), nitrosoureas, nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, chlorambucil, melphalan), ethyleneimine and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine), streptozocin (e.g., streptozocin), reptozocin), triazenes (decarbazine), antimetabolites (e.g., 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analogs (e.g., methotrexate), pyrimidine analogs (e.g., fluorouracil, floxuridine, cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.),Plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP), 16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g., cisplatin, oxaloplatin, carboplatin, ), anthracenediones (e.g., mitoxantrone), substituted ureas (e.g., hydroxyurea), methylhydrazine derivatives (e.g., procarbazine), adrenocortical hormone inhibitors (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunomycin, doxorubicin, bleomycin), enzymatic (e.g., L-asparaginase), mitogen-activated protein kinase signaling inhibitors (e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin or LY294002), mTOR inhibitors, antibodies (e.g., rituxan), 5-aza-2'-deoxycytidine, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldanamycin, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), bortezomib, trastuzumab, anastrozole; angiogenesis inhibitors; antiandrogens,Antiestrogens; antisense oligonucleotides; apoptosis gene modulators; apoptosis regulators; arginine deaminase; BCR / ABL antagonists; beta-lactam derivatives; bFGF inhibitors; bicalutamide; camptothecin derivatives; casein kinase inhibitors (ICOS); clomifene analogs; dacliximab; dexamethasone; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; non- Finasteride; fludarabine; fludoxorubicin hydrochloride; texaphyrin; gallium nitrate; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; immunostimulatory peptides; insulin-like growth factor-1 receptor inhibitors; interferon agonists; interferon; interleukin; letrozole; leukemia inhibitory factor; leukocyte interferon alpha; leuprolide + estrogen + progesterone; leuprorelin; matrilysin inhibitors; matrix metalloproteinase inhibitors; MIF inhibitors; mifepristone tone; mismatched double-stranded RNA; monoclonal antibody; mycobacterial cell wall extract; nitric oxide modulator; oxaliplatin; panomifene; pentrozole; phosphatase inhibitor; plasminogen activator inhibitor; platinum complex; platinum compound; prednisone; proteasome inhibitor; protein A-based immunomodulator; protein kinase C inhibitor; protein tyrosine phosphatase inhibitor; purine nucleotide phosphatase inhibitor; ras farnesyl protein transferase inhibitor; ras inhibitor; ras-GAP inhibitor; ribozyme; signal transduction inhibitor; signal transduction regulator; single-chain antigen binding protein; stem cell inhibitor; stem cell division inhibitor steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) (such as goserelin or leuprolide), adrenocortical steroids (e.g., prednisolone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinyl estradiol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone propionate,Fluanilamide), anti-androgens (e.g., flutamide), immunostimulants (e.g., Calmette-Guerin bacillus (BCG), levamisole, interleukin-2, α-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-Pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., conjugated to, U1 ln、 90 Y or 131 I anti-CD20 monoclonal antibody, etc.), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or treatment (e.g., gefitinib, TM ), erlotinib (Tarceva TM ), cetuximab (Erbitux TM ), lapatinib (Tykerb TM ), panitumumab (Vectibix TM ), vandetanib (Caprelsa TM), afatinib / BIBW2992, CI-1033 / canertinib, neratinib / HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib / PF299804, OSI-420 / desmethyl erlotinib, AZD8931, AEE788, pelitinib / EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, pyrrolobenzodiazepines (e.g., tomaymycin), carboplatin, CC-1065 and CC-1065 analogs (including amino-CBI), nitrogen mustards (such as chlorambucil and melphalan), dolastatin and dolastatin analogs (including auristatin: for example, monomethyl auristatin E), anthracyclines (such as doxorubicin, daunomycin, etc.), duocarmycin and duocarmycin analogs, enediynes (such as neocarzinostatin and calicheamicin), leptosporin, and leptomycin. antagonists, such as lincomycin, lincomycin derivatives, maytansinoids and maytansinoid analogs (e.g., mertansine), methotrexate, mitomycin C, taxoids, vinblastine alkaloids (such as vinblastine and vincristine), epothilones (e.g., epothilone B), camptothecins and their clinical analogs topotecan and irinotecan, ΓN�K128, PP242, PP121, MLN0128, AZD8055, AZD2014, VP-BEZ235, BGT226, SF1 126, Torin 1, Torin 2, WYE687, WYE 687 salt (e.g., hydrochloride), PF04691502, PI-103, CC-223, OSI-027, XL388, KU-0063794, GDC-0349, PKI-587, rapamycin, deforolimus (AP23573, MK-8669, ridaforolimus), temsirolimus (CCI-779), ABT478, everolimus (RAD001), and the like.
[0581] mTOR and treatment options
[0582] The term "mTOR" refers to the protein "mechanistic target of rapamycin (serine / threonine kinase)" or "mammalian target of rapamycin." The term "mTOR" may refer to the nucleotide sequence or protein sequence of human mTOR (e.g., Entrez2475, Uniprot P42345, RefSeq NM_004958, or RefSeq NP_004949) (SEQ ID NO: 1). The term "mTOR" may encompass both the wild-type form of the nucleotide sequence or protein and any mutations thereof. In some embodiments, "mTOR" is wild-type mTOR. In some embodiments, "mTOR" is one or more mutant forms. The term "mTOR" XYZ may refer to the nucleotide sequence or protein of a mutant mTOR, wherein the Y-numbered amino acid of mTOR that normally has amino acid X in the wild-type has amino acid Z in the mutant. In embodiments, the mTOR is human mTOR. In embodiments, the mTOR has a nucleotide sequence corresponding to reference number GL206725550 (SEQ ID NO: 2). In embodiments, the mTOR has a nucleotide sequence corresponding to RefSeq In an embodiment, the mTOR has the nucleotide sequence of NM_004958.3 (SEQ ID NO: 2). In an embodiment, the mTOR has the protein sequence corresponding to reference number GL4826730 (SEQ ID NO: 1). In an embodiment, the mTOR has the protein sequence corresponding to RefSeq NP_004949.1 (SEQ ID NO: 1). In an embodiment, the mTOR has the following amino acid sequence:
[0583]
[0584] In embodiments, the mTOR is a mutant mTOR. In embodiments, the mutant mTOR is associated with a disease not associated with wild-type mTOR. In embodiments, the mTOR may comprise at least one amino acid mutation compared to the above sequence (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations, or any range derivable therein).
[0585] The term "mTORC1" refers to a protein complex comprising mTOR and Raptor (mTOR regulatory-associated protein). mTORC1 may also comprise MLST8 (mammalian lethal factor containing SEC 13 protein 8), PRAS40, and / or DEPTOR. mTORC1 may serve as a nutrient / energy / redox sensor and regulator of protein synthesis. The terms "mTORC1 pathway" or "mTORC1 signaling pathway" may refer to a cellular pathway comprising mTORC1. The mTORC1 pathway includes pathway components upstream and downstream of mTORC1. The mTORC1 pathway is a signaling pathway regulated by regulating mTORC1 activity. In embodiments, the mTORC1 pathway is a signaling pathway regulated by regulating mTORC1 activity but not by regulating mTORC2 activity. In embodiments, the mTORC1 pathway is a signaling pathway that is regulated to a greater extent by regulating mTORC1 activity than by regulating mTORC2 activity.
[0586] The term "mTORC2" refers to a protein complex comprising mTOR and RICTOR (rapamycin-insensitive partner of mTOR). mTORC2 may also comprise GβL, mSIN1 (mammalian stress-initiated protein kinase interacting protein 1), Protor1 / 2, DEPTOR, TTI1 and / or TEL2. mTORC2 can regulate cellular metabolism and the cytoskeleton. The term "mTORC2 pathway" or "mTORC2 signaling pathway" may refer to a cellular pathway comprising mTORC2. The mTORC2 pathway includes pathway components upstream and downstream from mTORC2. The mTORC2 pathway is a signal transduction pathway regulated by regulating mTORC2 activity. In an embodiment, the mTORC2 pathway is a signal transduction pathway regulated by regulating mTORC2 activity but not by regulating mTORC1 activity. In an embodiment, the mTORC2 pathway is a signal transduction pathway that is regulated to a greater extent by regulating mTORC2 activity than by regulating mTORC1 activity.
[0587] The term "rapamycin" or "sirolimus" refers to a macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus. Rapamycin prevents the activation of T cells and B cells. Rapamycin has the IUPAC name (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexahydro-9,27-dihydroxy-3-[( 1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1c][1,4]-oxazacyclotriacontane-1,5,11,28,29(4H,6H,31H)-pentanone. Rapamycin has the CAS number 53123-88-9. Rapamycin can be synthesized (e.g., by chemical synthesis) or produced using a production method that does not include the use of Streptomyces hygroscopicus.
[0588] "Analog" is used according to its ordinary meaning in chemistry and biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called "reference" compound) but differs in composition, for example, in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or in the absolute stereochemistry of one or more chiral centers of the reference compound (including isomers thereof).
[0589] The term "rapamycin analog" or "rapalog" refers to an analog or derivative (eg, a prodrug) of rapamycin.
[0590] The terms "active site mTOR inhibitor" and "ATP mimetic" refer to compounds that inhibit the activity of mTOR (e.g., kinase activity) and bind to the active site of mTOR (e.g., the ATP binding site, overlaps with the ATP binding site, blocks ATP access to the ATP binding site of mTOR). Examples of active site mTOR inhibitors include, but are not limited to, INK128, PP242, PP121, MLN0128, AZD8055, AZD2014, NVP-BEZ235, BGT226, SF1126, Torin 1, Torin 2, WYE687, WYE 687 salt (e.g., hydrochloride), PF04691502, PI-103, CC-223, OSI-027, XL388, KU-0063794, GDC-0349, and PKI-587. In embodiments, the active site mTOR inhibitor is asTORi. In some embodiments, an "active site inhibitor" may refer to an "active site mTOR inhibitor."
[0591] The term "FKBP" refers to the protein peptidyl-prolyl cis-trans isomerase. For non-limiting examples of FKBP, see Cell Mol Life Sci. 2013 Sep; 70(18): 3243-75. In embodiments, "FKBP" may refer to "FKBP-12" or "FKBP 12" or "FKBP 1A". In embodiments, "FKBP" may refer to a human protein. Included in the term "FKBP" are wild-type and mutant forms of the protein. In embodiments, "FKBP" may refer to a wild-type human protein. In embodiments, "FKBP" may refer to a wild-type human nucleic acid. In embodiments, the FKBP is a mutant FKBP. In embodiments, the mutant FKBP is associated with a disease that is not associated with wild-type FKBP. In embodiments, the FKBP comprises at least one amino acid mutation compared to wild-type FKBP (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations, or any range derivable therein).
[0592] The term "FKBP-12" or "FKBP 12" or "FKBP1A" may refer to the protein "peptidyl-prolyl cis-trans isomerase FKBP 1A". In embodiments, "FKBP-12" or "FKBP 12" or "FKBP 1A" may refer to the human protein. Included in the term "FKBP-12" or "FKBP 12" or "FKBP 1A" are wild-type and mutant forms of the protein. In embodiments, "FKBP-12" or "FKBP 12" or "FKBP 1A" may refer to a protein related to Entrez Gene 2280, OMIM 186945, UniProt P62942, and / or RefSeq (protein) NP_000792 (SEQ ID NO: 3). In embodiments, the reference numbers immediately above may refer to proteins and related nucleic acids known as of the filing date of this application. In embodiments, "FKBP-12" or "FKBP 12" or "FKBP 1A" may refer to a wild-type human protein. In embodiments, "FKBP-12" or "FKBP 12" or "FKBP1A" may refer to a wild-type human nucleic acid. In embodiments, the FKBP-12 is a mutant FKBP-12. In embodiments, the mutant FKBP-12 is associated with a disease not associated with wild-type FKBP-12. In embodiments, the FKBP-12 may comprise at least one amino acid mutation (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations, or any range derivable therein) compared to wild-type FKBP-12. In embodiments, the FKBP-12 has a protein sequence corresponding to Reference Number GI: 206725550. In embodiments, the FKBP-12 has a protein sequence corresponding to RefSeq NP_000792.1 (SEQ ID NO: 3).
[0593] The term "4E-BP1" or "4EBP1" or "EIF4EBP1" refers to the protein "eukaryotic translation initiation factor 4E-binding protein 1". In embodiments, "4E-BP1" or "4EBP1" or "EIF4EBP 1" may refer to the human protein. Included in the term "4E-BP 1" or "4EBP 1" or "EIF4EBP1" are wild-type and mutant forms of the protein. In embodiments, "4E-BP1" or "4EBP1" or "EIF4EBP1" may refer to the protein related to Entrez Gene 1978, OMIM 602223, UniProt Q13541 and / or RefSeq (protein) NP_004086 (SEQ ID NO: 4). In embodiments, the reference numbers directly above may refer to the protein and related nucleic acids known as of the filing date of this application. In embodiments, "4E-BP1" or "4EBP1" or "EIF4EBP1" may refer to a wild-type human protein. In embodiments, "4E-BP1" or "4EBP1" or "EIF4EBP1" may refer to a wild-type human nucleic acid. In embodiments, the 4EBP1 is a mutant 4EBP1. In embodiments, the mutant 4EBP1 is associated with a disease not associated with wild-type 4EBP1. In embodiments, the 4EBP1 may comprise at least one amino acid mutation (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations, or any range derivable therein) compared to wild-type 4EBP1. In embodiments, the 4EBP1 has a protein sequence corresponding to reference number GL4758258. In embodiments, the 4EBP1 has a protein sequence corresponding to RefSeq NP_004086.1 (SEQ ID NO: 4).
[0594] The term "Akt" refers to a serine / threonine-specific protein kinase involved in cellular processes such as glucose metabolism, apoptosis, proliferation, and other functions, also known as "protein kinase B" (PKB) or "Akt1." In embodiments, "Akt" or "AM" or "PKB" may refer to a human protein. Included within the term "Akt" or "Akt1" or "PKB" are wild-type and mutant forms of the protein. In embodiments, "Akt" or "Akt1" or "PKB" may refer to a protein related to Entrez Gene 207, OMIM 164730, UniProt P31749, and / or RefSeq (protein) NP_005154 (SEQ ID NO: 5). In embodiments, the reference numbers immediately above may refer to proteins and related nucleic acids known as of the filing date of this application. In embodiments, "Akt" or "Akt1" or "PKB" may refer to a wild-type human protein. In embodiments, "Akt" or "Akt1" or "PKB" may refer to a wild-type human nucleic acid. In embodiments, the Akt is a mutant Akt. In embodiments, the mutant Akt is associated with a disease not associated with wild-type Akt. In embodiments, the Akt may comprise at least one amino acid mutation compared to wild-type Akt (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations, or any range derivable therein). In embodiments, the Akt has a protein sequence corresponding to reference number GI:62241011. In embodiments, the Akt has a protein sequence corresponding to RefSeqNP_005154.2 (SEQ ID NO:5).
[0595] The present invention provides a method for treating a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compositions or compounds. The present invention provides a method for preventing a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compositions or compounds. The present invention provides a method for reducing the risk of a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compositions or compounds.
[0596] In some embodiments, the disease is a cancer or an immune-mediated disease. In some embodiments, the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neurological cancer, spleen cancer, pancreatic cancer, hematopoietic proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors. In some embodiments, the disease is cirrhosis. In some embodiments, the immune-mediated disease is selected from resistance to transplantation of heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limbs, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis. In certain embodiments, the disease is tuberous sclerosis complex (TSC). In certain embodiments, the disease is pancreatic neuroendocrine tumor (PNET), mantle cell lymphoma (MCL), colorectal cancer or intestinal cancer (CRC), uterine cancer, ovarian cancer, bladder cancer, genitourinary tract cancer or renal cell carcinoma (RCC).
[0597] The present invention provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of one or more disclosed compositions or compounds. In some embodiments, the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, gastric cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, hematopoietic proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors. In some embodiments, the disease is cirrhosis. In certain embodiments, the disease is tuberous sclerosis complex (TSC). In certain embodiments, the disease is pancreatic neuroendocrine tumor (PNET), mantle cell lymphoma (MCL), colorectal or intestinal cancer (CRC), uterine cancer, ovarian cancer, bladder cancer, genitourinary tract cancer, or renal cell carcinoma (RCC).
[0598] In certain embodiments, cancer includes human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, and the like, including solid and lymphoid carcinomas, renal cancer, breast cancer, lung cancer, bladder cancer, colon cancer, ovarian cancer, prostate cancer, pancreatic cancer, stomach cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, testicular cancer, glioma, esophageal cancer, and liver cancer (including hepatocarcinoma), lymphomas (including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma, small cell lymphoma, and large cell lymphoma), Hodgkin's lymphoma), leukemias (including AML, ALL, and CML), or multiple myeloma. In certain embodiments, the disease is multiple myeloma. In certain embodiments, the disease is breast cancer. In certain embodiments, the disease is triple-negative breast cancer.
[0599] In certain embodiments, cancer includes cancers, neoplasms, or malignancies found in mammals (e.g., humans), including leukemias, carcinomas, and sarcomas. Exemplary cancers that can be treated with the compounds or methods provided herein include prostate cancer, thyroid cancer, endocrine system cancer, brain cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, liver cancer, kidney cancer, lung cancer, non-small cell lung cancer, melanoma, mesothelioma, ovarian cancer, sarcoma, gastric cancer, uterine cancer, medulloblastoma, colorectal cancer, and pancreatic cancer. Other examples may include Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, essential thrombocythemia, essential macroglobulinemia, primary brain tumor, malignant pancreatic insulinoma, malignant carcinoid, bladder cancer, premalignant skin lesions, testicular cancer, lymphoma, thyroid cancer, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenocortical carcinoma, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer / medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.
[0600] In certain embodiments, the disease is a leukemia. The term "leukemia" broadly refers to progressive, malignant diseases of blood-forming organs and is generally characterized by abnormal proliferation and development of white blood cells and their precursors in the blood and bone marrow. Leukemias are generally clinically classified based on: (1) the duration and characteristics of the disease, whether acute or chronic; (2) the cell type involved; myeloid (myeloid), lymphoid (lymphogenic), or monocytic; and (3) whether the number of abnormal cells in the blood leukemia or leukopenia (hyperleukemia) is increased or not. Exemplary leukemias that can be treated with the compounds or methods provided herein include, for example, acute non-lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute promyelocytic leukemia, adult T-cell leukemia, leukopenic leukemia, leukemic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, chronic myelogenous leukemia, leukemia cutis, embryonic leukemia, eosinophilic leukemia, Gross' leukemia, hairy cell leukemia, hemoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic Leukemia, lymphoid leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenic leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myelomorphic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasma cell leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.
[0601] In certain embodiments, the disease is a sarcoma. The term "sarcoma" generally refers to a tumor composed of a substance such as embryonic connective tissue and generally composed of tightly packed cells embedded in a fibrous or homogeneous substance. Sarcomas that can be treated with the compounds or methods provided herein include chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, liposarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chlorosarcoma, choriocarcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, fibrosarcoma, fibroblastic ... cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosauroma, malignant mesenchymal sarcoma, parosteal sarcoma, reticulum cell sarcoma, Rous sarcoma, serosal cystic sarcoma, synovial sarcoma, or telangiectatic sarcoma.
[0602] In certain embodiments, the disease is melanoma. The term "melanoma" means a tumor produced by the melanocyte system of the skin and other organs. Melanomas that can be treated with the compounds or methods provided herein include, for example, acral-lentiginous melanoma, non-melanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungual melanoma, or superficial spreading melanoma.
[0603] In certain embodiments, the disease is cancer.The term "cancer" refers to a malignant new growth composed of epithelial cells that tends to infiltrate surrounding tissues and give rise to metastases.Exemplary cancers that can be treated with the compounds or methods provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinar carcinoma, adenoid carcinoma, adenoid cystic carcinoma, adenocarcinoma, adrenal cortical carcinoma, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma (carcinoma basocellulare), basaloid carcinoma, basosquamous cell carcinoma, bronchoalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocarcinoma, choriocarcinoma, colloid carcinoma, comedocarcinoma, uterine corpus carcinoma, cribriform carcinoma, armor carcinoma, cutaneous carcinoma, cylindrical carcinoma, cylindrical cell carcinoma, ductal carcinoma, carcinoma durum, embryonal carcinoma, encephalioid carcinoma, epidermoid carcinoma, epithelial adenoid carcinoma, exophytic carcinoma, exo-ulcerative carcinoma, fibrocarcinoma, gelatin sponge carcinoma, colloid carcinoma, giant cell carcinoma (carcinoma basocellulare), cholangiocarcinoma, choriocarcinoma, colloid carcinoma, comedocarcinoma, uterine corpus carcinoma, cribriform carcinoma, armor carcinoma, cutaneous carcinoma, cylindrical carcinoma, cylindrical cell carcinoma, ductal carcinoma, carcinoma durum, embryonal carcinoma, encephalioid carcinoma, epidermoid carcinoma, epithelial adenoid carcinoma, exophytic carcinoma, exo-ulcerative carcinoma, fibrocarcinoma, gelatin sponge carcinoma, colloid carcinoma, gigantocellulare), adenocarcinoma, granular cell carcinoma, hair-stromal carcinoma, hematogenous carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, clear carcinoma, renal cell carcinoma, immature embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky cell carcinoma, large cell carcinoma, lenticular carcinoma (carcinoma lenticulare), lipomatous carcinoma, lymphoepithelial carcinoma, medullary carcinoma (carcinoma medullare), melanotic carcinoma, soft tissue carcinoma, mucinous carcinoma (carcinoma muciparum), mucinous cell carcinoma, mucoepidermoid carcinoma, and mucinous carcinoma (carcinoma mucosum / mucous) carcinoma), myxoma, nasopharyngeal carcinoma, oat cell carcinoma, ossifying carcinoma, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, acanthocyte carcinoma, pultaceous carcinoma, renal cell carcinoma, reserve cell carcinoma, sarcomatoid carcinoma, Schneiderian carcinoma, scirrhous carcinoma, scrotal carcinoma, signet ring cell carcinoma, simple carcinoma, small cell carcinoma, potato carcinoma, spherical cell carcinoma, spindle cell carcinoma, cavernous carcinoma, squamous cell carcinoma, squamous cell carcinoma, rope-shaped carcinoma, carcinoma telangiectaticum / carcinomate langiectodes, transitional cell carcinoma, carcinoma tuberosum / tuberous carcinoma, verrucous carcinoma, or villous carcinoma.
[0604] The present invention provides a method for treating an immune-mediated disease, comprising administering to a subject a therapeutically effective amount of one or more disclosed compositions or compounds. In some embodiments, the immune-mediated disease is selected from resistance to transplantation of heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limbs, muscle, nerve, duodenum, small intestine, or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis, and glomerulonephritis.
[0605] In certain embodiments, the disease is an autoimmune disease. As used herein, the term "autoimmune disease" refers to a disease or condition in which the immune system of a subject has an abnormal immune response to a substance that normally does not cause an immune response in a healthy subject. Examples of autoimmune diseases treatable with the compounds, pharmaceutical compositions, or methods described herein include acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune autonomic dysfunction, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune ovarian inflammation, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, axonal or neuronal neuropathy, Balo's disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman's disease, diarrheal diseases, Chagas disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss syndrome, cicatricial pemphigoid / benign mucosal neuropathy Pemphigoid, Crohn's disease, Cogan's syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathy, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressier's syndrome, endometrial translocation, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly Wegener's granulomatosis), Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosis, immunomodulatory lipoproteins,Included are body myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytic vasculitis, lichen planus, lichen sclerosus, woody conjunctivitis, linear IgA disease (LAD), systemic lupus erythematosus (SLE), Lyme disease, chronic Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCT), and inflammatory bowel disease. CTD), Mooren's ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's), neutropenia, ocular cicatricial pemphigoid, optic neuritis, relapsing rheumatic disease, PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococci), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parryberg's Romberg syndrome, Parsonnage-Turner syndrome, pars plana (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, autoimmune polyglandular syndromes types I, II, and III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, postpericardiotomy syndrome, progestogen-activated dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis Arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome, scleritis, scleroderma, Sjogren's syndrome, sperm and testicular autoimmunity, stiff-man syndrome person syndrome), subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes mellitus, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, cystic dermatosis, vitiligo, or Wegener's granulomatosis (ie, granulomatosis with polyangiitis [GPA]).
[0606] The present invention provides a method for treating an age-related condition comprising administering to a subject a therapeutically effective amount of one or more disclosed compositions or compounds. In certain embodiments, the age-related condition is selected from sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, hypertension, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, impaired kidney function, and age-related hearing loss, age-related disability (e.g., frailty), cognitive decline, age-related dementia, memory impairment, tendon stiffness, cardiac dysfunction (such as cardiac hypertrophy and systolic and diastolic dysfunction), immunosenescence, cancer, obesity, and diabetes.
[0607] In certain embodiments, the disclosed compositions or compounds can be used for immunosenescence. Immunosenescence can refer to a decline in immune function, resulting in, for example, an impaired immune response, particularly to cancer, vaccines, and infectious pathogens. It involves both the host's ability to respond to infection and the development of long-term immune memory (especially through vaccines). This immunodeficiency is ubiquitous and is seen in both long-lived and short-lived species as a function of their age relative to life expectancy rather than chronological time. This is considered to be a major contributing factor to the increased morbidity and mortality in the elderly. Immunosenescence is not a random deterioration phenomenon; on the contrary, it appears to repeat evolutionary patterns in reverse, and most parameters affected by immunosenescence appear to be under genetic control. Sometimes immunosenescence can also be envisioned as the result of unavoidable exposure to continuous challenges with various antigens (such as viruses and bacteria). Immunosenescence is a multifactorial condition that leads to many pathologically significant health problems (e.g., in the elderly population). Age-dependent biological changes (such as depletion of hematopoietic stem cells, an increase in PD1+ lymphocytes, a decrease in the total number of phagocytes and NK cells, and a decrease in humoral immunity) contribute to the onset of immunosenescence. In one aspect, immunosenescence can be measured in an individual by measuring telomere length of immune cells (see, e.g., U.S. Patent No. 5,741,677). Immunosenescence can also be determined by documenting a lower than normal number of naive CD4 and / or CD8 T cells, a T cell repertoire, a number of T cells expressing PD1 (e.g., lower than the normal number of PD-1 negative T cells), or a response to a vaccine in an individual 65 years of age or older. In certain embodiments, selective modulation of mTOR in certain T-cell populations can improve vaccine efficacy in elderly populations and enhance the effectiveness of cancer immunotherapy. The present invention provides a method for treating immunosenescence comprising administering to a subject a therapeutically effective amount of one or more disclosed compositions or compounds.
[0608] In certain embodiments, the disease that can be treated with the compounds, pharmaceutical compositions, or methods described herein is organ or tissue transplant rejection (e.g., heart, lung, combined heart-lung, liver, kidney, pancreas, skin, or corneal transplant; graft-versus-host disease), restenosis, hamartoma syndromes (e.g., tuberous sclerosis or Cowden's disease), lymphangioleiomyomatosis, retinitis pigmentosa, encephalomyelitis, insulin-dependent diabetes mellitus, lupus, dermatomyositis, arthritis, rheumatic diseases, steroid-resistant acute lymphoblastic leukemia, fibrosis, scleroderma, pulmonary fibrosis, renal fibrosis, cystic fibrosis, pulmonary hypertension, multiple sclerosis, VHL syndrome, Carney syndrome, familial adenomatous polyposis, juvenile polyposis syndrome, Birt-Hogg-Duke syndrome, familial hypertrophic cardiomyopathy, Wo lf-Parkinson-White syndrome, Parkinson's disease, Huntington's disease, Alzheimer's disease, dementia caused by tau mutations, spinocerebellar ataxia type 3, motor neuron disease caused by SOD1 mutations, neuronal lipid fucose / Batten disease (pediatric neurodegeneration), wet macular degeneration, dry macular degeneration, muscle wasting (atrophy, cachexia), myopathy (e.g., Danon's disease), bacterial infection, viral infection, M. tuberculosis, group A Streptococcus, HSV type 1, HIV infection, neurofibromatosis (e.g., neurofibromatosis type 1), or Peutz-Jeghers syndrome.
[0609] In certain embodiments, the disease is a neurodegenerative disease. As used herein, the term "neurodegenerative disease" refers to a disease or condition in which the function of the nervous system of an individual is impaired. Examples of neurodegenerative diseases that can be treated with the compounds, pharmaceutical compositions, or methods described herein include Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Batten's disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), bovine spongiform encephalopathy (BSE), Canavan's disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, and other neurodegenerative diseases. s disease, kuru, dementia with Lewy bodies, Machado-Joseph disease (spinocerebellar ataxia type 3), multiple sclerosis, multiple system atrophy, narcolepsy, neuroborreliosis, Parkinson's disease, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, prion disease, Refsum's disease, Sandhoff's disease, Schilder's disease, subacute mixed degeneration of the spinal cord secondary to pernicious anemia, schizophrenia, spinocerebellar ataxia (various types with varying features), spinal muscular atrophy, Steele-Richardson-Olszewski disease, or Tabes dorsalis.
[0610] In certain embodiments, the disease is a metabolic disease. As used herein, the term "metabolic disease" refers to a disease or condition in which the metabolism or metabolic system (e.g., the function of storing or utilizing energy) of an individual is impaired. Examples of metabolic diseases that can be treated with the compounds, pharmaceutical compositions, or methods described herein include diabetes (e.g., type I or type II), obesity, metabolic syndrome, or mitochondrial disease (e.g., mitochondrial dysfunction or abnormal mitochondrial function).
[0611] In certain embodiments, the disease is a fungal disease. As used herein, the term "fungal disease" refers to a disease or condition associated with a fungal infection in an individual. Examples of fungal diseases that can be treated with the compounds, pharmaceutical compositions, or methods described herein include, among others, infections caused by Mucor circinelloide, zygomycetes, Cryptococcus neoformans, Candida albicans, yeast, and Saccharomyces cerevisiae.
[0612] In certain embodiments, the disease is an inflammatory disease.As used herein, the term "inflammatory disease" refers to a disease or condition characterized by abnormal inflammation, e.g., increased levels of inflammation compared to a control, such as a healthy individual not suffering from the disease. Examples of inflammatory diseases include traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile-onset diabetes mellitus, type 1 diabetes, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, autoimmune thyroiditis, Behçet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma, allergic asthma, acne vulgaris, diarrheal diseases, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, transplant rejection, interstitial cystitis, atherosclerosis, and atopic dermatitis.
[0613] In certain embodiments, the disease is a cardiovascular disease. As used herein, the term "cardiovascular disease" refers to a disease or condition in which the function of the cardiovascular system of a subject is impaired. Examples of cardiovascular diseases that can be treated with the compounds, pharmaceutical compositions, or methods described herein include congestive heart failure, arrhythmia syndromes (e.g., paroxysmal tachycardia, delayed after depolarization, ventricular tachycardia, sudden tachycardia, exercise-induced arrhythmias, long QT syndrome, or bidirectional tachycardia), thromboembolic disease (e.g., arterial cardiovascular thromboembolism, venous cardiovascular thromboembolism, or ventricular thromboembolism), atherosclerosis, restenosis, peripheral arterial disease, coronary artery bypass grafting, carotid artery disease, arteritis, myocarditis, cardiovascular inflammation, vascular inflammation, coronary heart disease (CHD), unstable angina (UA), unstable refractory angina, stable angina (SA), chronic stable angina, acute coronary syndrome (ACS), myocardial infarction (first or recurrence), acute myocardial infarction (AMI), myocardial infarction, non-Q wave myocardial infarction, non-STE myocardial infarction, coronary artery disease, ischemic heart disease, myocardial ischemia, ischemia, sudden ischemic death, transient ischemic attack, stroke, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, thrombosis (e.g., associated with prosthetic valves or other grafts, indwelling catheters, stents, cardiopulmonary bypass, hemodialysis), thrombosis (e.g., associated with atherosclerosis, surgery, prolonged immobility, arterial fibrillation, congenital thrombophilia, cancer, diabetes, hormones, or pregnancy), or arrhythmia (e.g., supraventricular arrhythmia, atrial arrhythmia, atrial flutter, or atrial fibrillation).
[0614] In one aspect, a method of treating a disease associated with abnormal levels of mTOR activity in a subject in need of such treatment is provided. The disease may be caused by upregulation of mTOR. The method may comprise administering to the subject one or more compositions or compounds described herein. The method may comprise administering to the subject a therapeutically effective amount of one or more compositions or compounds described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).
[0615] In one aspect, one or more compositions or compounds as described herein are provided for use as a medicament. In embodiments, the medicament can be used to treat a disease caused by upregulation of mTOR. The use may comprise administering to the subject one or more compositions or compounds as described herein. The use may comprise administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).
[0616] In one aspect, one or more compositions or compounds as described herein are provided for use in treating a disease caused by an abnormal level of mTORC1 activity in a subject in need of such treatment. The disease may be caused by upregulation of mTORC1. The use may comprise administering to the subject one or more compositions or compounds as described herein. The use may comprise administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).
[0617] Upregulation of mTOR can result in an increase in mTOR activity compared to the normal level of mTOR activity in a particular subject or a population of healthy subjects. Increased mTOR activity can lead to, for example, excessive cell proliferation, thereby causing a disease state.
[0618] The subject being treated for a disease is typically a mammal. The mammal being treated with a compound (e.g., a compound described herein, an mTOR modulator (e.g., inhibitor)) can be a human, a non-human primate, and / or a non-human mammal (e.g., a carnivore, a canine).
[0619] In another aspect, provided is a method of treating a disease associated with mTOR activity in a subject in need of such treatment, the method comprising administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., claims, embodiments, examples, tables or claims)).
[0620] In another aspect, one or more compositions or compounds as described herein are provided for use as a medicament. In embodiments, the medicament can be used to treat a disease associated with mTORC1 activity in a subject in need of such treatment. In embodiments, the use can comprise administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables, or claims)).
[0621] In another aspect, one or more compositions or compounds are provided for use in treating a disease associated with mTOR activity in a subject in need of such treatment. In embodiments, the use may comprise administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables, or claims)).
[0622] In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is cancer. In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is an autoimmune disease. In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is an inflammatory disease. In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is a neurodegenerative disease. In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is a metabolic disease. In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is transplant rejection. In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is a fungal infection. In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is a cardiovascular disease.
[0623] In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is aging. In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is death due to an age-related disease. In embodiments, the mTOR activity-related disease or disease associated with abnormal levels of mTOR activity is an age-related condition. In certain embodiments, the age-related condition is selected from the group consisting of sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, hypertension, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, impaired kidney function, and age-related hearing loss, age-related disability (e.g., frailty), cognitive decline, age-related dementia, memory impairment, tendon stiffness, cardiac dysfunction (such as cardiac hypertrophy and systolic and diastolic dysfunction), immunosenescence, cancer, obesity, and diabetes. In certain embodiments, selective modulation of mTOR in certain T-cell populations can improve vaccine efficacy in elderly populations and enhance the effectiveness of cancer immunotherapy. The present invention provides a method for treating immunosenescence comprising administering to the subject a therapeutically effective amount of one or more disclosed compounds.
[0624] In an embodiment, the disease associated with mTOR activity or a disease associated with abnormal levels of mTOR activity is cancer (e.g., carcinoma, sarcoma, adenocarcinoma, lymphoma, leukemia, solid cancer, lymphoid carcinoma, kidney cancer, breast cancer, lung cancer, bladder cancer, colon cancer, gastrointestinal cancer, ovarian cancer, prostate cancer, pancreatic cancer, stomach cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, esophageal cancer, liver cancer, testicular cancer, glioma, hepatocellular carcinoma, lymphoma (including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphoma (e.g., Burkitt's, small cell and large cell lymphoma), Hodgkin's lymphoma), leukemia (including AML, ALL and CML), multiple myeloma and breast cancer (e.g., triple-negative breast cancer)).
[0625] In an embodiment, the mTOR activity-related disease or the disease associated with abnormal levels of mTOR activity is acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune autonomic dysfunction, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenia. ATP, autoimmune thyroid disease, autoimmune urticaria, axonal or neuronal neuropathy, Barlow's disease, Behçet's disease, bullous pemphigoid, cardiomyopathy, Castleman's disease, diarrheal illness, Chagas' disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic relapsing multifocal osteomyelitis (CRMO), Church-Strauss syndrome, cicatricial pemphigoid / benign mucous membrane pemphigoid, Crohn's disease, Cogan's syndrome, cold agglutinin disease, congenital heart block, coxsackie's myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathy, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica) , discoid lupus, Dreyfuss syndrome, endometrial translocation, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly Wegener's granulomatosis), Graves' disease, Guillain-Barré syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schwann purpura, herpes gestationis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosis, immunomodulatory lipoproteins, incorporation of myositis , interstitial cystitis, juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, woody conjunctivitis, linear IgA disease (LAD), lupus erythematosus (SLE), Lyme disease, chronic Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Moren's ulcer, Muhlenberg-Harris disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's), neutropenia, ocular cicatricial pemphigoid, optic neuritis, relapsing rheumatic disease, PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococci), paraneoplastic cerebellar degeneration,Paroxysmal nocturnal hemoglobinuria (PNH), Parry-Roberg syndrome, Prader-Thomas syndrome, pars plana (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, autoimmune polyglandular syndromes types I, II, and III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, postpericardiotomy syndrome, progestogen-activated dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome, scleritis, scleroderma, Shoemaker-Graham syndrome, sperm and testicular autoimmunity, stiff-man syndrome, subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes mellitus, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, cystic skin disease, vitiligo, Wegener's granulomatosis (i.e., granulomatosis with polyangiitis (GPA)), traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis , juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile-onset diabetes mellitus, type 1 diabetes mellitus, Guillain-Barré syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Shoemaker's syndrome, vasculitis, glomerulonephritis, autoimmune thyroiditis, Behçet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma, allergic asthma, acne vulgaris, diarrheal diseases, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, transplant rejection, interstitial cystitis, atherosclerosis, atopic dermatitis, Alexander's disease , Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Batten's disease (also known as Spielmeyer-Vogt-Sjögren-Batten disease), bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krashen's disease, Kulu's disease, dementia with Lewy bodies, Machado-Joseph disease (spinocerebellar ataxia type 3), multiple sclerosis, multiple system atrophy, narcolepsy, neuroborreliosis, Parkinson's disease,Perelman-Merzheimer disease, Pick's disease, primary lateral sclerosis, prion diseases, Refsum's disease, Sandhoff's disease, Sidley's disease, subacute mixed degeneration of the spinal cord secondary to pernicious anemia, schizophrenia, spinocerebellar ataxia (various types with varying features), spinal muscular atrophy, Steele-Richardson-Olszewski disease, tabes dorsalis, diabetes mellitus (e.g., type I or type II), obesity, metabolic syndrome, mitochondrial disorders (e.g., mitochondrial dysfunction or abnormal mitochondrial function) ), fungal infection, transplant rejection, or cardiovascular disease (e.g., congestive heart failure, arrhythmia syndromes (e.g., paroxysmal tachycardia, delayed afterdepolarization, ventricular tachycardia, sudden tachycardia, exercise-induced arrhythmia, long QT syndrome, or bidirectional tachycardia), thromboembolic disorders (e.g., arterial cardiovascular thromboembolism, venous cardiovascular thromboembolism, or ventricular thromboembolism), atherosclerosis, restenosis, peripheral arterial disease, coronary artery bypass graft surgery, carotid artery disease, arteritis, myocarditis, Cardiovascular inflammation, vascular inflammation, coronary heart disease (CHD), unstable angina (UA), unstable refractory angina, stable angina (SA), chronic stable angina, acute coronary syndrome (ACS), myocardial infarction (first or recurrent), acute myocardial infarction (AMI), myocardial infarction, non-Q wave myocardial infarction, non-STE myocardial infarction, coronary artery disease, ischemic heart disease, myocardial ischemia, ischemia, ischemic sudden death, transient ischemic attack, stroke, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis venous thrombosis, thrombophlebitis, arterial embolism, coronary thrombosis, cerebral arterial thrombosis, cerebral embolism, renal embolism, pulmonary embolism, thrombosis (e.g., associated with prosthetic valves or other grafts, indwelling catheters, stents, cardiopulmonary bypass, hemodialysis), thrombosis (e.g., associated with atherosclerosis, surgery, prolonged immobility, arterial fibrillation, congenital thrombophilia, cancer, diabetes, hormones, or pregnancy), or cardiac arrhythmias (e.g., supraventricular arrhythmias, atrial arrhythmias, atrial flutter, or atrial fibrillation).
[0626] In one aspect, a method for treating a disease is provided, comprising administering an effective amount of one or more compositions or compounds as described herein. In one aspect, one or more compositions or compounds as described herein are provided for use as medicine (e.g., for treating a disease). In one aspect, one or more compositions or compounds as described herein are provided for treating a disease (e.g., comprising administering an effective amount of one or more compositions or compounds as described herein). In embodiments, the disease is cancer. In embodiments, the disease is an autoimmune disease. In embodiments, the disease is an inflammatory disease. In embodiments, the disease is a neurodegenerative disease. In embodiments, the disease is a metabolic disease. In embodiments, the disease is a fungal infection. In embodiments, the disease is transplant rejection. In embodiments, the disease is a cardiovascular disease.
[0627] In embodiments, the disease is cancer (e.g., carcinoma, sarcoma, adenocarcinoma, lymphoma, leukemia, solid cancer, lymphoid carcinoma, kidney cancer, breast cancer, lung cancer, bladder cancer, colon cancer, ovarian cancer, prostate cancer, pancreatic cancer, stomach cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, esophageal cancer, liver cancer, testicular cancer, glioma, hepatocellular carcinoma, lymphoma (including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphoma (e.g., Burkitt's, small cell and large cell lymphoma), Hodgkin's lymphoma), leukemia (including AML, ALL and CML), multiple myeloma and breast cancer (e.g., triple negative breast cancer)).
[0628] In the embodiment, the disease is acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune autonomic dysfunction, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune Urticaria, axonal or neuronal neuropathy, Barlow's disease, Behçet's disease, bullous pemphigoid, cardiomyopathy, Castleman's disease, diarrheal illness, Chagas' disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic relapsing multifocal osteomyelitis (CRMO), Church-Strauss syndrome, cicatricial pemphigoid / benign mucous membrane pemphigoid, Crohn's disease, Corgan's syndrome, cold agglutinin disease, congenital heart block, Coxsackie's myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathy, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dreyfuss syndrome, endometrial translocation, eosinophilic esophagitis, eosinophilic esophagitis fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly Wegener's granulomatosis), Graves' disease, Guillain-Barré syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schwann purpura, herpes gestationis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosis, immunomodulatory lipoproteins, incorporation of myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile myositis , Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, woody conjunctivitis, linear IgA disease (LAD), lupus erythematosus (SLE), Lyme disease, chronic Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Moren's ulcer, Muhlenberg-Harris disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's), neutropenia, ocular cicatricial pemphigoid, optic neuritis, relapsing rheumatic disease, PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococci), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry-Roberg's syndrome, Parkinson's disease,Pars plana cyclitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, autoimmune polyglandular syndromes types I, II, and III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, postpericardiotomy syndrome, progestogen-activated dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome , scleritis, scleroderma, Shew-Graham syndrome, sperm and testicular autoimmunity, stiff-man syndrome, subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes mellitus, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, cystic skin disease, vitiligo, Wegener's granulomatosis (i.e., granulomatosis with polyangiitis (GPA)), traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis Strength, juvenile-onset diabetes, type 1 diabetes, Guillain-Barré syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, vasculitis, glomerulonephritis, autoimmune thyroiditis, Behçet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma, allergic asthma, acne vulgaris, diarrheal diseases, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, transplant rejection, interstitial cystitis, atherosclerosis, atopic dermatitis, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Batten's disease (also Spielmeyer-Vogt-Sjögren-Batten disease), bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington's disease, HTV-related dementia, Kennedy disease, Krabbe disease, Kulu disease, dementia with Lewy bodies, Machado-Joseph disease (spinocerebellar ataxia type 3), multiple sclerosis, multiple system atrophy, narcolepsy, neuroborreliosis, Parkinson's disease, Perelman-Merzheimer disease, Pick's disease, primary lateral sclerosis, prion diseases, Refsum's disease, Sandhoff's disease, Sidley's disease,Subacute mixed degeneration of the spinal cord secondary to pernicious anemia, schizophrenia, spinocerebellar ataxia (various types with varying features), spinal muscular atrophy, Steele-Richardson-Olszewski disease, tabes dorsalis, diabetes mellitus (e.g., type I or type II), obesity, metabolic syndrome, mitochondrial disorders (e.g., mitochondrial dysfunction or abnormal mitochondrial function), fungal infection, transplant rejection, or cardiovascular disease (e.g., congestive heart failure, arrhythmia syndromes (e.g., paroxysmal tachycardia, delayed afterdepolarization, ventricular tachycardia, sudden tachycardia, exercise-induced arrhythmia, long QT syndrome, or bidirectional tachycardia), thromboembolic disease (e.g., arterial cardiovascular thromboembolism, venous cardiovascular thromboembolism, or ventricular thromboembolism), atherosclerosis, restenosis, peripheral arterial disease, coronary artery bypass graft surgery, carotid artery disease, arteritis, myocarditis, cardiovascular inflammation, vascular inflammation, coronary heart disease (CHD), unstable angina (UA), unstable refractory angina, stable angina (SA), chronic stable angina, acute coronary syndrome (ACS), CS), myocardial infarction (first or recurrent), acute myocardial infarction (AMI), myocardial infarction, non-Q wave myocardial infarction, non-STE myocardial infarction, coronary artery disease, ischemic heart disease, myocardial ischemia, ischemia, sudden ischemic death, transient ischemic attack, stroke, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary artery thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, thrombosis (e.g., with prosthetic valves or other grafts, indwelling catheters, stents, cardiopulmonary bypass, hemodialysis), In embodiments, the disease is polycystic disease. In embodiments, the disease is polycystic kidney disease. In embodiments, the disease is stenosis. In embodiments, the disease is restenosis. In embodiments, the disease is neointimal hyperplasia. In embodiments, the disease is neointimal hyperplasia.
[0629] In another aspect, a method of treating aging in a subject in need of such treatment is provided, comprising administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., claims, embodiments, examples, tables, or claims)). The present invention provides a method of treating immunosenescence, comprising administering to the subject a therapeutically effective amount of one or more disclosed compounds or compositions.
[0630] In another aspect, one or more compositions or compounds as described herein are provided for use as a medicine. In embodiments, the medicine can be used to treat the aging of a subject in need of such treatment. In embodiments, the purposes may include administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables, or claims)).
[0631] In another aspect, one or more compositions or compounds disclosed herein are provided for use in treating aging in a subject in need of such treatment. In embodiments, the use may comprise administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables, or claims)).
[0632] In another aspect, a method of extending lifespan or inducing longevity in a subject in need of such treatment is provided, comprising administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., claims, embodiments, examples, tables or claims)).
[0633] In another aspect, one or more compositions or compounds as described herein are provided for use as medicines. In embodiments, the medicine can be used to extend life or induce longevity in a subject in need of such treatment. In embodiments, the purposes may include administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables, or claims)).
[0634] In another aspect, one or more compositions or compounds are provided for extending lifespan or inducing longevity in a subject in need of such treatment. In embodiments, the purposes may comprise administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables or claims)).
[0635] In one aspect, a method of treating a polycystic disease in a subject in need thereof is provided. The polycystic disease may be polycystic kidney disease. The method may comprise administering to the subject one or more compositions or compounds described herein. The method may comprise administering to the subject a therapeutically effective amount of one or more compositions or compounds described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).
[0636] In one aspect, one or more compositions or compounds as described herein are provided for use as a medicament. In embodiments, the medicament can be used to treat polycystic disease. The polycystic disease can be polycystic kidney disease. The use can include administering to the subject one or more compositions or compounds as described herein. The use can include administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).
[0637] In one aspect, one or more compositions or compounds as described herein are provided for use in treating a polycystic disease in a subject in need thereof. The polycystic disease may be polycystic kidney disease. The use may comprise administering to the subject one or more compositions or compounds as described herein. The use may comprise administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).
[0638] In one aspect, a method of treating stenosis in a subject in need thereof is provided. The stenosis may be restenosis. The method may comprise administering to the subject one or more compositions or compounds described herein. In embodiments, the one or more compositions or compounds are administered as a drug eluting stent. The method may comprise administering to the subject a therapeutically effective amount of one or more compositions or compounds described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).
[0639] In one aspect, one or more compositions or compounds as described herein are provided for use as a medicament. In embodiments, the medicament can be used to treat stenosis. The stenosis can be restenosis. The use may comprise administering to the subject one or more compositions or compounds as described herein. In embodiments, the compound is administered as a drug eluting stent. The use may comprise administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).
[0640] In one aspect, one or more compositions or compounds as described herein are provided for use in treating a stenosis in a subject in need thereof. The stenosis may be restenosis. The use may comprise administering to the subject one or more compositions or compounds as described herein. In embodiments, the one or more compositions or compounds are administered as a drug eluting stent. The use may comprise administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).
[0641] In embodiments, the disease is a disease described herein, the compound is a compound described herein, and the composition is a composition described herein.
[0642] Methods for regulating mTOR
[0643] In some embodiments, the compounds disclosed herein are more selective inhibitors of mTORC1 relative to mTORC2. In some embodiments, the compounds disclosed herein are more selective inhibitors of mTORC2 relative to mTORC1. In some embodiments, the compounds disclosed herein exhibit no difference in selectivity between mTORC1 and mTORC2.
[0644] In another aspect, a method of modulating mTORCl activity in a subject in need thereof is provided, comprising administering to the subject an effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof. In embodiments, the method comprises inhibiting mTORCl activity. In embodiments, the method comprises inhibiting mTORCl activity without inhibiting mTORC2 activity.
[0645] In embodiments, the method comprises inhibiting mTORC1 activity more than inhibiting mTORC2 activity. In embodiments, the method comprises inhibiting mTORC1 activity by at least 1.1-fold (e.g., at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000) of mTORC2 activity. 000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 700000, 800000, 900000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, or 1000000 times).
[0646] In another aspect, a method of modulating mTORC2 activity in a subject in need thereof is provided, comprising administering to the subject an effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof. In one embodiment, the method comprises inhibiting mTORC2 activity. In one embodiment, the method comprises inhibiting mTORC2 activity without inhibiting mTORC1 activity.
[0647] In embodiments, the method comprises inhibiting mTORC2 activity more than inhibiting mTORC1 activity. In embodiments, the method comprises inhibiting mTORC2 activity by at least 1.1-fold (e.g., at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000 000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 700000, 800000, 900000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, or 1000000 times).
[0648] In some embodiments, the mTOR is located in a cell. In some embodiments, the cell is a mammalian cell, such as a human cell. The cell can be isolated in vitro, form part of an in vitro tissue, or form part of an organism.
[0649] Exemplary embodiments
[0650] Some embodiments of the present invention are the following embodiment 1:
[0651] Embodiment I-1. A compound of formula I:
[0652]
[0653] or a pharmaceutically acceptable salt or tautomer thereof, wherein:
[0654] R 32 -H, =O or -OR 3 ;
[0655] R 28 is -H or -C(=Z 1 )-R 28a ;
[0656] R 40 is -H or -C(=Z 1 )-R 40a ;
[0657] where R 28 and R 40 At least one of them is not H;
[0658] Z1 O or S;
[0659] R 28a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B, -O-(C1-C6)alkyl, or -O-(C6-C 10 ) aryl; wherein the aryl is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen;
[0660] A 1 and A 2 are independently absent or independently selected from
[0661]
[0662]
[0663] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The key on the right side of the part is bound to B or L 3 ;
[0664] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0665] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0666] Each X 1 is a heteroarylene or heterocyclylene ring;
[0667] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0668] Each W 1 is a heteroarylene or heterocyclylene ring;
[0669] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0670] G 1 and G 2each independently a heteroarylene or heterocyclylene ring;
[0671] L 1 Selected from
[0672] L 2 and L 3 are independently absent or independently selected from
[0673]
[0674] B is selected from
[0675]
[0676] B 1 Selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, (C6-C 10 )arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-,
[0677] and
[0678] NR 3 -(C(R 3 )2)n -S(O)2-arylene-C(O)-, wherein as shown, B 1 On the left Bonded to A 2 、L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene groups are optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;
[0679] R 3 Each is independently H or (C1-C6) alkyl;
[0680] R 4 Each is independently H, (C1-C6) alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C6-C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 -heterocyclyl substitution;
[0681] R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0682] R 6 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0683] R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0684] R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R3 )2, wherein the alkyl group is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0685] Y is each independently C(R 3 )2 or key;
[0686] n is each independently a number from 1 to 12;
[0687] o are each independently a number from 0 to 30;
[0688] p is each independently a number from 0 to 12;
[0689] q is each independently a number from 0 to 30; and
[0690] r is each independently a number from 1 to 6.
[0691] Embodiment I-2. A compound of formula II:
[0692]
[0693] or a pharmaceutically acceptable salt or tautomer thereof, wherein:
[0694] R 32 -H, =O or -OR 3 ;
[0695] R 28 is -H or -C(=Z 1 )-R 28a ;
[0696] R 40 is -H or -C(=Z 1 )-R 40a ;
[0697] where R 28 and R 40 At least one of them is not H;
[0698] Z 1 O or S;
[0699] R 28a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -O-(C1-C6)alkyl, or -O-(C6-C 10 ) aryl; wherein the aryl is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen;
[0700] A 1 and A 2 are independently absent or independently selected from
[0701]
[0702]
[0703] As shown, A 1 The left bond is bound to -C(=Z 1 )-; and wherein, as shown, A 2 The bond on the right side of the part is bound to B;
[0704] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0705] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0706] Each X 1 is a heteroarylene or heterocyclylene ring;
[0707] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0708] Each W 1 is a heteroarylene or heterocyclylene ring;
[0709] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0710] G 1 and G 2 each independently a heteroarylene or heterocyclylene ring;
[0711] L 1 Selected from
[0712] B is selected from
[0713]
[0714] B 1 Selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n-(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, (C6-C 10 )arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-,
[0715] and
[0716] NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)-, wherein as shown, B 1 On the left Bonded to A 2 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene groups are optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;
[0717] R 3 Each is independently H or (C1-C6) alkyl;
[0718] R 4 Each is independently H, (C1-C6) alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C6-C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3-heterocyclyl substitution;
[0719] R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0720] R 6 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0721] R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0722] R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0723] Y is each independently C(R 3 )2 or key;
[0724] n is each independently a number from 1 to 12;
[0725] o are each independently a number from 0 to 30;
[0726] p is each independently a number from 0 to 12;
[0727] q is each independently a number from 0 to 30; and
[0728] r is each independently a number from 1 to 6.
[0729] Embodiment I-3. Compounds according to embodiment I-1 or I-2, wherein R 32 =O.
[0730] Embodiment I-4. A compound according to embodiment I-1 or I-2, wherein R 32 For-OR3 .
[0731] Embodiment I-5. A compound according to any one of Embodiments I-1 to I-4, wherein the compound is represented by the structure of Formula I-40:
[0732]
[0733] or a pharmaceutically acceptable salt thereof.
[0734] Embodiment I-6. A compound according to embodiment I-5, wherein Z 1 It is O.
[0735] Embodiment I-7. A compound according to embodiment I-5, wherein Z 1 For S.
[0736] Embodiment I-8. A compound according to any one of embodiments I-5 to I-7, wherein R 40a -A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.
[0737] Embodiment I-9. A compound according to any one of embodiments I-5 to I-7, wherein R 40a -A 1 -L 1 -A 2 -B, where A 2 Does not exist.
[0738] Embodiment I-10. A compound according to any one of embodiments I-5 to I-7, wherein R 40a -A 1 -L 1 -A 2 -B, where A 1 Does not exist.
[0739] Embodiment I-11. A compound according to any one of embodiments I-5 to I-7, wherein R 40a -A 1 -L 1 -A 2 -B.
[0740] Embodiment I-12. A compound according to any one of embodiments I-5 to I-7, wherein R 40a -A 1 -A 2 -B.
[0741] Embodiment I-13. A compound according to any one of embodiments I-5 to I-7, wherein R 40a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.
[0742] Embodiment I-14. A compound according to any one of embodiments I-5 to I-7, wherein R 40a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 Does not exist.
[0743] Embodiment I-15. A compound according to any one of embodiments I-5 to I-7, wherein R 40a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.
[0744] Embodiment I-16. A compound according to any one of embodiments I-5 to I-7, wherein R 40a is -O-(C1-C6)alkyl or -O-(C6-C 10 ) aryl; wherein the aryl is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen.
[0745] Embodiment I-17. A compound according to any one of Embodiments I-1 to I-4, wherein the compound is represented by the structure of Formula I-28:
[0746]
[0747] or a pharmaceutically acceptable salt thereof.
[0748] Embodiment I-18. A compound according to embodiment I-17, wherein Z 1 It is O.
[0749] Embodiment I-19. A compound according to embodiment I-17, wherein Z 1 For S.
[0750] Embodiment I-20. A compound according to any one of embodiments I-17 to I-19, wherein R28a -A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.
[0751] Embodiment I-21. A compound according to any one of embodiments I-17 to I-19, wherein R 28a -A 1 -L 1 -A 2 -B, where A 2 Does not exist.
[0752] Embodiment I-22. A compound according to any one of embodiments I-17 to I-19, wherein R 28a -A 1 -L 1 -A 2 -B, where A 1 Does not exist.
[0753] Embodiment I-23. A compound according to any one of embodiments I-17 to I-19, wherein R 28a -A 1 -L 1 -A 2 -B.
[0754] Embodiment I-24. A compound according to any one of embodiments I-17 to I-19, wherein R 28a -A 1 -A 2 -B.
[0755] Embodiment I-25. A compound according to any one of embodiments I-17 to I-19, wherein R 28a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.
[0756] Embodiment I-26. A compound according to any one of embodiments I-17 to I-19, wherein R 28a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 Does not exist.
[0757] Embodiment I-27. A compound according to any one of embodiments I-17 to I-19, wherein R 28a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.
[0758] Embodiment I-28. A compound according to any one of embodiments I-17 to I-19, wherein R 28a is -O-(C1-C6)alkyl or -O-(C6-C 10 ) aryl; wherein the aryl is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen.
[0759] Embodiment 1-29. A compound according to any one of embodiments 1-1 to 1-11, 1-13 to 1-15, 1-17 to 1-23, and 1-25 to 1-27, wherein L 1 for
[0760] Embodiment I-30. A compound according to any one of Embodiments I-1 to I-11, I-13 to I-15, I-17 to I-23, and I-25 to I-27, wherein L 1 for
[0761] Embodiment I-31. A compound according to any one of Embodiments I-1 to I-11, I-13 to I-15, I-17 to I-23 and I-25 to I-27, wherein L 1 for
[0762] Embodiment 1-32. A compound according to any one of embodiments 1-1 to 1-11, 1-13 to 1-15, 1-17 to 1-23, and 1-25 to 1-27, wherein L 1 for
[0763] Embodiment 1-33. A compound according to any one of embodiments 1-1 to 1-11, 1-13 to 1-15, 1-17 to 1-23, and 1-25 to 1-27, wherein L 1 for
[0764] Embodiment I-34. A compound according to any one of Embodiments I-1 to I-7, I-15, I-17 to I-19 and I-27, wherein L 2 for
[0765] Embodiment 1-35. A compound according to any one of embodiments 1-1 to 1-7, 1-13 to 1-14, 1-17 to 1-19 and 1-25 to 1-26, wherein L 3 for
[0766] Embodiment 1-36. A compound according to any one of embodiments 1-1 to 1-8, 1-10, 1-13, 1-17 to 1-19, 1-20, 1-22, 1-25 and 1-29 to 1-35, wherein A 1 Does not exist.
[0767] Embodiment 1-37. A compound according to any one of Embodiments 1-1 to 1-7, 1-9, 1-11 to 1-12, 1-14 to 1-15, 1-17 to 1-19, 1-21, 1-23 to 1-24, 1-26 to 1-27, and 1-29 to 1-35, wherein A 1 for
[0768] Embodiment 1-38. A compound according to any one of embodiments 1-1 to 1-7, 1-9, 1-11 to 1-12, 1-14 to 1-15, 1-17 to 1-19, 1-21, 1-23 to 1-24, 1-26 to 1-27, and 1-29 to 1-35, wherein A 1 for
[0769] Embodiment 1-39. A compound according to any one of embodiments 1-1 to 1-7, 1-9, 1-11 to 1-12, 1-14 to 1-15, 1-17 to 1-19, 1-21, 1-23 to 1-24, 1-26 to 1-27, and 1-29 to 1-35, wherein A 1 for
[0770] Embodiment 1-40. A compound according to any one of embodiments 1-1 to 1-7, 1-9, 1-11 to 1-12, 1-14 to 1-15, 1-17 to 1-19, 1-21, 1-23 to 1-24, 1-26 to 1-27, and 1-29 to 1-35, wherein A 1 for
[0771] Embodiment 1-41. A compound according to any one of embodiments 1-1 to 1-7, 1-9, 1-11 to 1-12, 1-14 to 1-15, 1-17 to 1-19, 1-21, 1-23 to 1-24, 1-26 to 1-27, and 1-29 to 1-35, wherein A 1 for
[0772] Embodiment 1-42. A compound according to any one of embodiments 1-1 to 1-7, 1-9, 1-11 to 1-12, 1-14 to 1-15, 1-17 to 1-19, 1-21, 1-23 to 1-24, 1-26 to 1-27, and 1-29 to 1-35, wherein A 1 for
[0773] Embodiment 1-43. A compound according to any one of embodiments 1-1 to 1-7, 1-9, 1-11 to 1-12, 1-14 to 1-15, 1-17 to 1-19, 1-21, 1-23 to 1-24, 1-26 to 1-27, and 1-29 to 1-35, wherein A 1 for
[0774] Embodiment 1-44. A compound according to any one of embodiments 1-1 to 1-7, 1-9, 1-11 to 1-12, 1-14 to 1-15, 1-17 to 1-19, 1-21, 1-23 to 1-24, 1-26 to 1-27, and 1-29 to 1-35, wherein A 1 for
[0775] Embodiment 1-45. A compound according to any one of embodiments 1-1 to 1-9, 1-17 to 1-21 and 1-29 to 1-44, wherein A 2 Does not exist.
[0776] Embodiment 1-46. A compound according to any one of embodiments 1-1 to 1-7, 1-10 to 1-15, 1-17 to 1-19, 1-22 to 1-27, and 1-29 to 1-44, wherein A 2 for
[0777] Embodiment 1-47. A compound according to any one of embodiments 1-1 to 1-7, 1-10 to 1-15, 1-17 to 1-19, 1-22 to 1-27, and 1-29 to 1-44, wherein A 2 for
[0778] Embodiment 1-48. A compound according to any one of embodiments 1-1 to 1-7, 1-10 to 1-15, 1-17 to 1-19, 1-22 to 1-27, and 1-29 to 1-44, wherein A 2 for
[0779] Embodiment 1-49. A compound according to any one of embodiments 1-1 to 1-7, 1-10 to 1-15, 1-17 to 1-19, 1-22 to 1-27, and 1-29 to 1-44, wherein A 2 for
[0780] Embodiment I-50. A compound according to any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27, and I-29 to I-44, wherein A 2 for
[0781] Embodiment I-51. A compound according to any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27, and I-29 to I-44, wherein A 2 for
[0782] Embodiment 1-52. A compound according to any one of embodiments 1-1 to 1-7, 1-10 to 1-15, 1-17 to 1-19, 1-22 to 1-27, and 1-29 to 1-44, wherein A 2 for
[0783] Embodiment 1-53. A compound according to any one of embodiments 1-1 to 1-7, 1-10 to 1-15, 1-17 to 1-19, 1-22 to 1-27, and 1-29 to 1-44, wherein A 2 for
[0784] Embodiment I-54. A compound according to any one of Embodiments I-1 to I-53, wherein B is
[0785] Embodiment I-55. A compound according to any one of embodiments I-1 to I-53, wherein B is
[0786] Embodiment I-56. A compound according to any one of embodiments I-1 to I-53, wherein B 1 for NR 3 -(C(R 3 )2) n -.
[0787] Embodiment I-57. A compound according to any one of Embodiments I-1 to I-53, wherein B 1 for
[0788] Embodiment I-58. A compound according to any one of embodiments I-1 to I-57, wherein R 4 is optionally replaced by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN or -C(O)NR 3 -heteroaryl-substituted 5- to 12-membered heteroaryl.
[0789] Embodiment I-59. A compound according to any one of Embodiments I-1 to I-58, or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound has the following formula:
[0790]
[0791] Embodiment 1-60. A compound selected from:
[0792]
[0793]
[0794]
[0795]
[0796]
[0797]
[0798]
[0799]
[0800]
[0801]
[0802]
[0803]
[0804]
[0805]
[0806]
[0807]
[0808] or a pharmaceutically acceptable salt or isomer thereof.
[0809] Embodiment I-61. A pharmaceutical composition comprising a compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.
[0810] Embodiment 1-62. A method of treating a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments 1-1 to 1-60, or a pharmaceutically acceptable salt thereof.
[0811] Embodiment 1-63. A method for preventing a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments 1-1 to 1-60, or a pharmaceutically acceptable salt thereof.
[0812] Embodiment 1-64. A method of reducing the risk of a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments 1-1 to 1-60, or a pharmaceutically acceptable salt thereof.
[0813] Embodiment 1-65. The method of any one of embodiments 1-62 to 1-64, wherein the disease is cancer or an immune-mediated disease.
[0814] Embodiment 1-66. A method as described in embodiment 1-65, wherein the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors.
[0815] Embodiment 1-67. A method as described in embodiment 1-65, wherein the immune-mediated disease is selected from resistance to transplantation of heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limb, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type 1 diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis.
[0816] Embodiment 1-68. A method of treating cancer, comprising administering to a subject a therapeutically effective amount of one or more compounds according to any one of Embodiments 1-1 to 1-60, or a pharmaceutically acceptable salt thereof.
[0817] Embodiment 1-69. A method as described in embodiment 1-68, wherein the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors.
[0818] Embodiment 1-70. A method of treating an immune-mediated disease comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments 1-1 to 1-60 or a pharmaceutically acceptable salt thereof.
[0819] Embodiment 1-71. A method according to embodiment 1-70, wherein the immune-mediated disease is selected from resistance to transplantation of heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limb, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type 1 diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis.
[0820] Embodiment 1-72. A method of treating an age-related condition comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments 1-1 to 1-60, or a pharmaceutically acceptable salt thereof.
[0821] Embodiment 1-73. A method according to embodiment 1-72, wherein the age-related condition is selected from sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, hypertension, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, impaired kidney function, and age-related hearing loss, age-related disability (e.g., frailty), cognitive decline, age-related dementia, memory impairment, tendon stiffness, cardiac dysfunction (such as cardiac hypertrophy and systolic and diastolic dysfunction), immunosenescence, cancer, obesity and diabetes.
[0822] Embodiment 1-74. A compound according to any one of Embodiments 1-1 to 1-60, or a pharmaceutically acceptable salt thereof, for use in treating, preventing, or reducing the risk of a disease or condition mediated by mTOR.
[0823] Embodiment I-75. Use of a compound according to any one of Embodiments I-1 to I-60, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating, preventing, or reducing the risk of a disease or condition mediated by mTOR.
[0824] Embodiment 1-76. A compound according to any one of Embodiments 1-1 to 1-60, or a pharmaceutically acceptable salt thereof, for use in treating cancer.
[0825] Embodiment I-77. Use of a compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating cancer.
[0826] Embodiment 1-78. A compound according to any one of Embodiments 1-1 to 1-60, or a pharmaceutically acceptable salt thereof, for use in treating an immune-mediated disease.
[0827] Embodiment I-79. Use of a compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of an immune-mediated disease.
[0828] Embodiment I-80. A compound according to any one of Embodiments I-1 to I-60, or a pharmaceutically acceptable salt thereof, for use in treating an age-related condition.
[0829] Embodiment I-81. Use of a compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating an age-related condition.
[0830] Some embodiments of the present invention are the following embodiment II:
[0831] Embodiment II-1. A compound of formula Ic:
[0832]
[0833] or a pharmaceutically acceptable salt or tautomer thereof, wherein:
[0834] R 32 -H, =O, -OR 3 、-N3 or -OC(=Z 1 )-R 32a ;
[0835] R 28 is -H, (C1-C6) alkyl or -C(=Z 1 )-R 28a ;
[0836] R 40 is -H or -C(=Z 1 )-R 40a ;
[0837] When R 28 and R 40 When H, R 32 Not = O;
[0838] Z 1 Each independently is O or S;
[0839] R 28a 、R 32a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B, -O-(C1-C6)alkyl, or -O-(C6-C 10 ) aryl; wherein -O-(C6-C 10 ) the aryl group of the aryl group is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen;
[0840] A 1 and A 2 are independently absent or independently selected from
[0841]
[0842] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The key on the right side of the part is bound to B or L 3 ;
[0843] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0844] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0845] X 1 each independently a heteroarylene or heterocyclylene ring;
[0846] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0847] W 1 each independently a heteroarylene or heterocyclylene ring;
[0848] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0849] G 1 and G 2 each independently a heteroarylene or heterocyclylene ring;
[0850] L 1 Each independently selected from
[0851]
[0852] L 2 and L 3 are independently absent or independently selected from
[0853]
[0854] B are each independently selected from
[0855]
[0856] B 1 Each independently selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, NR 3 -(C(R 3 )2) n -heteroarylene-(C(R 3 )2) n -、 (C6-C 10)arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-,
[0857]
[0858] S(O)2-arylene-C(O)- and NR 3 -(C(R 3 )2) n -S(O)2-arylene-(C(R 3 )2) n -, where as depicted, B 1 On the left Bonded to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;
[0859] R 3 Each is independently H or (C1-C6) alkyl;
[0860] R 4 Each is independently H, (C1-C6) alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C6-C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 -heterocyclyl substitution;
[0861] R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R3 )2OR-OR 3 replace;
[0862] R 6 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0863] R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0864] R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0865] Y is each independently C(R 3 )2 or key;
[0866] n is each independently an integer from 1 to 12;
[0867] o are each independently an integer from 0 to 30;
[0868] p is each independently an integer from 0 to 12;
[0869] q is each independently an integer from 0 to 30; and
[0870] r is an integer of 1 to 6, each independently.
[0871] Embodiment II-1A. A compound of formula Ia:
[0872]
[0873] or a pharmaceutically acceptable salt or tautomer thereof, wherein:
[0874] R 32 -H, =O, -OR 3 、-N3 or -OC(=Z 1 )-R 32a ;
[0875] R 28 is -H, (C1-C6) alkyl or -C(=Z 1 )-R 28a ;
[0876] R 40 is -H or -C(=Z 1 )-R 40a ;
[0877] When R 28 and R 40 When H, R 32 Not = O;
[0878] Z 1 Each independently is O or S;
[0879] R 28a 、R 32a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B, -O-(C1-C6)alkyl, or -O-(C6-C 10 ) aryl; wherein -O-(C6-C 10 ) the aryl group of the aryl group is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen;
[0880] A 1 and A 2 are independently absent or independently selected from
[0881]
[0882] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The key on the right side of the part is bound to B or L 3 ;
[0883] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0884] Each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0885] X 1 each independently a heteroarylene or heterocyclylene ring;
[0886] W is each independently absent or 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0887] W 1 each independently a heteroarylene or heterocyclylene ring;
[0888] Each G is independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;
[0889] G 1 and G 2 each independently a heteroarylene or heterocyclylene ring;
[0890] L 1 Each independently selected from
[0891]
[0892] L 2 and L 3 are independently absent or independently selected from
[0893]
[0894] B are each independently selected from
[0895]
[0896] B 1 Selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, (C6-C 10 )arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-、 NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 )arylene-, Heteroarylene-heterocyclylene-(C6-C 10 )arylene-,
[0897] and
[0898] NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)-, wherein as shown, B 1 On the left Bonded to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene groups are optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;
[0899] R 3 Each is independently H or (C1-C6) alkyl;
[0900] R 4 Each is independently H, (C1-C6) alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C6-C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 )2、-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 -heterocyclyl substitution;
[0901] R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0902] R 6Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0903] R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0904] R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally replaced by -N(R 3 )2OR-OR 3 replace;
[0905] Y is each independently C(R 3 )2 or key;
[0906] n is each independently an integer from 1 to 12;
[0907] o are each independently an integer from 0 to 30;
[0908] p is each independently an integer from 0 to 12;
[0909] q is each independently an integer from 0 to 30; and
[0910] r is an integer of 1 to 6, each independently.
[0911] Embodiment II-2. Compounds according to embodiment II-1, wherein R 32 =O.
[0912] Embodiment II-3. A compound according to embodiment II-1, wherein R 32 For-OR 3 .
[0913] Embodiment II-4. A compound according to any one of Embodiments II-1 to II-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound is represented by the structure of Formula (I-40b):
[0914]
[0915] where R 40 -C(=Z 1 )-R 40a .
[0916] Embodiment II-5. A compound according to embodiment II-4, wherein Z 1 It is O.
[0917] Embodiment II-6. A compound according to embodiment II-4, wherein Z 1 For S.
[0918] Embodiment II-7. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a -A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.
[0919] Embodiment II-8. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a -A 1 -L 1 -A 2 -B, where A 2 Does not exist.
[0920] Embodiment II-9. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a -A 1 -L 1 -A 2 -B, where A 1 Does not exist.
[0921] Embodiment II-10. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a -A 1 -L 1 -A 2 -B.
[0922] Embodiment II-11. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a -A 1 -A 2 -B.
[0923] Embodiment II-12. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a -L 2 -A 1 -L 1-A 2 -L 3 -B, where L 2 and A 1 Does not exist.
[0924] Embodiment II-13. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 Does not exist.
[0925] Embodiment II-14. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.
[0926] Embodiment II-15. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a is -O-(C1-C6)alkyl or -O-(C6-C 10 ) aryl; wherein -O-(C6-C 10 ) The aryl group of the aryl group is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen.
[0927] Embodiment II-16. A compound according to any one of Embodiments II-1 to II-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound is represented by the structure of Formula (I-28b):
[0928]
[0929] where R 28 -C(=Z 1 )-R 28a .
[0930] Embodiment II-17. A compound according to embodiment II-16, wherein Z 1 It is O.
[0931] Embodiment II-18. A compound according to embodiment II-16, wherein Z 1 For S.
[0932] Embodiment II-19. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a -A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.
[0933] Embodiment II-20. A compound according to any one of embodiments II-16 to II-18, wherein R 28a -A 1 -L 1 -A 2 -B, where A 2 Does not exist.
[0934] Embodiment II-21. A compound according to any one of embodiments II-16 to II-18, wherein R 28a -A 1 -L 1 -A 2 -B, where A 1 Does not exist.
[0935] Embodiment II-22. A compound according to any one of embodiments II-16 to II-18, wherein R 28a -A 1 -L 1 -A 2 -B.
[0936] Embodiment II-23. A compound according to any one of embodiments II-16 to II-18, wherein R 28a -A 1 -A 2 -B.
[0937] Embodiment II-24. A compound according to any one of embodiments II-16 to II-18, wherein R 28a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.
[0938] Embodiment II-25. A compound according to any one of embodiments II-16 to II-18, wherein R 28a -L 2 -A 1 -L 1 -A 2 -L3 -B, where L 2 Does not exist.
[0939] Embodiment II-26. A compound according to any one of embodiments II-16 to II-18, wherein R 28a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.
[0940] Embodiment II-27. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a is -O-(C1-C6)alkyl or -O-(C6-C 10 ) aryl; wherein -O-(C6-C 10 ) The aryl group of the aryl group is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen.
[0941] Embodiment II-28. The compound of Embodiment II-1 or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound is represented by the structure of Formula (I-32b):
[0942]
[0943] where R 32 = -OC( 1 )-R 32a .
[0944] Embodiment II-29. A compound according to embodiment II-28, wherein Z 1 It is O.
[0945] Embodiment II-30. A compound according to embodiment II-28, wherein Z 1 For S.
[0946] Embodiment II-31. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a -A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.
[0947] Embodiment II-32. A compound according to any one of embodiments II-28 to II-30, wherein R 32a -A 1 -L 1-A 2 -B, where A 2 Does not exist.
[0948] Embodiment II-33. A compound according to any one of embodiments II-28 to II-30, wherein R 32a -A 1 -L 1 -A 2 -B, where A 1 Does not exist.
[0949] Embodiment II-34. A compound according to any one of embodiments II-28 to II-30, wherein R 32a -A 1 -L 1 -A 2 -B.
[0950] Embodiment II-35. A compound according to any one of embodiments II-28 to II-30, wherein R 32a -A 1 -A 2 -B.
[0951] Embodiment II-36. A compound according to any one of embodiments II-28 to II-30, wherein R 32a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.
[0952] Embodiment II-37. A compound according to any one of embodiments II-28 to II-30, wherein R 32a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 Does not exist.
[0953] Embodiment II-38. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.
[0954] Embodiment II-39. A compound according to any one of embodiments II-28 to II-30, wherein R 32a is -O-(C1-C6)alkyl or -O-(C6-C 10 ) aryl; wherein -O-(C6-C 10 ) The aryl group of the aryl group is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen.
[0955] Embodiment II-40. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for
[0956] Embodiment II-41. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for
[0957] Embodiment II-42. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, 24 to 35 and 36 to 39, wherein L 1 for
[0958] Embodiment II-43. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for
[0959] Embodiment II-44. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for
[0960] Embodiment II-45. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for
[0961] Embodiment II-46. A compound according to any one of Embodiments II-1 to II-6, II-12 to II-18, II-24 to II-30, and II-36 to II-45, wherein L 2for
[0962] Embodiment II-47. A compound according to any one of Embodiments II-1 to II-6, II-12 to II-18, II-24 to II-30, and II-36 to II-45, wherein L 3 for
[0963] Embodiment II-48. A compound according to any one of Embodiments II-1 to II-7, II-9, II-12, II-16 to II-19, II-21, II-24, II-28 to II-31, II-33, II-36, and II-39 to II-45, wherein A 1 Does not exist.
[0964] Embodiment II-49. A compound according to any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35, and II-37 to II-45, wherein A 1 for
[0965] Embodiment II-50. A compound according to any one of embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35, and II-37 to II-45, wherein A 1 for
[0966] Embodiment II-51. A compound according to any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35, and II-37 to II-45, wherein A 1 for
[0967] Embodiment II-52. A compound according to any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35, and II-37 to II-45, wherein A 1 for
[0968] Embodiment II-53. A compound according to any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35, and II-37 to II-45, wherein A 1 for
[0969] Embodiment II-54. A compound according to any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35, and II-37 to II-45, wherein A 1 for
[0970] Embodiment II-55. A compound according to any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35, and II-37 to II-45, wherein A 1 for
[0971] Embodiment II-56. A compound according to any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35, and II-37 to II-45, wherein A 1 for
[0972] Embodiment II-57. A compound according to any one of Embodiments II-1 to II-8, II-15 to II-20, II-27 to II-32, and II-39 to II-45, wherein A 2 Does not exist.
[0973] Embodiment II-58. A compound according to any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30, and II-33 to II-45, wherein A 2 for
[0974] Embodiment II-59. A compound according to any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30, and II-33 to II-45, wherein A 2 for
[0975] Embodiment II-60. A compound according to any one of embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30, and II-33 to II-45, wherein A 2 for
[0976] Embodiment II-61. A compound according to any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30, and II-33 to II-45, wherein A 2 for
[0977] Embodiment II-62. A compound according to any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30, and II-33 to II-45, wherein A 2 for
[0978] Embodiment II-63. A compound according to any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30, and II-33 to II-45, wherein A 2 for
[0979] Embodiment II-64. A compound according to any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30, and II-33 to II-45, wherein A 2 for
[0980] Embodiment II-65. A compound according to any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30, and II-33 to II-45, wherein A 2 for
[0981] Embodiment II-66. A compound according to any one of Embodiments II-1 to II-65, wherein B is
[0982] Embodiment II-67. A compound according to any one of Embodiments II-1 to II-65, wherein B is
[0983] Embodiment II-68. A compound according to any one of Embodiments II-1 to II-65, wherein B 1 for NR 3 -(C(R 3 )2) n -.
[0984] Embodiment II-69. A compound according to any one of Embodiments II-1 to II-65, wherein B 1 for
[0985] Embodiment II-70. A compound according to any one of Embodiments II-1 to II-69, wherein R 4 is optionally replaced by -N(R 3 )2、OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN or -C(O)NR 3 -heteroaryl-substituted 5- to 12-membered heteroaryl.
[0986] Embodiment II-71. A compound according to any one of Embodiments II-1 to II-70, or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound has the following formula:
[0987]
[0988] Embodiment II-72. A compound selected from:
[0989]
[0990]
[0991]
[0992]
[0993]
[0994]
[0995]
[0996]
[0997]
[0998]
[0999]
[1000]
[1001]
[1002]
[1003]
[1004]
[1005] or a pharmaceutically acceptable salt or tautomer thereof.
[1006] Embodiment II-73. A compound selected from:
[1007]
[1008]
[1009]
[1010]
[1011]
[1012]
[1013]
[1014]
[1015]
[1016]
[1017]
[1018]
[1019]
[1020]
[1021] or a pharmaceutically acceptable salt or tautomer thereof.
[1022] Embodiment II-74. A compound selected from:
[1023]
[1024]
[1025]
[1026]
[1027] or a pharmaceutically acceptable salt or tautomer thereof.
[1028] Embodiment II-75. A pharmaceutical composition comprising a compound according to any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.
[1029] Embodiment II-76. A method of treating a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof.
[1030] Embodiment II-77. A method for preventing a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof.
[1031] Embodiment II-78. A method of reducing the risk of a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof.
[1032] Embodiment II-79. The method of any one of embodiments II-76 to II-78, wherein the disease is cancer or an immune-mediated disease.
[1033] Embodiment II-80. A method as described in embodiment II-79, wherein the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors.
[1034] Embodiment II-81. A method according to embodiment II-79, wherein the immune-mediated disease is selected from resistance to transplantation of heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limb, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis.
[1035] Embodiment II-82. A method of treating cancer, comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof.
[1036] Embodiment II-83. A method as described in embodiment II-82, wherein the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors.
[1037] Embodiment II-84. A method of treating an immune-mediated disease comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof.
[1038] Embodiment II-85. A method according to embodiment II-84, wherein the immune-mediated disease is selected from resistance to transplantation of heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limb, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis.
[1039] Embodiment II-86. A method of treating an age-related condition comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof.
[1040] Embodiment II-87. A method according to embodiment II-86, wherein the age-related condition is selected from sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, hypertension, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, impaired kidney function, and age-related hearing loss, age-related disability (e.g., frailty), cognitive decline, age-related dementia, memory impairment, tendon stiffness, cardiac dysfunction (such as cardiac hypertrophy and systolic and diastolic dysfunction), immunosenescence, cancer, obesity and diabetes.
[1041] Embodiment II-88. A compound according to any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof, for use in treating, preventing, or reducing the risk of a disease or condition mediated by mTOR.
[1042] Embodiment II-89. Use of a compound according to any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating, preventing, or reducing the risk of a disease or condition mediated by mTOR.
[1043] Embodiment II-90. A compound according to any one of claims 1-74, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
[1044] Embodiment II-91. Use of a compound according to any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating cancer.
[1045] Embodiment II-92. A compound according to any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof, for use in treating an immune-mediated disease.
[1046] Embodiment II-93. Use of a compound according to any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an immune-mediated disease.
[1047] Embodiment II-94. A compound according to any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof, for use in treating an age-related condition.
[1048] Embodiment II-95. Use of a compound according to any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an age-related condition.
[1049] Example
[1050] The present invention is further illustrated by the following examples and synthesis examples, which should not be construed as limiting the present invention to the specific procedures described herein in terms of scope or spirit. It should be understood that these examples are intended to illustrate certain embodiments and do not limit the scope of the present invention. It should be further understood that various other embodiments, modifications, and their equivalents may be employed, which may indicate themselves to those skilled in the art without departing from the spirit of the present invention and / or the scope of the appended claims.
[1051] The definitions used in the following examples and elsewhere herein are:
[1052] CH2Cl2、DCM dichloromethane
[1053] CH3CN, MeCN, acetonitrile
[1054] DIPEA Diisopropylethylamine or Hunig's base
[1055] DMA dimethylacetamide
[1056] DME dimethoxyethane
[1057] DMF N,N-dimethylformamide
[1058] EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
[1059] EtOAc
[1060] h hour
[1061] H2O water
[1062] HCl
[1063] HOBt Hydroxybenzotriazole
[1064] HPLC high-performance liquid chromatography
[1065] LCMS liquid chromatography-mass spectrometry
[1066] MeOH methanol
[1067] MTBE methyl tert-butyl ether
[1068] Na2SO4 sodium sulfate
[1069] PEG polyethylene glycol
[1070] TBDMS tert-butyldimethylsilyl
[1071] TFA trifluoroacetic acid
[1072] THF Tetrahydrofuran
[1073] TMS Tetramethylsilane
[1074] Series 1 bifunctional rapamycin analogs
[1075] The general structure of the series 1 bifunctional rapalogs is shown in Scheme 1 below. For these types of bifunctional rapalogs, the linker may contain variations where q = 0 to 30, such as q = 1 to 7, and r = 1 to 6. The linker amine may contain substituents such as R = H and C1-C6 alkyl. The carbamate moiety (where Z 1 =O or S) can be in R 40 or R 28 (Formulas I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.
[1076] Scheme 1. Series 1 bifunctional rapamycin analogs.
[1077]
[1078] Series 2 bifunctional rapamycin analogs
[1079] The general structure of a series 2 bifunctional rapalog is shown below in Scheme 2. For these types of bifunctional rapalogs, the linker may comprise variations where q = 0 to 30, such as q = 1 to 7. The linker amine may comprise substituents such as R = H and C1-C6 alkyl. The pre-linker amine may comprise substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formulas I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.
[1080] Scheme 2. Series 2 bifunctional rapamycin analogs.
[1081]
[1082] Series 3 bifunctional rapamycin analogs
[1083] The general structure of a series 3 bifunctional rapalog is shown below in Scheme 3. For these types of bifunctional rapalogs, the linker may comprise variations where q = 0 to 30, such as q = 1 to 7. The linker amine may comprise substituents such as R = H and C1-C6 alkyl. The latter linker amine may comprise substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formulas I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.
[1084] Scheme 3. Series 3 Bifunctional Rapalogs
[1085]
[1086] Series 4 bifunctional rapamycin analogs
[1087] The general structure of a series 4 bifunctional rapalog is shown in Scheme 4 below. For these types of bifunctional rapalogs, the linker may comprise variations where q = 0 to 30, such as q = 1 to 7. The linker amine may comprise substituents such as R = H and C1-C6 alkyl. The front linker amine and the back linker amine may each comprise substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formulas I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.
[1088] Scheme 4. Series 4 Bifunctional Rapalogs
[1089]
[1090] Series 5 bifunctional rapamycin analogs
[1091] The general structure of a series 5 bifunctional rapalog is shown below in Scheme 5. For these types of bifunctional rapalogs, the front linker amine may contain a substituent such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R28 (Formulas I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.
[1092] Scheme 5. Series 5 Bifunctional Rapaxoids
[1093]
[1094] Series 6 bifunctional rapamycin analogs
[1095] The general structure of a series 6 bifunctional rapalog is shown below in Scheme 6. For these types of bifunctional rapalogs, the linker may comprise variations where q = 0 to 30, such as q = 1 to 7. The linker amine may comprise substituents such as R = H and C1-C6 alkyl. The latter linker amine may comprise substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formulas I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.
[1096] Scheme 6. Series 6 Bifunctional Rapaxoids
[1097]
[1098] Series 7 bifunctional rapamycin analogs
[1099] The general structure of a series 7 bifunctional rapalogs is shown below in Scheme 7. For these types of bifunctional rapalogs, the linker may comprise variations where q = 0 to 30, such as q = 1 to 7. The linker amine may comprise substituents such as R = H and C1-C6 alkyl. The front linker amine and the back linker amine may each comprise substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formulas I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.
[1100] Scheme 7. Series 7 Bifunctional Rapaxoids
[1101]
[1102] Series 8 bifunctional rapamycin analogs
[1103] The general structure of a series 8 bifunctional rapalog is shown below in Scheme 8. For these types of bifunctional rapalogs, the linker may comprise variations where q = 0 to 30, such as q = 1 to 7. The linker amine may comprise substituents such as R = H and C1-C6 alkyl. The latter linker amine may comprise substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formulas I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.
[1104] Scheme 8. Series 8 Bifunctional Rapaxoids
[1105]
[1106] Table 1. Carbonate- and thiocarbonate-containing rapamycin monomers.
[1107]
[1108]
[1109]
[1110] Table 2. Active site inhibitor monomers.
[1111]
[1112]
[1113]
[1114]
[1115]
[1116]
[1117] Table 3. Active site inhibitor monomers
[1118]
[1119]
[1120] Table 4. Amine containing front and back linkers.
[1121]
[1122]
[1123]
[1124]
[1125]
[1126]
[1127] Preparation of active site inhibitor monomers
[1128] Monomer A. 5-(4-amino-1-(4-(aminomethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.
[1129]
[1130] Step 1: Synthesis of tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate
[1131] To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3.8 g, 14.56 mmol, 1.0 eq) in DMF (20 mL) at 0° C., NaH (582.27 mg, 14.56 mmol, 60 wt%, 1.0 eq) was added and the reaction solution was stirred at this temperature for 30 minutes. Tert-butyl 4-(bromomethyl)benzylcarbamate (4.59 g, 15.29 mmol, 1.05 eq) was then added to the reaction at 0° C. and the reaction solution was stirred at room temperature for 2 hours. The solution was poured into H O (80 mL) and the precipitated solid was filtered. The solid filter cake was washed with H2O (2 x 10 mL) and then dried under reduced pressure to give tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate (5 g, 53% yield) as a yellow solid. LCMS (ESI) m / z: [M+Na] for C 18 H 21 Calculated value of IN6O2: 503.07; measured value 503.2.
[1132] Step 2: Synthesis of tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate
[1133] To a biphasic suspension of tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate (5 g, 7.68 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (2.40 g, 9.22 mmol, 1.2 equiv), and Pd(PPh3)4 (887.66 mg, 768.16 μmol, 0.1 equiv) in DME (100 mL) and H2O (50 mL) was added Na2CO3 (1.91 g, 23.04 mmol, 3.0 equiv) at room temperature under N2. The mixture was stirred at 110°C for 3 hours. The reaction mixture was cooled to room temperature and filtered, and the filtrate was extracted with EtOAc (3x 50mL). The organic phase was combined and washed with brine (10mL), dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel chromatography (0 → 20% MeOH / EtOAc) to obtain tert-butyl 4-((4-amino-3-(2-aminobenzo [d] oxazole-5-yl) -1H- pyrazolo [3,4-d] pyrimidin-1-yl) methyl) benzylcarbamate (4.5g, 82% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 25 H 26 Calculated value of N8O3: 487.22; measured value: 487.2.
[1134] Step 3: Synthesis of 5-(4-amino-1-(4-(aminomethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine
[1135] To a solution of tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate (4.5 g, 6.29 mmol, 1.0 equiv) in DCM (50 mL) was added TFA (30.80 g, 270.12 mmol, 20 mL, 42.95 equiv) at 0°C. The reaction solution was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to give a residue, which was dissolved in 10 mL of MeCN and then poured into MTBE (100 mL). The precipitated solid was then filtered and the solid cake was dried under reduced pressure to give 5-[4-amino-1-[[4-(aminomethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzoxazol-2-amine (2.22 g, 71% yield, TFA) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 20 H 18 Calculated N8O value: 387.16; measured value: 387.1.
[1136] Monomer B. 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-6-ol trifluoroacetate.
[1137]
[1138] Step 1: Synthesis of tert-butyl N-(4-{4-amino-3-[6-(benzyloxy)-1H-indol-2-yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}butyl)carbamate
[1139] To a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)benzylcarbamate (300 mg, 694 μmol, 1.0 equiv) and (6-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-indol-2-yl)boronic acid (763 mg, 2.08 mmol, 3.0 equiv) in DMF (2.6 mL), EtOH (525 μL) and H2O (350 μL) were added Pd(OAc)2 (15.5 mg, 69 μmol, 0.1 equiv), triphenylphosphine (36.1 mg, 138 μmol, 0.2 equiv) and sodium carbonate (440 mg, 4.16 mmol, 6.0 equiv). The reaction was heated at 80 ° C for 20 hours, cooled to room temperature, and quenched with H2O (10 mL) and EtOAc (10 mL). The mixture was transferred to a separatory funnel and the aqueous phase was extracted with EtOAc (3x 20 mL). The combined organic phases were washed with saturated aqueous NaCl solution (1x 20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude material was purified by silica gel chromatography (20→85% EtOAc / heptane) to give the product (201 mg, 46% yield) as an orange solid. LCMS (ESI) m / z: [M+H] for C 29 H 33 Calculated value of N7O3: 528.27; measured value: 528.2.
[1140] Step 2: Synthesis of tert-butyl (4-(4-amino-3-(6-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate
[1141] To a solution of tert-butyl N-(4-{4-amino-3-[6-(benzyloxy)-1H-indol-2-yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}butyl)carbamate (1.0 equiv) in EtOH was added Pd / C (10 mol%). The reaction was purged with H2 and allowed to stir under an H2 atmosphere until the starting material was consumed as determined by LCMS. The reaction was then diluted with EtOAc, filtered through celite, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography to give the desired product.
[1142] Step 3: Synthesis of 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-6-ol
[1143] To a solution of tert-butyl (4-(4-amino-3-(6-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) in anhydrous DCM was added TFA (50 equiv) dropwise at 0°C. The reaction was stirred at 0°C and warmed to room temperature. Once the reaction was complete, as determined by LCMS, the reaction was concentrated under reduced pressure. The residue was triturated with MeCN and then added dropwise to MTBE over 10 minutes. The supernatant was removed and the precipitate was collected by filtration under N2 to give 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-6-ol.
[1144] Monomer C. 5-(4-amino-1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.
[1145]
[1146] Step 1. Synthesis of tert-butyl 6-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[1147] To a suspension of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (5 g, 19.16 mmol, 1.0 equiv) in DMF (50.0 mL) at 4°C was added NaH (766.22 mg, 19.16 mmol, 60 wt%, 1.0 equiv). The mixture was stirred at 4°C for 30 minutes. To the reaction mixture was added tert-butyl 6-(bromomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (6.87 g, 21.07 mmol, 1.1 equiv) in DMF (30 mL) at 4°C. The mixture was stirred at room temperature for 2 hours. The mixture was then cooled to 4°C, and H2O (400 mL) was added and stirred for 30 minutes. The resulting precipitate was collected by filtration to give crude tert-butyl 6-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (9.7 g, 76% yield) as a light yellow solid. The crude product was used directly in the next step.
[1148] Step 2: Synthesis of tert-butyl 6-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[1149] To a biphasic suspension of tert-butyl 6-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (9.7 g, 14.63 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (4.57 g, 17.55 mmol, 1.2 equiv), and Na2CO3 (7.75 g, 73.14 mmol, 5.0 equiv) in DME (120.0 mL) and H2O (60 mL) was added Pd(PPh3)4 (1.69 g, 1.46 mmol, 0.1 equiv) at room temperature under N2. The mixture was stirred at 110°C for 3 hours. The reaction mixture was then cooled to room temperature and partitioned between EtOAc (100 mL) and H2O (100 mL). The aqueous layer was separated and extracted with EtOAc (2 x 60 mL). The organic layers were combined, washed with brine (80 mL) and dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (1 → 100% EtOAc / petroleum ether, then 20 → 50% MeOH / EtOAc) to give tert-butyl 6-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (4.5 g, 58% yield) as a light yellow solid.
[1150] Step 3: Synthesis of 5-(4-amino-1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine
[1151] To neat TFA (32.5 mL, 438.97 mmol, 50.0 equiv) was added tert-butyl 6-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (4.5 g, 8.78 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 30 minutes and then concentrated under reduced pressure. The oily residue was triturated with MeCN (8 mL) and then added dropwise to MTBE (350 mL) over 10 minutes. The supernatant was removed and the precipitate was then collected by filtration under N2 to give 5-(4-amino-1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (5.72 g, over 100% yield, TFA) as a light pink solid. LCMS (ESI) m / z: [M+H] for C 22 H20 Calculated N8O value: 413.18; measured value: 413.2.
[1152] Monomer D. 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-7-ol trifluoroacetate.
[1153]
[1154] Step 1. Synthesis of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-methoxy-1H-indole-1-carboxylate
[1155] To a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) and (1-(tert-butyloxycarbonyl)-7-methoxy-1H-indol-2-yl)boronic acid (3.0 equiv) in DME and H2O was added Pd(PPh3)4 (0.1 equiv) and sodium carbonate (6.0 equiv). The reaction was heated at 80°C until complete, as determined by LCMS and TLC analysis. The reaction was then quenched with H2O and EtOAc. The mixture was transferred to a separatory funnel and the aqueous phase was extracted with EtOAc. The organic phase was washed with saturated aqueous NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The desired product was isolated after chromatography on silica gel.
[1156] Step 2: Synthesis of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-hydroxy-1H-indole-1-carboxylate
[1157] To a solution of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-methoxy-1H-indole-1-carboxylate (1.0 equiv) in DCM was added BBr (2.0 equiv) at -10 °C. The reaction was allowed to stir until the starting material was consumed as determined by LCMS. The reaction was quenched by the slow addition of saturated aqueous NaHCO, transferred to a separatory funnel and the mixture was extracted with DCM. The organic phase was washed with saturated aqueous NaCl, dried over NaSO, filtered and concentrated under reduced pressure. The desired product was isolated after chromatography on silica gel.
[1158] Step 3: Synthesis of 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-7-ol
[1159] To a solution of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-hydroxy-1H-indole-1-carboxylate (1.0 equiv) in DCM was added TFA dropwise at 0°C. The reaction was stirred at 0°C and warmed to room temperature. Once the reaction was complete, as determined by LCMS, the reaction was concentrated under reduced pressure. The residue was triturated with MeCN and then added dropwise to MTBE over 10 minutes. The supernatant was removed and the precipitate was collected by filtration under N2 to give 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-7-ol.
[1160] Monomer E. 5-(4-amino-1-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.
[1161]
[1162] Step 1: Synthesis of tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate
[1163] To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3 g, 11.49 mmol, 1.0 equiv) in DMA (30 mL) was added tert-butyl 4-(bromomethyl)piperidine-1-carboxylate (3.36 g, 12.07 mmol, 1.05 equiv) and KCO (4.77 g, 34.48 mmol, 3.0 equiv), and the reaction was stirred at 80° C. for 3 hours. The reaction mixture was filtered to remove the KCO and the filtrate was poured into H0 (200 mL). The precipitated solid was then filtered to give tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (3 g, 57% yield) as a light yellow solid. LCMS (ESI) m / z: [M+H] for C 16 H 23 Calculated value of IN6O2: 459.10; measured value: 459.1.
[1164] Step 2: Synthesis of tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate
[1165] To a biphasic suspension of tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (3 g, 6.55 mmol, 1.0 equiv) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (2.04 g, 7.86 mmol, 1.2 equiv) and NaCO (3.47 g, 32.73 mmol, 5.0 equiv) in DME (60 mL) and H O (30 mL) at room temperature under N was added Pd(PPh) (756.43 mg, 654.60 μmol, 0.1 equiv). The mixture was stirred at 110° C. for 3 h and the two batches were combined. The reaction mixture was cooled and partitioned between EtOAc (500 mL) and H2O (500 mL). The aqueous layer was separated and extracted with EtOAc (3 x 300 mL). All organic layers were combined, washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (4.5 g, 74% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 23 H 28 Calculated value of N8O3: 465.24; measured value: 465.2.
[1166] Step 3: Synthesis of 5-(4-amino-1-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine
[1167] A solution of tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (2.5 g, 5.38 mmol, 1.0 equiv) in TFA (25 mL) was stirred at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure to remove TFA. The residue was added to MTBE (400 mL), and the precipitated solid was then filtered to give 5-(4-amino-1-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (2.7 g, over 100% yield, TFA) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 18 H 20 Calculated N8O value: 365.18; measured value: 365.1.
[1168] Monomer F. 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol trifluoroacetate.
[1169]
[1170] Step 1: Synthesis of tert-butyl (4-(4-amino-3-(5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate
[1171] To a solution of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 g, 2.31 mmol, 1.0 equiv) in dioxane (10.5 mL) and H2O (3.5 mL) at room temperature under N2 were added (1-(tert-butoxycarbonyl)-5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)boronic acid (1.54 g, 2.78 mmol, 1.2 equiv), K3PO4 (1.47 g, 6.94 mmol, 3.0 equiv), Pd2(dba)3 (211.84 mg, 231.34 μmol, 0.1 equiv) and SPhos (189.95 mg, 462.69 μmol, 0.2 equiv). The sealed tube was heated at 150 ° C in a microwave for 20 minutes. Repeat this 9 additional batches. Merge 10 batches and the reaction mixture is cooled and distributed between EtOAc (60 mL) and H2O (80 mL). The water layer is separated and extracted with EtOAc (2x 50 mL). The organic layer is combined, washed with brine (60 mL) and dried over anhydrous Na2SO4. The suspension is filtered and the filtrate is concentrated under reduced pressure. The crude material is purified by silica gel chromatography (1 → 75% EtOAc / petroleum ether). The required fractions are merged and evaporated under reduced pressure to obtain tert-butyl (4-(4-amino-3-(5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (10 g, 60% yield) as a light yellow solid.
[1172] Step 2: Synthesis of tert-butyl (4-(4-amino-3-(5-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate
[1173] To a mixture of tert-butyl (4-(4-amino-3-(5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (10 g, 18.12 mmol, 1.0 equiv) in THF (100 mL) at room temperature under N2 was added TBAF.3H2O (1 M, 54.37 mL, 3.0 equiv) in one portion. The mixture was stirred for 1 hour, and then H2O (100 mL) was added to the reaction mixture. The layers were separated and the aqueous phase was extracted with EtOAc (2 x 80 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (1→67% EtOAc / petroleum ether) to give tert-butyl (4-(4-amino-3-(5-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (7 g, 87% yield) as a light pink solid.
[1174] Step 3: Synthesis of 2-[4-amino-1-(4-aminobutyl)pyrazolo[3,4-d]pyrimidin-3-yl]-1H-indol-5-ol
[1175] To TFA (50.0 mL, 675.26 mmol, 38.9 equiv) was added tert-butyl (4-(4-amino-3-(5-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (7.6 g, 17.37 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 40 minutes and then concentrated under reduced pressure. The oily residue was triturated with MeCN (20 mL) and then added dropwise to MTBE (300 mL) for 10 minutes. The supernatant was removed, and the precipitate was then collected by filtration under N2 to give 2-[4-amino-1-(4-aminobutyl)pyrazolo[3,4-d]pyrimidin-3-yl]-1H-indol-5-ol (7.79 g, 91% yield, TFA) as a light yellow solid. LCMS (ESI) m / z: [M+H] for C 17 H 19 Calculated N7O value: 338.17; measured value: 338.2.
[1176] Monomer G. 5-(4-amino-1-(azetidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.
[1177]
[1178] Step 1: Synthesis of tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate
[1179] To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (4 g, 15.32 mmol, 1.0 equiv), tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (3.01 g, 16.09 mmol, 1.05 equiv) and PPh (6.03 g, 22.99 mmol, 1.5 equiv) in THF (80 mL) cooled to 0° C. was added DIAD (4.47 mL, 22.99 mmol, 1.5 equiv) dropwise. After the addition was complete, the reaction was stirred at room temperature for 14 hours. The reaction was poured into H O (200 mL) and then extracted with EtOAc (3 x 50 mL). The organic layers were combined and washed with brine (2 x 50 mL). The organic phase was dried over Na SO, filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (0→100% EtOAc / petroleum ether) to give tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate (4.2 g, 64% yield) as a white solid. LCMS (ESI) m / z: [M+H] for C 14 H 19 Calculated value of IN6O2: 431.07; measured value: 431.0.
[1180] Step 2: Synthesis of tert-butyl 3-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate
[1181] To a biphasic suspension of tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate (4 g, 9.30 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (2.90 g, 11.16 mmol, 1.2 equiv) and Na2CO3 (4.93 g, 46.49 mmol, 5.0 equiv) in DME (100 mL) and H2O (50 mL) was added Pd(PPh3)4 (1.07 g, 929.71 μmol, 0.1 equiv) at room temperature under N2. The mixture was stirred at 110°C for 3 hours. The reaction mixture was then cooled to room temperature and filtered, and the filtrate was extracted with EtOAc (3x50mL). The organic layers were combined and washed with brine (10mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (0 → 20% MeOH / EtOAc) to give tert-butyl 3-((4-amino-3-(2-aminobenzo [d] oxazol-5-yl) -1H- pyrazolo [3,4-d] pyrimidin-1-yl) methyl) azetidine-1-carboxylate (3.5 g, 80% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 21 H 24 Calculated value of N8O3: 437.20; measured value: 437.2.
[1182] Step 3: Synthesis of 5-(4-amino-1-(azetidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine
[1183] To a solution of tert-butyl 3-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate (3.29 g, 6.87 mmol, 1.0 equiv) in DCM (20 mL) was added TFA (7.50 mL, 101.30 mmol, 14.7 equiv) at 0°C. The reaction was warmed to room temperature and stirred for 2 hours. The reaction solution was concentrated under reduced pressure to give a residue. The residue was dissolved in MeCN (6 mL) and then poured into MTBE (80 mL). The precipitated solid was filtered and the solid cake was dried under reduced pressure to give 5-[4-amino-1-(azetidin-3-ylmethyl)pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzoxazol-2-amine (4.34 g, over 100% yield, TFA) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 16 H16 Calculated N8O value: 337.15; measured value: 337.1.
[1184] Monomer H. 5-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]-oxazol-2-amine trifluoroacetate.
[1185]
[1186] This monomer was synthesized following the procedure outlined in Nature 2015, 534, 272-276 (incorporated by reference in its entirety).
[1187] Monomer I. 5-(4-amino-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.
[1188]
[1189] Step 1: Synthesis of tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate
[1190] A suspension of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (4.5 g, 17.24 mmol, 1.0 equiv), tert-butyl 3-(bromomethyl)pyrrolidine-1-carboxylate (4.78 g, 18.10 mmol, 1.05 equiv), and KCO (7.15 g, 51.72 mmol, 3.0 equiv) in DMA (40 mL) was heated to 85° C. The reaction was stirred at 85° C. for 3 hours, at which point the solution was cooled to room temperature. HO (80 mL) was then added to the reaction, and a solid precipitated. The mixture was filtered, and the solid cake was washed with H2O (2 x 40 mL) and then dried under reduced pressure to give tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate (6 g, 78% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 15 H 21 Calculated value of IN6O2: 445.08; measured value: 445.1.
[1191] Step 2: Synthesis of tert-butyl 3-[[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]pyrrolidine-1-carboxylate
[1192] To a biphasic suspension of tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate (4 g, 9.00 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (2.81 g, 10.80 mmol, 1.2 equiv) and NaCO (4.77 g, 45.02 mmol, 5.0 equiv) in DME (120 mL) and H O (60 mL) was added Pd(PPh) (1.04 g, 900.35 μmol, 0.1 equiv) at room temperature under N. The mixture was stirred at 110° C. for 3 h. The reaction mixture was cooled to room temperature and filtered, and the filtrate was extracted with EtOAc (3x 50 mL). The organic phase was combined and washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (0 → 20% MeOH / EtOAc) to give tert-butyl 3-((4-amino-3-(2-aminobenzo [d] oxazol-5-yl) -1H- pyrazolo [3,4-d] pyrimidin-1-yl) methyl) pyrrolidine-1-carboxylate (3 g, 64% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 22 H 26 Calculated value of N8O3: 451.21, measured value 451.2.
[1193] Step 3: Synthesis of 5-(4-amino-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine
[1194] To a solution of tert-butyl 3-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate (3 g, 6.66 mmol, 1.0 equiv) in DCM (40 mL) was added TFA (20 mL) dropwise at 0°C. The reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction solution was then concentrated under reduced pressure to give a residue. The residue was dissolved in MeCN (4 mL) and then poured into MTBE (100 mL), and a solid precipitated out. The solid was filtered and the filter cake was dried under reduced pressure to give 5-(4-amino-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (4.00 g, over 100% yield, TFA) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 17 H 18 Calculated N8O value: 351.17; measured value: 351.2.
[1195] Monomer J. 1-(4-Aminobutyl)-3-(7-methoxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trifluoroacetate.
[1196]
[1197] Step 1: Synthesis of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-methoxy-1H-indole-1-carboxylate
[1198] To a mixture of tert-butyl (4-(4-amino-3-indol-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) and (1-(tert-butoxycarbonyl)-7-methoxy-1H-indol-2-yl)boronic acid (3.0 equiv) in DME and H2O was added Pd(PPh3)4 (0.1 equiv) and sodium carbonate (6.0 equiv). The reaction was heated at 80°C until complete, as determined by LCMS and TLC analysis. The reaction was then quenched with H2O and EtOAc. The mixture was transferred to a separatory funnel and the aqueous phase was extracted with EtOAc. The organic phase was washed with saturated aqueous NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The desired product was isolated after chromatography on silica gel.
[1199] Step 2: Synthesis of 1-(4-aminobutyl)-3-(7-methoxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
[1200] To a solution of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-methoxy-1H-indole-1-carboxylate (1.0 equiv) in DCM was added TFA dropwise at 0°C. The reaction was stirred at 0°C and warmed to room temperature. Once the reaction was complete, as determined by LCMS, the reaction was concentrated under reduced pressure. The residue was triturated with MeCN and then added dropwise to MTBE over 10 minutes. The supernatant was removed and the precipitate was collected by filtration under N2 to give 1-(4-aminobutyl)-3-(7-methoxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine.
[1201] Monomer K. Synthesis of 1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trifluoroacetate.
[1202]
[1203] Step 1: Synthesis of tert-butyl (4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate
[1204] To a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (300 mg, 694 μmol, 1.0 equiv) in MeOH (14 mL) at 0°C was added zinc dust (226 mg, 3.46 mmol, 5.0 equiv). Saturated aqueous NHCl (14 mL) was added to the reaction mixture and the reaction was warmed to room temperature and stirred for 18 hours. The reaction was quenched with EtOAc (40 mL) and H2O (10 mL) and the mixture was transferred to a separatory funnel. The aqueous phase was extracted with EtOAc (3 x 20 mL) and the combined organic phases were washed with saturated aqueous NaHCO3 (15 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the product as a light yellow solid (210 mg, 99% yield), which was used without further purification. LCMS (ESI) m / z: [M+H] for C 14 H 22 Calculated value of N6O2: 307.19; measured value: 307.1.
[1205] Step 2: Synthesis of 1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
[1206] To a solution of tert-butyl (4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (210 mg, 691 μmol) in DCM (3.5 mL) at 0° C., TFA (3.5 mL) was added dropwise. After 3 hours, the reaction was warmed to room temperature and concentrated under reduced pressure to give the trifluoroacetic acid salt of the product as a brown oil (220 mg, 99% yield), which was used without further purification. LCMS (ESI) m / z: [M+H] for C9H 14 N6 calculated value: 207.13; measured value: 207.1.
[1207] Monomer L. 1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-(quinolin-3-yl)-1H,2H-benzo[h]1,6-naphthyridin-2-one
[1208]
[1209] The preparation of this monomer has been previously reported in the literature. See the following references: i) Liu, Qingsong, Chang, Jae Won, Wang, Jinhua, Kang, Seong A., Thoreen, Carson C., Markhard, Andrew, Hur, Wooyoung, Zhang, Jianming, Sim, Taebo, Sabatini, David M., et al., Journal of Medicinal Chemistry (2010), 53(19), 7146-7155. ii) Gray, Nathanael, Chang, Jae Won, Zhang, Jianming, Thoreen, Carson C., Kang, Seong Woo Anthony, Sabatini, David M., Liu, Qingsong, PCT Int. Appl. (2010), WO 2010044885A2, which are incorporated by reference in their entirety.
[1210] Monomer M. 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.
[1211]
[1212] Step 1: Synthesis of 3-iodo-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
[1213] A suspension of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (10.5 g, 40.23 mmol, 1.0 equiv) in DMF (170.0 mL) was treated with CsCO (19.7 g, 60.34 mmol, 1.5 equiv) and [chloro(diphenyl)methyl]benzene (13.5 g, 48.27 mmol, 1.2 equiv) at room temperature. The reaction mixture was stirred at 70 °C under a nitrogen atmosphere for 4 hours. The reaction mixture was added to HO (1200 mL). The precipitate was filtered and washed with HO. The residue was purified by silica gel chromatography (0→60% EtOAc / petroleum ether) to give 3-iodo-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (15.40 g, 73.5% yield) as a white solid.
[1214] Step 2: Synthesis of 3-iodo-N,N-dimethyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
[1215] To a suspension of NaH (2.98 g, 74.50 mmol, 60 wt%, 2.5 eq) in DMF (150 mL) at 0°C was added a solution of 3-iodo-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (15.0 g, 29.80 mmol, 1.0 eq) in DMF (50 mL). The mixture was stirred at 0°C for 10 minutes. Methyl iodide (16.92 g, 119.20 mmol, 7.42 mL, 4.0 eq) was then added to the reaction mixture at 0°C. The mixture was stirred at room temperature for 2 hours, at which time H2O (1400 mL) was added at 0°C. The mixture was stirred at 0°C for an additional 10 minutes. The resulting precipitate was collected by filtration to give the crude product, which was purified twice by silica gel chromatography (1%→25% EtOAc / petroleum ether) to give 3-iodo-N,N-dimethyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (9.0 g, 89% yield) as a white solid.
[1216] Step 3: Synthesis of 3-iodo-N,N-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
[1217] At 4 ° C, 3-iodo-N, N-dimethyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (9.10 g, 17.12 mmol, 1.0 equiv) was added to a cooled solution of TFA (19.1 mL, 258.1 mmol, 15.0 equiv) in DCM (100.0 mL). The mixture was stirred at room temperature for 1 hour. The residue was poured into H2O (100 mL) and the aqueous phase was extracted with DCM (2x50 mL). Saturated NaHCO3 aqueous solution was then added to the aqueous phase until the solution was pH 8. The resulting precipitate was collected by filtration to obtain 3-iodo-N, N-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3.40 g, 68.7% yield) as a white solid.
[1218] Step 4: Synthesis of tert-butyl (4-(4-(dimethylamino)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate
[1219] To a suspension of 3-iodo-N,N-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7 g, 5.88 mmol, 1.0 equiv) in DMF (20 mL) at 4°C was added NaH (247 mg, 6.17 mmol, 60 wt%, 1.05 equiv). The mixture was stirred at 4°C for 30 minutes. Tert-butyl N-(4-bromobutyl)carbamate (2.22 g, 8.82 mmol, 1.81 mL, 1.5 equiv) in DMF (10 mL) was then added to the reaction mixture at 4°C. The mixture was stirred at room temperature for 2 hours. H2O (100 mL) was then added to the mixture at 4°C. The mixture was stirred at 4°C for an additional 30 minutes and the resulting precipitate was collected by filtration to obtain the crude product. The residue was purified by silica gel chromatography (0→75% EtOAc / petroleum ether) to give tert-butyl (4-(4-(dimethylamino)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (2.0 g, 56% yield) as a white solid.
[1220] Step 5: Synthesis of tert-butyl (4-(3-(2-aminobenzo[d]oxazol-5-yl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate
[1221] To a biphasic suspension of tert-butyl (4-(4-(dimethylamino)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (4.0 g, 8.69 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (3.4 g, 13.03 mmol, 1.5 equiv), and NaCO (4.6 g, 43.45 mmol, 5.0 equiv) in DME (80.0 mL) and H2O (40.0 mL) at room temperature under N2 was added Pd(PPh3)4 (1.0 g, 868.98 μmol, 0.1 equiv). The mixture was stirred at 110°C for 3 h. The reaction mixture was then cooled and distributed between EtOAc (300 mL) and H o (600 mL). The aqueous layer was separated and extracted with EtOAc (2 x 100 mL). The organic layers were combined, washed with brine (2 x 60 mL) and dried over anhydrous Na sO , filtered and concentrated under reduced pressure. The crude material was purified by silica gel chromatography (50% EtOAc / hexane, then 20% MeOH / EtOAc). The desired fractions were combined and concentrated under reduced pressure to obtain tert-butyl (4-(3-(2-aminobenzo [d] oxazole-5-yl)-4-(dimethylamino)-1H-pyrazolo [3,4-d] pyrimidin-1-yl) butyl) carbamate (3.2 g, 78.9% yield) as a light brown solid.
[1222] Step 6: Synthesis of 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine
[1223] To TFA (20.82 mL, 281.27 mmol, 36.5 equiv) at room temperature was added tert-butyl (4-(3-(2-aminobenzo[d]oxazol-5-yl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (3.6 g, 7.72 mmol, 1.0 equiv). The mixture was stirred for 30 minutes, at which point the mixture was concentrated under reduced pressure. The oily residue was triturated with MeCN (8 mL) and MTBE (60 mL) for 10 minutes. The supernatant was removed, and the precipitate was then collected by filtration under N2 to give 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (4.0 g, crude, TFA) as a light brown solid.
[1224] To 1 M NaOH (107.2 mL, 14.7 equiv) was added 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (3.5 g, crude, TFA) at room temperature. The mixture was stirred for 10 minutes, and the aqueous phase was then extracted with DCM (3 x 50 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. TFA (539.37 μL, 7.28 mmol, 1.0 equiv) was added and concentrated under reduced pressure. MeCN (10 mL) was then added, followed by MTBE (150 mL). The resulting precipitate was collected by filtration to give 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (1.3 g, 36.6% yield, TFA) as a light brown product. LCMS (ESI) m / z: [M+H] for C 18 H 22 Calculated N8O value: 367.19; measured value: 367.1.
[1225] Monomer N. 6-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo-[d]isoxazol-3-amine trifluoroacetate.
[1226]
[1227] Step 1: Synthesis of tert-butyl (6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazol-3-yl)carbamate
[1228] To a solution of tert-butyl (6-bromobenzo[d]isoxazol-3-yl)carbamate (1.0 equiv) in dioxane was added Pd(PPh) (0.1 equiv), sodium carbonate (6.0 equiv) and bis(pinacolato)diboron (3.0 equiv). The reaction mixture was stirred and heated until completion, as determined by LCMS and TLC analysis. The reaction was cooled to room temperature, quenched with saturated aqueous NaHCO3 solution and the mixture was transferred to a separatory funnel. The aqueous phase was extracted with EtOAc and the organic phase was washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered and concentrated under reduced pressure. The desired product was isolated after purification by silica gel chromatography.
[1229] Step 2: Synthesis of tert-butyl (4-(4-amino-3-(3-((tert-butoxycarbonyl)amino)benzo[d]isoxazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate
[1230] To a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) and tert-butyl (6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazol-3-yl)carbamate (3.0 equiv) in DME and H2O was added Pd(PPh3)4 (0.1 equiv) and sodium carbonate (6.0 equiv). The reaction was heated at 80°C until complete, as determined by LCMS and TLC analysis. The reaction was then quenched with H2O and EtOAc. The mixture was transferred to a separatory funnel and the aqueous phase was extracted with EtOAc. The organic phase was washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered, and concentrated under reduced pressure. The desired product was isolated after chromatography on silica gel.
[1231] Step 3: Synthesis of 6-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo-[d]isoxazol-3-amine
[1232] To a solution of tert-butyl (4-(4-amino-3-(3-((tert-butoxycarbonyl)amino)benzo[d]isoxazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) in DCM was added TFA dropwise at 0°C. The reaction was stirred at 0°C and warmed to room temperature. Once the reaction was complete, as determined by LCMS, the reaction was concentrated under reduced pressure. The residue was triturated with MeCN and then added dropwise to MTBE over 10 minutes. The supernatant was removed and the precipitate was collected by filtration under N2 to give 6-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo-[d]isoxazol-3-amine.
[1233] Monomer O. 4-(5-(4-morpholino-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-1H-indol-1-yl)butan-1-amine trifluoroacetate.
[1234]
[1235] The synthesis of this monomer was carried out by alkylating WAY-600 (CAS No. 1062159-35-6) with tert-butyl (4-bromobutyl)carbamate under basic conditions, followed by deprotection using TFA to produce the TFA salt.
[1236] Reference for the preparation of WAY-600: Discovery of Potent and Selective Inhibitors of the Mammalian Target of Rapamycin (mTOR) Kinase: Nowak, P., Cole, DC, Brooijmans, N., Bursavich, MG, Curran, KJ, Ellingboe, JW, Gibbons, JJ, Hollander, I., Hu, Y., Kaplan, J., Malwitz, DJ, Toral-Barza, L., Verheijen, JC, Zask, A., Zhang, W.-G., Yu, K. 2009; Journal of Medicinal Chemistry, Vol. 52, No. 22, 7081-89, the entire text of which is incorporated by reference.
[1237] Monomer P. 2-(4-(8-(6-(aminomethyl)quinolin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropionitrile trifluoroacetate.
[1238]
[1239] The synthesis of this monomer begins with the synthesis of the Suzuki reaction coupling partner (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane)quinolin-6-yl)-N-boc-methylamine from methyl 3-bromoquinoline-6-carboxylate. The methyl ester is reduced with lithium aluminum hydride, followed by a Mitsunobu reaction with phthalimide and hydrazine cleavage to afford the benzylamine. The benzylamine is then protected with di-tert-butyl dicarbonate, followed by a Miyaura borylation reaction to afford (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane)quinolin-6-yl)-N-boc-methylamine.
[1240] S-Hydroxybenzoic Acid of 2-(4-aminophenyl)-2-methylpropionitrile Using 6-bromo-4-chloro-3-nitroquinoline N Ar reaction yields a substituted amino-nitro-pyridine. Reduction of the nitro group with Raney nickel under a hydrogen atmosphere, followed by cyclization with trichloromethyl chloroformate, affords the aryl-substituted urea. The free NH of the urea is substituted with methyl iodide mediated by tetrabutylammonium bromide and sodium hydroxide, followed by Suzuki coupling of (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane)quinolin-6-yl)-N-boc-methylamine, and subsequent deprotection with TFA Boc- to produce the TFA salt.
[1241] Reference for preparation of 2-[4-(8-bromo-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)phenyl]-2-methyl-propionitrile: Vannucchi, AM, Bogani, C., Bartalucci, N. 2016. JAK PI3K / mTOR combination therapy. US9358229. Novartis Pharma AG, Incyte Corporation, incorporated by reference in its entirety.
[1242] Monomer Q. 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1H,2H,3H-imidazo[4,5-c]quinolin-2-one
[1243]
[1244] This monomer is commercially available as BGT226 (CAS No. 1245537-68-1). At the time of preparing this application, it was available as the free amine from several suppliers.
[1245] Monomer R. 3-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4,5-dihydrothiazol-2-yl)benzamide trifluoroacetate.
[1246]
[1247] Step 1: Synthesis of tert-butyl (4-(4-amino-3-(3-((4,5-dihydrothiazol-2-yl)carbamoyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate
[1248] To a solution of (3-((4,5-dihydrothiazol-2-yl)carbamoyl)phenyl)boronic acid (500 mg, 1.15 mmol, 1.0 equiv) and tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (575 mg, 2.30 mmol, 2.0 equiv) in dioxane (19.1 mL), EtOH (3.8 mL), and H2O (2.3 mL) was added Pd(PPh3)4 (265 mg, 230 μmol, 0.2 equiv) and sodium carbonate (730 mg, 6.89 mmol, 6.0 equiv). The reaction mixture was sonicated until a clear yellow solution formed and then heated at 80°C for 14 h. The reaction was then diluted with saturated aqueous NaCl (30 mL) and the mixture was transferred to a separatory funnel. The aqueous phase was extracted with DCM (3 x 25 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated under reduced pressure. The desired product was isolated as a yellow solid (324 mg, 53% yield) after silica gel chromatography (0→15% MeOH / DCM). LCMS (ESI) m / z: [M+H] for C 24 H 30 Calculated value of N8O3S: 511.22; measured value: 511.2.
[1249] Step 2: Synthesis of 3-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4,5-dihydrothiazol-2-yl)benzamide
[1250] To a solution of tert-butyl (4-(4-amino-3-(3-((4,5-dihydrothiazol-2-yl)carbamoyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (324 mg, 614 μmol) in DCM (4.1 mL) at 0° C. was added TFA (1.5 mL) dropwise. After 1 hour, the reaction was warmed to room temperature and concentrated under reduced pressure to give the trifluoroacetic acid salt of the product as a yellow solid (320 mg, 99% yield). This was used without further purification. LCMS (ESI) m / z: [M+H] for C 19 H 22 N8OS calculated value: 411.16; measured value: 411.1
[1251] Monomer S. 2-(5-(4-morpholino-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-1H-indol-3-yl)ethan-1-amine.
[1252]
[1253] The synthesis of this monomer is carried out by condensation of 2,4,6-trichloropyrimidine-5-carboxaldehyde and 3-((4-hydrazinopiperidin-1-yl)methyl)pyridine hydrochloride. The product is reacted with morpholine, followed by a Suzuki reaction with a boronate ester to obtain a Boc-protected amine. Finally, the protecting group is removed using TFA to obtain the monomer. This synthetic route closely follows the preparation method of the highly related structure reported in the following references: i) Nowak, Pawel, Cole, Derek C., Brooijmans, Natasja, Curran, Kevin J., Ellingboe, John W., Gibbons, James J., Hollander, Irwin, Hu, Yong Bo, Kaplan, Joshua, Malwitz, David J., et al. from Journal of Medicinal Chemistry (2009), 52(22), 7081-7089. ii) Zask, Arie, Nowak, Pawel Wojciech, Verheijen, Jeroen, Curran, Kevin J., Kaplan, Joshua, Malwitz, David, Bursavich, Matthew Gregory, Cole, Derek Cecil, Ayral-Kaloustian, Semiramis, Yu, Ker, et al. from PCT Int. Appl. (2008), WO 2008115974 A220080925, incorporated by reference in its entirety.
[1254] Monomer T. 1-(4-Aminobutyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine trifluoroacetate.
[1255]
[1256] To a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (496 mg, 1.14 mmol, 1.0 equiv) in DCM (5.7 mL) at 0° C. was added TFA (1.5 mL) dropwise. The reaction was allowed to stir at 0° C. for 1 hour, at which time the reaction was concentrated under reduced pressure to give a yellow solid (505 mg, 99% yield) which was used without further purification. LCMS (ESI) m / z: [M+H] for C9H 13 IN6 calculated value: 333.02; measured value 332.9.
[1257] Monomer U. 5-(4-amino-1-(4-(methylamino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.
[1258]
[1259] Step 1: Synthesis of tert-butyl (4-hydroxybutyl)(methyl)carbamate
[1260] At room temperature, to a solution of 4-(methylamino)butan-1-ol (0.5 g, 4.85 mmol, 104.2 mL, 1.0 equivalent) in DCM (10 mL) was added Boc O (1.06 g, 4.85 mmol, 1.11 mL, 1.0 equivalent). The mixture was stirred at room temperature for 3 hours, and then the mixture was concentrated under reduced pressure at 30 ° C. The residue was purified by silica gel chromatography (100 / 1 to 3 / 1 petroleum ether / EtOAc) to give tert-butyl (4-hydroxybutyl)(methyl)carbamate (0.9 g, 91.4% yield) as a colorless oil.
[1261] Step 2: Synthesis of tert-butyl (4-bromobutyl)(methyl)carbamate
[1262] To a solution of tert-butyl (4-hydroxybutyl) (methyl) carbamate (0.9 g, 4.43 mmol, 1.0 equiv) in THF (20 mL) was added PPh (2.21 g, 8.41 mmol, 1.9 equiv) and CBr (2.79 g, 8.41 mmol, 1.9 equiv) at room temperature. The mixture was stirred for 1 hour, and the reaction mixture was then filtered and concentrated. The residue was purified by silica gel chromatography (1 / 0 to 4 / 1 petroleum ether / EtOAc) to give tert-butyl (4-bromobutyl) (methyl) carbamate (1.1 g, 93.3% yield) as a colorless oil.
[1263] Step 3: Synthesis of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate
[1264] At 4 ° C, NaH (137.92 mg, 3.45 mmol, 60% by weight, 1.0 equivalent) was added to a suspension of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (0.9 g, 3.45 mmol, 1.0 equivalent) in DMF (10 mL). The mixture was stirred at 4 ° C for 30 minutes, and then a solution of tert-butyl (4-bromobutyl)(methyl)carbamate (1.01 g, 3.79 mmol, 25.92 mL, 1.1 equivalents) in DMF (3 mL) was added. The mixture was stirred at room temperature for 3 hours, and then H2O (100 mL) was added. The aqueous phase was extracted with EtOAc (3 x 30 mL) and the combined organic phase was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (1 / 0 to 0 / 1 petroleum ether / EtOAc) to give tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate (1.2 g, 78% yield) as a white solid. LCMS (ESI) m / z: [M+H] for C 15 H 23 Calculated value of IN6O2: 447.10; measured value: 447.1.
[1265] Step 4: Synthesis of tert-butyl (4-(4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate
[1266] To a biphasic suspension of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate (1.2 g, 2.69 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (1.19 g, 3.23 mmol, 1.2 equiv) and Na2CO3 (1.42 g, 13.44 mmol, 5.0 equiv) in DME (20 mL) and H2O (10 mL) at rt was added Pd(PPh3)4 (310.71 mg, 268.89 μmol, 0.1 equiv). The mixture was stirred at 110 ° C for 3 hours, and the reaction mixture was then cooled and distributed between EtOAc (20 mL) and H o (15 mL). The aqueous layer was separated and extracted with EtOAc (3x 20 mL). The combined organic layer was washed with brine (2x20 mL), dried over anhydrous Na sO , filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (1 / 0 to 4 / 1 EtOAc / MeOH) to obtain tert-butyl (4-(4-amino-3-(2-aminobenzo [d] oxazol-5-yl) -1H- pyrazolo [3,4-d] pyrimidin-1-yl) butyl) (methyl) carbamate (0.78 g, 62.5% yield) as an orange solid.
[1267] Step 5: Synthesis of 5-(4-amino-1-(4-(methylamino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine
[1268] A solution of tert-butyl (4-(4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate (0.78 g, 1.72 mmol, 1.0 equiv) in TFA (5 mL) was stirred at room temperature for 30 minutes. The solution was concentrated under reduced pressure and the oily residue was triturated with MeCN (1 mL) and then added to MTBE (100 mL). The supernatant was removed, and the precipitate was then collected by filtration under N2 to give 5-(4-amino-1-(4-(methylamino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine bistrifluorosulfonate (0.959 g, 93% yield) as an orange solid. LCMS (ESI) m / z: [M+H] for C 17 H 20 Calculated N8O value: 353.18; measured value: 353.1.
[1269] Monomer V. 1-(4-(4-(5-(aminomethyl)pyrimidin-2-yl)piperazin-1-yl)-3-(trifluoromethyl)phenyl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one.
[1270]
[1271] Step 1: Synthesis of tert-butyl N-tert-butoxycarbonyl-N-[(2-chloropyrimidin-5-yl)methyl]carbamate
[1272] At 0 ° C, to a solution of tert-butyl N-tert-butoxycarbonylcarbamate (7.33 g, 33.74 mmol, 1.0 eq) in DMF (80 mL) was added NaH (1.62 g, 40.49 mmol, 60 wt %, 1.2 eq). The mixture was stirred at 0 ° C for 30 minutes, and then 5-(bromomethyl)-2-chloro-pyrimidine (7 g, 33.74 mmol, 1 eq) was added. The reaction mixture was stirred at room temperature for 1.5 hours, and then the mixture was poured into saturated NH4Cl (300 mL) and stirred for 5 minutes. The aqueous phase was extracted with EtOAc (3x80 mL) and the combined organic phase was washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (20:1 to 1:1 petroleum ether / EtOAc) to give tert-butyl N-tert-butoxycarbonyl-N-[(2-chloropyrimidin-5-yl)methyl]carbamate (7.0 g, 60.3% yield) as a white solid. LCMS (ESI) m / z: [M+H] for C 15 H 22 Calculated value of ClN3O4: 344.14; found 344.2.
[1273] Step 2: Synthesis of tert-butyl N-tert-butoxycarbonyl-N-[[2-[4-[4-[8-(6-methoxy-3-pyridinyl)-3-methyl-2-oxo-imidazo[4,5-c]quinolin-1-yl]-2-(trifluoromethyl)phenyl]piperazin-1-yl]pyrimidin-5-yl]methyl]carbamate
[1274] To a solution of 8-(6-methoxy-3-pyridinyl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one (0.4 g, 748.32 μmol, 1.0 eq) in MeCN (7 mL) was added tert-butyl N-tert-butoxycarbonyl-N-[(2-chloropyrimidin-5-yl)methyl]carbamate (514.55 mg, 1.50 mmol, 2.0 eq) and KCO (413.69 mg, 2.99 mmol, 4 eq) at room temperature. The reaction mixture was stirred at 80° C. for 14 hours, and then the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by washing with MTBE (5 mL) to give tert-butyl N-tert-butoxycarbonyl-N-[[2-[4-[4-[8-(6-methoxy-3-pyridinyl)-3-methyl-2-oxo-imidazo[4,5-c]quinolin-1-yl]-2-(trifluoromethyl)phenyl]piperazin-1-yl]pyrimidin-5-yl]methyl]carbamate (0.57 g, 90.5% yield) as a light yellow solid. LCMS (ESI) m / z: [M+H] for C 43 H 46 Calculated value of F3N9O6: 842.36; measured value 842.7.
[1275] Step 3: Synthesis of 1-[4-[4-[5-(aminomethyl)pyrimidin-2-yl]piperazin-1-yl]-3-(trifluoromethyl)phenyl]-8-(6-methoxy-3-pyridinyl)-3-methyl-imidazo[4,5-c]quinolin-2-one
[1276] A solution of tert-butyl N-tert-butoxycarbonyl-N-[[2-[4-[4-[8-(6-methoxy-3-pyridinyl)-3-methyl-2-oxo-imidazo[4,5-c]quinolin-1-yl]-2-(trifluoromethyl)phenyl]piperazin-1-yl]pyrimidin-5-yl]methyl]carbamate (0.95 g, 1.13 mmol, 1 equiv) in TFA (10 mL) was stirred at room temperature for 1 hour, at which time the solvent was concentrated. The residue was dissolved in MeCN (10 mL), and the solution was then added dropwise to MTBE (150 mL). The precipitate was collected to give 1-[4-[4-[5-(aminomethyl)pyrimidin-2-yl]piperazin-1-yl]-3-(trifluoromethyl)phenyl]-8-(6-methoxy-3-pyridinyl)-3-methyl-imidazo[4,5-c]quinolin-2-one trifluoromethanesulfonate (0.778 g, 84.8% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 33 H 30 Calculated value of F3N9O2: 642.26; measured value: 642.4.
[1277] Monomer W. 1-(4-aminobutyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-4-amine.
[1278]
[1279] Step 1: Synthesis of tert-butyl N-[4-[4-amino-3-(1H-indol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]carbamate
[1280] To a biphasic suspension of tert-butyl N-[4-(4-amino-3-iodo-pyrazolo[3,4-d]pyrimidin-1-yl)butyl]carbamate (8 g, 18.51 mmol, 1 eq), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (5.42 g, 22.21 mmol, 1.2 eq) and NaCO (9.81 g, 92.54 mmol, 5 eq) in diglyme (160 mL) and H O (80 mL) was added Pd(PPh) (2.14 g, 1.85 mmol, 0.1 eq) at room temperature under N. The mixture was stirred at 110° C. for 3 h. The reaction mixture is cooled to room temperature, filtered and the filtrate is distributed between EtOAc (500mL) and H o (500mL). The water layer is separated and extracted with EtOAc (3x 300mL). The organic layer is combined, washed with brine (20mL) and dried over anhydrous Na sO , then filtered and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel chromatography (1 / 0 to 0 / 1 petroleum ether / EtOAc then 4 / 1 EtOAc / MeOH) to obtain N- [4- [4- amino -3- (1H- indol -5- bases) pyrazolo [3,4-d] pyrimidin -1- bases] butyl] tert-butyl carbamate (6.6g, 84.6% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 22 H 27 Calculated value of N7O2: 422.22; measured value: 423.3.
[1281] Step 2: Synthesis of 1-(4-aminobutyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-4-amine
[1282] To tert-butyl N-[4-[4-amino-3-(1H-indol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]carbamate (6.6 g, 15.66 mmol, 1 equivalent) was added TFA (66 mL) and then stirred at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure to remove TFA, and then MTBE (400 mL) was added to the residue. The suspension was stirred for 15 minutes, at which time the yellow solid was filtered, and the solid filter cake was dried under reduced pressure to give 1-(4-aminobutyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-4-amine (10.2 g, 97.1% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 16 H 18 N8 calculated value: 323.17; measured value 323.1.
[1283] Monomer X. 2-(4-amino-1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol 2,2,2-trifluoroacetate.
[1284]
[1285] Step 1: Synthesis of tert-butyl 6-((4-amino-3-(5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[1286] To a solution of tert-butyl 6-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1 g, 1.97 mmol, 1.0 equiv) in dioxane (10.5 mL) and H2O (3.5 mL) at room temperature under N2 was added (1-(tert-butoxycarbonyl)-5-(tert-butyldimethylformamide) The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours. The mixture was stirred for 3 hours. The mixture was stirred for 3 hours. The mixture was stirred for 3 hours. The mixture was stirred for 3 hours. The mixture was stirred for 4 hours. The mixture w...
Claims
1. Compound of formula Ic: or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein : R 32 is -H, -OR 3 , -N 3 or -O-C(=Z 1 )-R 32a ; R 28 -H, (C 1 -C 6 )alkyl or -C(=Z 1 )-R 28a ; R 40 =Z 1 )-R 40a ; Z 1 Each independently is O or S; R 28a , R 32a and R 40a Independently -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; -L 2 -A 1 -L 1 -A 2 -L 3 -B;-O-(C 1 -C 6 )alkyl; or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C 10 ) The aryl group is unsubstituted or substituted with 1 to 5 selected from -NO 2 and halogen substitution; A 1 and A 2 is independently absent or independently selected from As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The right side of the key is connected to B or L 3 ; Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; X 1 each independently is a heteroarylene or heterocyclylene ring; W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; W 1 each independently is a heteroarylene or heterocyclylene ring; G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring; L 1 Each independently selected from L 2 and L 3 is independently absent or independently selected from B are each independently selected from B 1 Each independently selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-(C(R 3 ) 2 ) n -、 (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -Arylene-C(O)- and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-(C(R 3 ) 2 ) n -, where as depicted, B 1 The left side Bond to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy; R 3 Each independently is H or (C 1 -C 6 )alkyl; R 4 Each independently is H, (C 1 -C 6 )alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution; R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace; R 6 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace; R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace; R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace; Y is each independently C(R 3 ) 2 or key; n is each independently an integer from 1 to 12; o are each independently an integer from 0 to 30; p is each independently an integer from 0 to 12; q is each independently an integer from 0 to 30; and r is an integer of 1 to 6 each independently.
2. The compound according to claim 1, or a pharmaceutically acceptable salt, an oxepane isomer or a tautomer thereof, wherein R 32 For-OR 3 .
3. A compound according to any one of claims 1 to 2, or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein the compound is represented by the structure of formula (I-40b): Where R 40 =Z 1 )-R 40a .
4. The compound according to claim 3, or a pharmaceutically acceptable salt, an oxepane isomer or a tautomer thereof, wherein Z 1 is O.
5. The compound according to claim 3, or a pharmaceutically acceptable salt, an oxepane isomer or a tautomer thereof, wherein Z 1 For S.
6. The compound according to any one of claims 3 to 5, or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.
7. The compound according to any one of claims 3 to 5, or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 2 Does not exist.
8. The compound according to any one of claims 3 to 5, or a pharmaceutically acceptable salt, an oxepane isomer or a tautomer thereof, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 1 Does not exist.
9. The compound according to any one of claims 3 to 5, or a pharmaceutically acceptable salt, an oxepane isomer or a tautomer thereof, wherein R 40a For-A 1 -L 1 -A 2 -B.
10. The compound according to any one of claims 3 to 5, or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein R 40a For-A 1 -A 2 -B.
